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ABSTRACT
SPATIAL LEARNING AND MEMORY IN BRAIN-INJURED AND NON-INJURED MICE:
INVESTIGATING THE ROLES OF DIACYLGLYCEROL LIPASE-α AND -β.
Lesley D. Schurman, Master of Science
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2018
Advisor: Aron H. Lichtman, PhD Professor of Pharmacology and Toxicology

A growing body of evidence implicates the importance of the endogenous
cannabinoid 2-arachidonyl glycerol (2-AG) in memory regulation. The biosynthesis of 2AG occurs primarily through the diacylglycerol lipases (DAGL-α and -β), with 2-AG
serving as a bioactive lipid to both activate cannabinoid receptors and as a rate limiting
precursor for the production of arachidonic acid and subsequent pro-inflammatory
mediators. Gene deletion of DAGL-α shows decrements in synaptic plasticity and
hippocampal neurogenesis suggesting this biosynthetic enzyme may be important for
processes of normal spatial memory. Additionally, 2-AG is elevated in response to
pathogenic events such as traumatic brain injury (TBI), suggesting its regulatory role
may extend to conditions of neuropathology. As such, this dissertation investigates the
in vivo role of DAGL-α and -β to regulate spatial learning and memory in the healthy
brain and following neuropathology (TBI).

The first part of this dissertation developed a mouse model of learning and
memory impairment following TBI, using hippocampal-dependent tasks of the Morris
water maze (MWM). We found modest, but distinct differences in MWM performance
between left and right unilateral TBI despite similar motor deficits, histological damage,
and glial reactivity. These findings suggest that laterality in mouse MWM deficit might be
an important consideration when modeling TBI-induced functional consequences. The
second part of this dissertation work evaluated DAGL-β as a target to protect against
TBI-induced learning and memory deficit given its selective expression on microglia and
the role of 2-AG as a precursor for eicosanoid production. The gene deletion of DAGL-β
did not protect against TBI-induced MWM or motor deficits, but unexpectedly produced
a survival protective phenotype. These findings suggest that while DAGL-β does not
contribute to injury-induced memory deficit, it may contribute to TBI-induced mortality.
The third and final set of experiments investigated the role of DAGL-α in mouse spatial
learning and memory under physiological conditions (given the predominantly neuronal
expression of DAGL-α). Complementary pharmacological and genetic manipulations
produced task specific impaired MWM performance, as well as impaired long-term
potentiation and alterations to endocannabinoid lipid levels. These results suggest that
DAGL-α may play a selective role in the integration of new spatial information in the
normal mouse brain.
Overall, these data point to DAGL-α, but not DAGL-β, as an important contributor
to hippocampal-dependent learning and memory. In contrast, DAGL-β may contribute to
TBI-induced mortality.

Chapter I
General Introduction

How our brains acquire, store, and later retrieve representations of our experience
influence not only our behavior and basic survival, but fundamentally contribute to our
sense of who we are. Our ability to learn impacts our perceived usefulness and in part
enables us to imagine our future. Our ability to remember connects us to our past. The
following body of work examines critical components of a neuromodulatory system, the
endocannabinoid system; one key feature of which is its action on the neurobiology of
learning and memory. The examination of two endocannabinoid biosynthetic enzymes
was conducted in the context of memory pathology produced as a result of traumatic
brain injury in a mouse model organism.
A historical perspective of memory pathology. At the end of the nineteenth
century, French psychologist Théodule Ribot studied clinical cases of brain pathology in
an attempt to understand the normal organization of memory. His classic work Diseases
of Memory (Ribot, 1882) proposed that the dissolution of memory which accompanies
pathology follows an orderly temporal progression. Ribot proposed that older memories
are most resistant to dissolution, followed by habits and emotional memories, with more
recent memories being the first to be lost (now referred to as Ribot’s Law). His insights,
though now may seem obvious, were ground breaking for their implications toward the
existence of different categories of memory, and in turn the possibility that they be
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supported by different neural systems. He described various clinical cases of what
might now be referred to as traumatic brain injuries (the most common causes of which
in the 1880s seemed to be gentlemen being thrown out of carriages and thrown from
horses) with descriptions of subsequent memory impairments mirroring deficits
commonly familiar in the current century. A detailed description of the learning and
memory deficits arising from traumatic brain injuries are presently described in detail in
the Chapter Introduction for Chapter 2 (pages 39-40).
The endocannabinoid system as a memory modulator. Our basic
understanding of the endocannabinoid system (as well as its name) arose from
research investigating the pharmacological properties of the cannabis plant. Cannabis
use has been recorded in China since 2727 BCE as medicinal (Booth, 2003), though
cannabis has been widely used for centuries as a psychoactive drug. Most notably, ∆9tetrahydrocannabinol (∆9-THC, the major psychoactive component of the cannabis
plant) shares a pharmacophore with the primary endocannabinoid ligands; anandamide
(AEA) and 2-arachidonyl glycerol (2-AG, the most abundant endocannabinoid ligand) in
that they bind and activate cannabinoid receptors. While a detailed description of the
endocannabinoid system, its components and functional characteristics, is contained in
the subsequent Chapter 1 “Endocannabinoids: A Promising Impact for Traumatic Brain
Injury” pages 5-9, the endocannabinoid system can be most succinctly understood as a
neuromodulator, a braking system used to restore physiology to states of homeostasis.
The evidence which links the endocannabinoid system to the regulation of memory
comes primarily from the ability of cannabinoid receptors to inhibit synaptic transmission
(Kano et al, 2009) through the inhibition of neurotransmitter release. The understanding
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specifically of 2-AG as a biologically active lipid in its own right, is however only part of a
complicated memory story in which 2-AG also participates as an intermediate in a
pathway which ultimately releases inflammatory mediators (Nomura et al, 2011). States
of inflammation being intimately linked to impairments of learning and memory, 2-AG
and its biosynthetic pathways are therefore the primary focus of the present work.
Summary. In the present dissertation, the enzymes responsible for 2-AG
biosynthesis, the diacylglycerol lipases (DAGLs) are explored as targets to further
understand the role this endocannabinoid system plays in learning and memory
regulation. While Chapter 2 presents work completed to establish a mouse model of
brain injury induced deficits, Chapter 3 explores considerations of 2-AG biosynthesis
disruption (DAGL-β disruption) on mouse memory pathology as a result of traumatic
brain injury. Finally, Chapter 4 examines 2-AG biosynthesis disruption (DAGL-α
disruption) on mouse memory under conditions of normal physiology. First, a review of
the present literature, concerning manipulations of the endocannabinoid system
following traumatic brain injury, is evaluated.
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Endocannabinoids: A Promising Impact for Traumatic Brain Injury
(Front Pharmacol 8:69, 2017)

Introduction
Traumatic brain injury (TBI) accounts for approximately 10 million deaths and/or
hospitalizations annually in the world, and approximately 1.5 million annual emergency
room visits and hospitalizations in the US (Langlois et al., 2006). Young men are
consistently over-represented as being at greatest risk for TBI (Langlois et al., 2006).
While half of all traumatic deaths in the USA are due to brain injury (Mayer et al., 2010),
the majority of head injuries are considered mild and often never receive medical
treatment (Corrigan et al., 2010). Survivors of TBI are at risk for lowered life expectancy,
dying at a 3.2 times more rapid rate than the general population (Baguley et al, 2012).
Survivors also face long term physical, cognitive, and psychological disorders that
greatly diminish quality of life. Even so-called mild TBI without notable cell death may
lead to enduring cognitive deficits (Niogi et al, 2008; Rubovitch et al, 2011). A 2007
study estimated that TBI results in $330,827 of average lifetime costs associated with
disability and lost productivity, and greatly outweighs the $65,504 estimated costs for
initial medical care and rehabilitation (Faul et al, 2007b), demonstrating both the long
term financial and human toll of TBI.
The development of management protocols in major trauma centers (Brain
Trauma Foundation, 2007) has improved mortality and functional outcomes (Stein et al,
2010). Monitoring of intracranial pressure is now standard practice (Bratton et al, 2007),
and advanced MRI technologies help define the extent of brain injury in some cases
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(Shah et al, 2012). Current treatment of major TBI is primarily managed through surgical
intervention by decompressive craniotomy (Bullock et al., 2006) which involves the
removal of skull segments to reduce intracranial pressure. Delayed decompressive
craniotomy is also increasingly used for intractable intracranial hypertension (Sahuquillo
and Arikan, 2006). The craniotomy procedure is associated with considerable
complications, such as hematoma, subdural hygroma, and hydrocephalus (Stiver,
2009). At present, the pathology associated with TBI remains refractive to currently
available pharmacotherapies (Meyer et al, 2010) and as such represents an area of
great research interest and in need of new potential targets. Effective TBI drug
therapies have yet to be proven, despite promising preclinical data (Lu et al, 2007;
Mbye et al, 2009; Sen and Gulati, 2010) plagued by translational problems once
reaching clinical trials (Mazzeo et al, 2009; Tapia-Perez et al, 2008; Temkin et al, 2007).
The many biochemical events that occur in the hours and months following TBI
have yielded preclinical studies directed toward a single injury mechanism. However, an
underlying premise of the present review is an important need to address the multiple
targets associated with secondary injury cascades following TBI. A growing body of
published scientific research indicates that the endogenous cannabinoid
(endocannabinoid; eCB) system possesses several targets uniquely positioned to
modulate several key secondary events associated with TBI. Here we review the
preclinical work examining the roles that the different components of the eCB system
play in ameliorating pathologies associated with TBI.

The Endocannabinoid (eCB) System
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Originally, “Cannabinoid” was the collective name assigned to the set of naturally
occurring aromatic hydrocarbon compounds in the Cannabis sativa plant (Mechoulam
and Goani, 1967). Cannabinoid now more generally refers to a much more broad set of
chemicals of diverse structure whose pharmacological actions or structure closely mimic
that of plant-derived cannabinoids. Three predominant categories are currently in use;
plant-derived phytocannabinoids (reviewed in Gertsch et al., 2010), synthetically
produced cannabinoids used as research (Wiley et al, 2014) or recreational drugs (Mills
et al., 2015), and the endogenous cannabinoids, N-arachidonoylethanolamine
(anandamide) (Devane et al., 1992) and 2-arachidonyl glycerol (2-AG) (Mechoulam et
al, 1995; Sugiura et al, 1995).
These three broad categories of cannabinoids generally act through cannabinoid
receptors, two types of which have so far been identified, CB 1 (Devane et al, 1988) and
CB2 (Munro et al, 1993). Both CB1 and CB2 receptors are coupled to signaling cascades
predominantly through Gi/o-coupled proteins. CB1 receptors mediate most of the
psychomimetic effects of cannabis, its chief psychoactive constituent Δ9tetrahydrocannabinol (THC), and many other CNS active cannabinoids. These
receptors are predominantly expressed on pre-synaptic axon terminals (Alger and Kim,
2011), are activated by endogenous cannabinoids that function as retrograde
messengers, which are released from post-synaptic cells, and their activation ultimately
dampens pre-synaptic neurotransmitter release (Mackie, 2006). Acting as a
neuromodulatory network, the outcome of cannabinoid receptor signaling depends on
cell type and location. CB1 receptors are highly expressed on neurons in the central
nervous system (CNS) in areas such as cerebral cortex, hippocampus, caudate-

6

putamen (Herkenham et al, 1991). In contrast, CB2 receptors are predominantly
expressed on immune cells, microglia in the CNS, and macrophages, monocytes, CD4+
and CD8+ T cells, and B cells in the periphery (Cabral et al, 2008). Additionally, CB2
receptors are expressed on neurons, but to a much less extent than CB1 receptors
(Atwood and Mackie, 2010). The abundant, yet heterogeneous, distribution of CB1 and
CB2 receptors throughout the brain and periphery likely accounts for their ability to
impact a wide variety of physiological and psychological processes (e.g. memory,
anxiety, and pain perception, reviewed in Di Marzo, 2008) many of which are impacted
following TBI.
Another unique property of the endocannabinoid (eCB) system is the functional
selectivity produced by its endogenous ligands. Traditional neurotransmitter systems
elicit differential activation of signaling pathways through activation of receptor subtypes
by one neurotransmitter (Siegel, 1999). However, it is the endogenous ligands of eCB
receptors which produce such signaling specificity. Although several endogenous
cannabinoids have been described (Chu et al., 2003; Heimann et al., 2007; Porter et al.,
2002) the two most studied are anandamide (Devane et al., 1992) and 2-AG
(Mechoulam et al, 1995; Sugiura et al, 1995). 2-AG levels are three orders of magnitude
higher than those of anandamide in brain (Béquet et al., 2007). Additionally, their
receptor affinity (Pertwee and Ross, 2002; Reggio, 2002) and efficacy differ, with 2-AG
acting as a high efficacy agonist at CB1 and CB2 receptors, while anandamide behaves
as a partial agonist (Hillard, 2000a). In addition, anandamide binds and activates
TRPV1 receptors (Melck et al, 1999; Smart et al, 2000; Zygmunt et al, 1999), whereas
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2-AG also binds GABAA receptors (Sigel et al, 2011). As such, cannabinoid ligands
differentially modulate similar physiological and pathological processes.
Distinct sets of enzymes, which regulate the biosynthesis and degradation of the
eCBs and possess distinct anatomical distributions (see Figure 1), exert control over
CB1 and CB2 receptor signaling. Inactivation of anandamide occurs predominantly
through fatty acid amide hydrolase (FAAH) (Cravatt et al, 1996, 2001), localized to
intracellular membranes of postsynaptic somata and dendrites (Gulyas et al, 2004), in
areas such as the neocortex, cerebellar cortex, and hippocampus (Egertová et al,
1998). Inactivation of 2-AG proceeds primarily via monoacylglycerol lipase (MAGL)
(Blankman et al, 2007; Dinh et al, 2002), expressed on presynaptic axon terminals
(Gulyas et al, 2004), and demonstrates highest expression in areas such as the
thalamus, hippocampus, cortex, and cerebellum (Dinh et al, 2002). The availability of
pharmacological inhibitors for eCB catabolic enzymes has allowed the selective
amplification of anandamide and 2-AG levels following brain injury as a key strategy to
enhance endocannabinoid signaling and to investigate their potential neuroprotective
effects.
Finally, 2-AG functions not only as a major cannabinoid receptor signaling
molecule, but also serves as a major precursor for arachidonic acid (AA), and therefore
plays a role in inflammatory pathways (see Figure 2). Although AA is a degradative
product of both 2-AG (Bell et al, 1979) and anandamide (Deutsch et al, 1997), MAGL
represents a rate-limiting biosynthetic enzyme of this highly bioactive lipid in brain, liver,
and lung (Nomura et al, 2011). Historically, cytosolic phospholipase A2 (cPLA2) was
considered to be the primary rate-limiting enzyme in AA production (reviewed in
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Buczynski et al., 2009). However, MAGL contributes ~80% and cPLA2 ~20% of LPSstimulated eicosanoids in mouse brain. In contrast, cPLA2 is the dominant enzyme to
control AA production in spleen (Nomura et al, 2011). Therefore, MAGL and cPLA2
appear to play differential roles in AA production, and concomitantly its eicosanoid
metabolites in a tissue-specific manner (Nomura et al, 2011). As such, 2-AG functions
not only as an endogenous CB1 and CB2 receptor ligand, but also an
immunomodulator by virtue of its being a major precursor for AA, making it a versatile
target for the treatment of TBI related pro-inflammatory pathologies. Understanding the
biosynthesis mechanisms of eCBs may prove useful in modulating their entry into proinflammatory pathways. While 2-AG is known to be synthesized by diacylglycerol lipaseα and –β (DAGL-α and DAGL-β) (Bisogno et al, 2003b), the mechanisms mediating
anandamide production are incompletely understood (Blankman and Cravatt, 2013).

Traumatic Brain Injury Pathology
Traumatic brain injuries are heterogeneous in their etiology, clinical presentation,
severity, and pathology. The sequelae of molecular, biochemical, and physiological
events that follow the application of an external mechanical force produce interacting
acute and delayed pathologies, described as primary and secondary injuries. The initial
insult produces an immediate mechanical disruption of brain tissue (Reilly, 2001). This
primary injury consists of contusion, blood vessel disruption and brain oedema,
localized necrotic cell death, as well as diffuse axonal injury producing degeneration of
cerebral white matter (Adams et al., 1989; Gaetz, 2004).
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Secondary injury mechanisms are initiated within minutes, in which necrotic and
apoptotic cell death in contused areas and pericontusional penumbra continue over a
period of days to months (Raghupathi, 2004). Neuronal disruption spills excitatory
amino acids into the interstitial space, producing glutamate-mediated excitotoxicity
(Bullock et al, 1998). Massive influx of Ca2+ into cells (Floyd et al, 2010) produce
mitochondrial dysfunction and the release of reactive oxygen species (ROS) which lead
to further apoptosis (Zhao et al, 2005). Injury-induced activation of CNS resident glial
cells, microglia, as well as recruitment of circulating inflammatory cells, e.g.
macrophages, then produce secretion of inflammatory mediators, cytokines and
chemokines (reviewed in Woodcock and Morganti-Kossmann, 2013). Increased
intracranial pressure leads to reductions in cerebral blood flow (Shiina et al, 1998), while
injury-induced breakdown of the cerebrovascular endothelium contributes to dysfunction
of the blood brain barrier (BBB) (Chodobski et al, 2012). Extracranial pathologies are
also evident following TBI with pulmonary complications being the most common (Pelosi
et al, 2005). Neurogenic pulmonary oedema often develops early after brain injury,
producing hypoxemia and further aggravating secondary brain injury (Brambrink and
Dick, 1997; Oddo et al., 2010). These varied and interacting disease processes
highlight the necessity to address the multiple targets associated with secondary injury
cascades following TBI.
While there are many types of CNS injury models (e.g. spinal cord injury, lesion
studies, focal and global ischemic injury etc. (Arai and Lo, 2009; Titomanlio et al, 2015),
this review will focus primarily on the work investigating manipulations of the eCB
system in preclinical models of traumatic brain injury.
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Pre-Clinical Evaluation of Cannabinoids to Treat TBI
While basal anandamide and 2-AG levels differ within various structures in the CNS,
levels increase on demand in response to a given stimuli (e.g. the induction of nausea
[Sticht et al., 2016] or pain states [Costa et al., 2008]). eCBs are lipid messengers not
stored in synaptic vesicles (likely due to their hydrophobicity) but rather synthesized in
an activity-dependent manner from membrane phospholipid precursors (Alger and Kim,
2011). Consequently, endocannabinoid signaling is enhanced by a stimulus-response
synthesis and release mechanism.
eCB levels increase in selected CNS tissue following neuronal damage, which
may reflect a self-neuroprotective response. NMDA excitotoxicity produces elevations of
anandamide in ipsilateral cortex of rats by 4-fold at 4 h, and 14-fold at 24 h, but with no
changes in 2-AG levels (Hansen et al, 2002). Concussive head trauma in rats produces
a similar pattern of findings in which modest increases of anandamide levels occur in
ipsilateral cortex, and again with no change in 2-AG levels (Hansen et al, 2002). This
pattern was replicated by Tchantchou et al., 2014, who found a 1.5 fold increase of
anandamide levels at three days post-TBI in ipsilateral mouse brain, and with no
change in 2-AG. In contrast, Panikashvili et al., 2001 reported that TBI in mice led to
increases of 2-AG in ipsilateral brain from 1 h to 24 h with elevations as high as 10-fold.
Thus, further research is needed to discern whether species differences, the model
used to elicit neurotrauma, and/or other procedural considerations contribute to the
differential elevation of these eCBs (Mechoulam and Lichtman, 2003).
A lack of studies systematically investigating the consequences of TBI on
changes in eCB levels in specific brain regions perhaps point to the difficulty in
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measuring changes in the volatile eCBs, prone to rapid degradation (Deutsch and Chin,
1993; Dinh et al, 2002). While pharmacological and genetic manipulations of the eCB
system continue to be evaluated following TBI; full characterization of how eCB
biosynthetic and degradative enzymes, receptors, and endogenous ligands, their
precursors and catabolic products, change as a consequence of TBI remains to be fully
illuminated.

Treatment of Cellular and Molecular Pathophysiology of TBI
In this section, we review preclinical studies of cannabinoids in the context of their
potential to protect against cellular and molecular TBI pathology, (see Table. 1).
CNS Cell Death. TBI-induced neuronal loss occurs almost immediately as
necrotic cell death and continues for months following the initial insult via both necrotic
and apoptotic cell death (Raghupathi, 2004). From a traumatic insult, the initial contused
area forms a regional primary lesion or infarct surrounding which is the pericontusional
penumbra, the area immediately adjacent to the primary lesion and at risk for further
neurodegeneration. The evolution of the pericontusional penumbra occurs largely due
to secondary injury mechanisms and has long been considered a candidate for
interventions to protect against, or salvage from, further injury (Wang et al, 2014). The
investigation of cannabinoids on traumatic CNS cell death have thus far demonstrated
efficacy in two areas; attenuated neurodegeneration and reduced lesion volume.
Neurodegeneration, commonly measured by reductions in the neuronal marker
fluoro-jade C, has been found to be readily attenuated in mice by CB2 receptor agonists
(Amenta et al, 2012), as well as by inhibitors of FAAH (Tchantchou et al, 2014) and
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MAGL (Zhang et al, 2014). Additionally, FAAH inhibitors produce reductions in lesion
volume, and increased production of the heat shock proteins Hsp70, known to be
structurally protective, and Hsp72, a negative regulator of apoptosis (Tchantchou et al,
2014). Tchantchou et al., 2014 also showed that FAAH inhibition increased expression
of the anti-apoptotic protein Bcl-2.
Several enzymes hydrolyze 2-AG including MAGL, which accounts for an
estimated 85% of its total hydrolysis, as well as α/β-hydrolase domain-6 (ABHD6) and
ABHD12, which are responsible for much of the remaining 15% (Blankman et al, 2007).
Tchantchou and Zhang, 2013 found that inhibition of ABHD6 also reduced lesion
volume and lowered neurodegeneration in a mouse CCI model. A CB 1 receptor
antagonist attenuated the protective effects on lesion volume, while CB 1 and CB2
receptor antagonists prevented the protective effects on neurodegeneration
(Tchantchou and Zhang, 2013).
Combined, this evidence suggests that inhibitors of eCB hydrolysis offer
protection against TBI-induced cell death which involve CB1 and CB2 receptors, though
the distinction between the eCBs remains to be clarified. Few studies have evaluated
interactions between anandamide and 2-AG in laboratory models of TBI. One study
using a model of cerebral focal ischemia found that exogenously administered
anandamide and 2-AG in combination reduced infarct size in rats, but with no facilitatory
effects beyond anandamide or 2-AG alone (Wang et al, 2009). Given the recent
availability of dual FAAH/MAGL inhibitors (Long et al, 2009; Niphakis et al, 2012),
simultaneous blockade of these enzymes following TBI may further reveal some insight
into the relationship between anandamide and 2-AG on TBI-induced cell death.
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Excitotoxicity. Previous efforts to attenuate the effects of excitotoxicity following
brain injury focused on NMDA receptor antagonists, presumably with the understanding
that the induction of depressed NMDA receptor function would counteract TBI-induced
excitotoxicity. This class of drugs showed promise in laboratory animal models of TBI
(Shohami et al, 1995), but failed to produce long-term beneficial outcomes in clinical
trials, despite some acute benefits of improved intracranial pressure and cerebral
perfusion pressure (Knoller et al, 2002; Maas et al, 2006). Research investigating
manipulations of the eCB system on glutamatergic functioning following TBI have thus
far focused primarily on 2-AG, and paradoxically, its effectiveness to protect the integrity
of glutamate receptor function.
Several studies investigating the effects of cannabinoids in laboratory animal
models of TBI have focused on expression changes of metabotropic (mGluR 1, mGluR5),
AMPA (GluA1, GluA2), and NMDA (GluN1, GluN2A, GluN2B) glutamatergic receptors.
Specifically, post-injury administration of the MAGL inhibitor JZL184 reversed TBIinduced reductions of GluN2A, GluN2B, and GluA1 receptor expression, but with no
impact on GluN1 or GluA2 receptors (Zhang et al, 2014). The CB1 receptor antagonist
Rimonabant did not alter injury-induced lowered expression of mGluR1, but surprisingly
reversed reduced mGluR5 receptor expression six weeks following TBI (Wang et al,
2016). Both findings were completed 30 days post injury (Wang et al, 2016; Zhang et al,
2014), suggesting long term changes in glutamatergic function following acute
administration of cannabinoids post-injury. However, little overlap is found between
receptor expression endpoints across papers. In an example of contradictory patterns of
GluA1 expression after injury, GluA1 expression was reduced in a study that subjected
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mice to a daily mild closed head injury on three consecutive days (Zhang et al., 2014),
and was increased in rats subjected to a single lateral fluid percussion brain injury
(Mayeux et al., 2016). In these studies, MAGL inhibition ameliorated both the reduced
(Zhang et al., 2014) and increased (Mayeux et al., 2016) GluA1 expression. As
discussed above (see Section 4), systematic investigation of species (mice vs. rat),
brain injury model, number of injuries, and other experimental variables are needed to
understand the consequences of brain injury on glutamate receptor changes.
eCBs are known to depress glutamate release from pre-synaptic terminals, and
in particular, 2-AG has been explored in its ability to influence the functioning of
electrochemical neurotransmission. MAGL inhibition has been found to protect against
injury-induced increases in frequency and amplitude of excitatory post-synaptic currents
(EPSC) in pyramidal neurons at the site of injury (Mayeux et al, 2016), which may
suggest changes in pre-synaptic transmitter release or post-synaptic strength (Zhang et
al, 2005). MAGL inhibition has also protected against injury-induced long term
potentiation (LTP) impairments at hippocampal CA3-CA1 synapses (Zhang et al, 2014),
implicating the restoration of glutamate receptor function in protection against TBIinduced memory impairments.
Finally, the excitotoxicity resulting from TBI is part of the sequelae of events that
lead to release of damaging ROS. Antioxidants are known to prevent oxidation of free
radicals and thus protect against the cellular damage in response to sudden ROS
elevation. Endocannabinoids have been linked to the neuroprotective production of
antioxidants as the administration of exogenous 2-AG following injury has been found
to increase levels of antioxidants (Panikashvili et al, 2006).
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Combined, these data suggest that MAGL represents a promising target to
reduce the damaging effects of injury-induced excitotoxicity through complementary
molecular pathways.
Neuroinflammation. Hydrolytic enzymes of anandamide and 2-AG produce a
shared metabolic product in the formation of free AA, the major substrate of the
biosynthetic enzymes of pro-inflammatory eicosanoids (Nomura et al, 2011). Therefore,
eCB oxidation not only produces inactivation at cannabinoid receptors, but also leads to
the production of bioactive lipids involved in inflammatory responses during the early
stages of injury. Manipulations of the endocannabinoid system have proved effective in
downregulating inflammation in many experimental models, such as inflammatory pain
(Ahn et al, 2009), and multiple sclerosis (Mestre et al, 2005). The use of cannabinoids
following TBI have thus far been linked to two predominant features of inflammation;
decreased inflammatory cell activation, and decreases in pro-inflammatory cytokine
production.
Pro-inflammatory activated microglia are known to exacerbate TBI-induced
neuroinflammation (Kigerl et al, 2009). Thus, decreasing TBI-inductions of inflammatory
cell activation is an attractive treatment strategy. MAGL inhibition protects against TBIinduced microglial activation (Katz et al, 2015; Zhang et al, 2014), while ABHD6
inhibition promotes microglia/macrophage shift from a pro-inflammatory M1 to an antiinflammatory M2 phenotype (Tchantchou and Zhang, 2013). A parsimonious
explanation for these findings is that prevention of 2-AG hydrolysis leads to reduced
levels of AA and concomitant reductions of pro-inflammatory mediators. Given the
contribution of 2-AG catabolism to eicosanoid production, it is unsurprising that several
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studies have reported eCBs as demonstrating pro-inflammatory roles, some examples
of which include models of nephropathy (Mukhopadhyay et al, 2010a), cardiomyopathy
(Mukhopadhyay et al, 2010b), and experimental dermatitis (Oka et al, 2006). Most of
such pro-inflammatory effects are attributed to 2-AG and not anandamide, likely due to
its considerable abundance over anandamide. However, FAAH inhibition, similarly has
been found to protect against TBI-induced microglial activation (Katz et al, 2015), as too
has activation of CB2 receptors (Amenta et al, 2012). Thus, a need exists to disentangle
the potential contributions of 2-AG to pro-inflammatory processes from its role as a
substrate for AA production, versus anti-inflammatory effects through cannabinoid
receptors, following TBI.
Inhibition of eCB degradative enzymes has also produced decreases in TBIinduced pro-inflammatory mediators. Reductions in the expression of inducible enzymes
that trigger eicosanoid production following brain injury, COX-2 enzyme (which converts
free AA to prostaglandins) and iNos (which produces the free radical nitric oxide in
response to cytokine signaling), are seen in response to ABHD6 inhibition (Tchantchou
and Zhang, 2013) and FAAH inhibition (Tchantchou et al, 2014). Reductions in TBIinduced pro-inflammatory cytokine mRNA (Il-1β, TNFα, and IL-6) have also been found
following treatment with exogenous 2-AG (Panikashvili et al, 2006). These findings
seem counter-intuitive given the possibility of the rapid oxidation of 2-AG and its
consequent contribution to eicosanoid production. However, exogenous 2-AG has also
been shown to ameliorate TBI-induced transactivation of the nuclear factor NF-kB
(linked to cytokine production) in wild type mice, but not in CB1 knockout mice,
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suggesting that CB1 receptors mediate the protective effects of exogenous 2-AG
(Panikashvili et al, 2005).
Cerebrovascular Breakdown. The blood vessels which carry oxygen rich blood
to the brain are lined by endothelial cells as well as astrocytes. These cells, combined
with specific transport proteins and enzymes, strictly regulate movement between the
general circulation and CNS extracellular fluid, and are collectively known as the blood
brain barrier (BBB). TBI has been well documented in producing cerebral blood flow
pathology (Kelly et al, 1997) as well as interfering with BBB integrity (Başkaya et al,
1997). Given that cannabinoids are known to exert vascular effects, producing
vasodilation as well as hypotension (reviewed in Hillard, 2000b), their manipulation may
hold promise as protectants against cerebrovascular damage. Below, we review studies
examining the effects of cannabinoids on TBI-induced disruption of BBB integrity.
Exogenous administration of 2-AG (Panikashvili et al, 2006), as well as MAGL
inhibition (Katz et al, 2015), and ABHD6 inhibition (Tchantchou and Zhang, 2013)
administered post-injury protect against BBB breakdown. However, Panikashvili et al.,
2006 found that the expression of proteolytic enzymes implicated in BBB breakdown
were unaffected by exogenous 2-AG post-injury. These enzymes include matrix
metallopeptidase-9 (MMP9) involved in extracellular matrix degradation, and tumor
necrosis factor-α-converting enzyme (TACE), which cleaves membrane-bound proteins.
The mechanism by which 2-AG acts as a protectant of BBB integrity following traumatic
insult is yet to be resolved.
One study found that post-surgery administration of a FAAH inhibitor protected
against BBB breakdown (Katz et al, 2015), suggesting that anandamide and/or other
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substrates of this enzyme play a protective role. While the mechanism underlying the
structural protection of the BBB was not explored following TBI, anandamide has been
found to decrease BBB permeability in a model of ischaemic stroke by transient
receptor potential cation channel, subfamily V, member 1 (TRPV1) (Hind et al, 2015).
Given that activation of TRPV1 receptors disrupts BBB integrity (Hu et al, 2005), it is
possible that anandamide, as a partial agonist at TRPV1 channels (Pertwee and Ross,
2002), maybe be acting as a functional antagonist against a high efficacy endogenous
agonist to produce its structurally protective effects of the cerebral microvascular
endothelium. The exploration of how anandamide may be exerting its protective effects
of BBB integrity may yet yield further novel targets for the treatment of TBI.
In cerebral circulation, CB1 receptor activation produces vasodilation. Indeed, the
CB1 receptor antagonist rimonabant inhibited hypotension induced by endotoxin shock
and hemorrhagic shock, as well as increasing survival (Varga et al, 1998). Though
cannabinoids are yet to be explored in the context of TBI-induced changes in cerebral
blood flow, CB1 receptor antagonism may prove to be a potential target for the
treatment of TBI-induced hypotension.
Cell Structure/Remodeling. The key biological idea that structure dictates
function also holds true for the neurophysiology of TBI. The shearing and tearing forces
of TBI and subsequent secondary injury cascades produce changes in cell architecture,
extracellular matrices, and the balance of fluid homeostasis, that impair neuronal
function often both in a focal and/or diffuse manner throughout the brain (Gaetz, 2004).
The use of cannabinoids has thus far been linked to protection against several of the
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CNS structural changes associated with TBI, with 2-AG being the most frequently
studied eCB in this area.
While a traumatic insult can result in the rapid onset of cerebral oedema,
exogenously administered 2-AG protects against TBI-induced oedema (Panikashvili et
al, 2001, 2005). The observation that no such oedema protection was found following 2AG administration in CB1 receptor-/- mice (Panikashvili et al, 2005) suggests that this
protection requires CB1 receptor activation. Changes in protein physiology have also
been found to occur following TBI. Specifically, the presence of protein aggregates such
as amyloid-β plaques (Johnson et al, 2010), hyperphosphorylated tau (p-tau) (Goldstein
et al, 2012), and TAR DNA-binding protein 43 (TDP-43) (Smith et al., 1999), have been
found within hours following TBI. These proteins are thought to accumulate from
damaged axons and as a result of a disturbed balance between genesis and catabolism
(Johnson et al, 2010). MAGL inhibitors decrease amyloid-β protein and its precursor
molecule amyloid precursor protein (APP), as well as p-tau and TDP-43 (Zhang et al,
2014). MAGL inhibition also decreases astrocyte activation (Mayeux et al, 2016), while
exogenous 2-AG following TBI reduces hippocampal CA-3 neuron loss (Panikashvili et
al, 2001). These consistent protective effects of 2-AG across varied TBI-related
structural pathologies point to its important role in maintaining cell structure and
promoting remodeling.
Protective roles played by anandamide in injury-induced structural changes are
yet to be ascertained. Though FAAH inhibition decreases APP expression post-injury,
as well as increases synaptophysin (Tchantchou et al, 2014), a synaptic vesicle protein
whose elimination impairs object recognition and spatial learning in mice (Schmitt et al,
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2009). Furthermore, eCBs may not be working alone to offer protection from TBIinduced structural impairments. For example, estradiol decreased the number of TBIinduced immunoreacitve astrocytes, which was inhibited by CB1 and CB2 receptor
antagonists, while also increasing cerebral cortex mRNA levels of CB2 receptors (Lopez
Rodriguez et al, 2011). These findings suggest that the regulatory activity of the eCB
receptors in response to TBI may be mediated by endocrine as well as paracrine
signaling mechanisms.
TBI is well described to increase CB1 and CB2 receptor expression, which
includes disruption of diurnal rhythms of CB1 receptor expression (Martinez-Vargas et
al, 2013). Post-injury treatment with a CB1 receptor antagonist reduces CB1 receptor
expression at 6 weeks following injury (Wang et al, 2016), whereas ABHD6 inhibition
produces increased CB1 and CB2 receptor expression (Tchantchou and Zhang, 2013).
As such, TBI-induced increases in cannabinoid receptor expression are perhaps
facilitated by 2-AG.
Neurogenic Pulmonary Oedema. Pulmonary complications are reported in 2025% of TBI patients (Holland et al, 2003), and its severity is related to brain injury
magnitude (Alvarez et al, 2015). The exact CNS circuits involved in neurogenic
pulmonary oedema (NPE) have yet to be identified, though a sudden rise in intracranial
pressure, rapid sympathetic surge, increased systemic vascular resistance and increase
in hydrostatic pressure in the pulmonary vasculature, as well as release of proinflammatory mediators may all contribute to interstitial pulmonary oedema formation
(Brambrink and Dick, 1997). NPE rapidly occurs within hours of TBI onset in clinical
populations (Alvarez et al, 2015), and within minutes in animal models (Atkinson et al.,
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1998), producing CNS hypoxia (Oddo et al, 2010) which further contributes to
secondary injury. NPE is a much needed area of interest in the study of TBI.
While at the present time there are no studies evaluating the contributions of, or
protection by, the eCB system to NPE following TBI, this may prove an interesting area
of future investigation. Specifically, the lung possesses a basal tone of 2-AG (Avraham
et al, 2008; Nomura et al, 2008), and recently it has been shown that resident lung
macrophages express major components of the eCB system, CB1 and CB2 receptors as
well as anandamide and 2-AG (Staiano et al, 2015). Furthermore, MAGL inhibition has
already been found to be protective against LPS-induced acute lung injury in mice, and
attenuated with CB1 and CB2 receptor antagonists (Costola-de-Souza et al, 2013).

Treatment of Behavioral Deficits of TBI
The heterogeneous clinical presentation of TBI pathology in populations of survivors is
reminiscent of its cellular and molecular pathophysiology described above. TBI patients
report changes in mental health (depression, irritability, anxiety, and personality
changes), sleep disturbance, post-traumatic headaches, persistent fatigue, epilepsy,
learning and memory deficits (manifested also as impairments in attention and
processing speed [Vakil, 2005]), and balance disorders (Stéfan et al, 2016). Most
frequently investigated measures in the pre-clinical TBI literature include neurological
motor, and learning and memory impairments, leaving a wide breadth of TBI clinical
effects yet to be studied. Once again, components of the eCB system may become
active to compensate for TBI symptomology given what is currently known of its
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regulatory effects within these areas, two examples being pain, and anxiety and
depression (Corcoran et al, 2015).
In this section, we review what is currently known of cannabinoids in the context
of their ability to alter post-traumatic animal behavior (see Table. 2).
Learning and Memory. Learning and memory impairments are among the most
frequently reported symptoms following TBI, and are slow to recover with deficiencies
reported ten years later (Zec et al, 2001). The eCB system has been shown to play a
well-documented role in memory regulation (reviewed in Mechoulam and Parker, 2011),
and as such its manipulation holds considerable promise to address such a profound
consequence of TBI.
Inhibition of the eCB hydrolytic enzymes FAAH (Tchantchou et al, 2014), MAGL
(Zhang et al, 2014), and ABHD6 (Tchantchou and Zhang, 2013) have been shown to
protect against TBI-induced memory impairments, suggesting that anandamide and 2AG elevation post-TBI may offer protection from TBI-induced learning and memory
deficits. The protective effects of 2-AG appear to be task specific, with ABHD6 inhibition
showing learning and memory protection in a Y-maze task, but not a Morris water maze
task. To date, only a Y-maze task has been used to evaluate the memory protective
effects of FAAH inhibition, and this task-specific effect did not occur with a MAGL
inhibitor. Mice are a well-used pre-clinical model organism to study the memory effects
of TBI; however, they are known to perform behavioral tasks more readily, and with less
error, when the task does not rely on aversive motivation (Stranahan, 2011). This
attribute of mice may, in some part, contribute to the task-related differences seen
between the Y-maze task (which uses exploratory behaviors associated with novelty)
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and the aversively motivated escape behavior necessary in the Morris water maze.
Regardless, in clinical populations the most common memory process vulnerable to TBI
involves difficulties applying active or effortful strategies in the learning or retrieval
process (Vakil, 2005). Moving forward, the use of behavioral tasks able to selectively
assess such frontal lobe-type memory impairments might improve the translational
capacity of eCB TBI pre-clinical assessments (one such example being the Morris water
maze Reversal Task, which evaluates cognitive flexibility).
Neurological Motor. TBI-induced neurological motor impairments currently
represent the most frequently studied behavioral outcome measure in the TBIcannabinoid literature. In clinical populations, neurological motor impairments seen as a
result of TBI show spontaneous improvement over time, but one third of patients
continue to experience neuromotor abnormalities two years after injury (Walker and
Pickett, 2007). A variety of eCB system manipulations have thus far been found to be
protective against the neurological motor deficits associated with murine models of TBI.
Both 2-AG and anandamide elevation provide protection against TBI-induced
neurological motor deficits. MAGL inhibitors (Katz et al, 2015; Mayeux et al, 2016;
Zhang et al, 2014), ABHD6 inhibitors (Tchantchou and Zhang, 2013), and exogenous 2AG administration (Panikashvili et al, 2001), improve Neurological Severity Score (NSS)
in laboratory animal models of TBI. Moreover, ABHD6 inhibition also protects against
TBI-induced rotarod deficits (Tchantchou and Zhang, 2013). Administration of
exogenous 2-AG did not enhance NSS scores in CB1 receptor knockout mice subjected
to TBI (Panikashvili et al, 2005), suggesting a CB1 receptor mechanism of action. FAAH
inhibition has produced mixed findings in neurological motor tests, such as beam-walk
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deficit protection (Tchantchou et al, 2014) but no improvement on TBI-induced NSS
deficits (Katz et al, 2015). In support of anandamide being protective against TBIinduced motor deficits, exogenous anandamide has also produced improved NSS
performance (Martinez-Vargas et al, 2013). Full reversal, and partial reversal, of FAAH
inhibitor mediated beam-walk deficit protection by respective CB2 and CB1 receptor
antagonists (Tchantchou et al, 2014), suggest a role of both of these receptors in
anandamide’s neuromotor deficit sparing effects. The involvement of the CB 2 receptor is
further supported by rotarod deficit protection from a CB2 receptor agonist (Amenta et
al, 2012).
The role of entourage effects has also been evaluated in the area of TBI-induced
neurological motor impairments. Co-release of endogenous fatty acid derivatives can
potentiate 2-AG signaling, termed an entourage effect (Ben-Shabat et al, 1998;
Lambert, D. M., Di Marzo, 1999; Lichtman et al, 2002). Administration of 2-AG with two
related lipids that do not bind cannabinoid receptors, 2-linoleoyl-glycerol (2-LG) and 2palmitoyl-glycerol (2-PG), enhances recovery from TBI-induced NSS deficits
(Panikashvili et al, 2001). Given FAAH is responsible for the degradation of various fatty
acid amides in addition to anandamide (Boger et al, 2000), its various substrates may
work in concert to ameliorate pathologies related to TBI. Thus any inferences drawn
about anandamide through the use of FAAH inhibition need to consider contributions of
noncannabinoid fatty acid amides.
Anxiety and Post-Traumatic Seizures. The signs of post-traumatic anxiety
have been difficult to replicate in murine models of TBI (Tucker et al, 2016). Also, as
there is a limited number of studies evaluating eCBs in this area, no definitive
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conclusions can be made. Thus far, only FAAH inhibition has been explored to address
post-traumatic anxiety, and was found to protect against TBI-induced increases in
anxiety-like behavior in mice (Tchantchou et al, 2014). This protection in the zero maze
was unaffected by either CB1 or CB2 receptor antagonists, suggesting that these
receptors are dispensable. Modeling post-traumatic epilepsy is time consuming and
faces other challenges such as a low percentage of animals that develop epilepsy
(Mazarati, 2006), however, recent models that produce consistent replication of
spontaneous seizure activity following a TBI are available (Ping and Jin, 2016). Contrary
to preclinical research demonstrating that the eCB system plays a protective roles
against seizures (Marsicano et al., 2003; Wallace et al., 2001), a CB1 receptor
antagonist has protected against injury-induced seizure threshold deficits as well as
lowered seizure mortality (Wang et al, 2016), potentially through the disinhibition of
GABAergic terminals.
This nascent body of data suggests that eCB manipulations hold promise to treat
injury-induced clinical symptoms outside of the more popular areas of learning and
memory and neurological motor impairments.

Primary Phytocannabinoids and Traumatic Brain Injury
Although currently well over one hundred phytocannabinoids have been elucidated from
the Cannabis Sativa plant (Elsohly et al, 2017), the most extensively studied of these
are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). The investigation of
phytocannabinoids on TBI pathology not only holds topical relevance, but also holds
promise as potential treatment for TBI and other disorders.
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Without exception, all of the experimental work reviewed and listed in Tables 1
and 2 have used post-injury drug administration times ranging from 15 minutes to
several days, clearly an attempt to simulate clinical intervention timing possibilities.
However, clinical and pre-clinical findings provide evidence suggesting that the primary
psychoactive constituent of Cannabis Sativa, THC, is neuroprotective when
administered prior to a traumatic insult. In a three year retrospective study of patients
who had sustained a TBI, urine toxicology screen results showed decreased mortality in
individuals with a positive THC screen (Nguyen et al, 2014a). In two mouse models of
CNS injury that yield cognitive deficits, pentylenetetrazole (an excitotoxic agent) and
carbon monoxide induced hypoxic injury, prior administration of THC provided
impairment protection (Assaf et al, 2011). Curiously, an extraordinarily low dose of THC
(i.e. 0.002 mg.kg-1) reduced injury-induced cognitive deficits in mice (Assaf et al, 2011).
The authors explained this effect through the known biphasic effects of THC producing
analgesia, acute hypothermia, and decreased locomotion at high doses (10 mg.kg -1),
and producing hyperalgesia, hyperthermia, and increased locomotion at a low dose
(0.002 mg.kg-1) (reviewed in Sarne et al., 2011). Such low dose effects of THC have
been found to potentiate calcium entry into cells in vitro (Okada et al., 1992), increasing
glutamate release, and thus may be mildly neurotoxic. Therefore, Assaf et al., 2011
hypothesized that low dose THC pre-treatment produced a pre-conditioning effect,
where a mildly noxious stimulus becomes protective against a more severe subsequent
insult, an effect known to occur in cardiology (Dirnagl et al, 2003) as well as cerebral
ischaemia (kitagawa et al., 1991). Moreover, the molecular signalling cascades behind
cardiac and cerebral ischaemia preconditioning include activation of ERK and Akt
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(Dirnagl et al, 2003; Gidday, 2006), also shown to mediate the protective effects of
ABHDB (Tchantchou and Zhang, 2013) and MAGL (Mayeux et al, 2016) inhibition
following TBI.
Even though 80-90% of THC is excreted from individuals within five days of
administration, the remaining slow release of lipophilic THC from lipid-storage
compartments result in its long terminal half-life in plasma (Huestis, 2007). As such,
individuals may experience very low plasma THC concentrations for prolonged periods
after each application. Although the clinical study of TBI-induced mortality reported no
data to quantify levels of THC in the THC positive individuals, the low dose THC in CNS
injured mice may mimic the pharmacokinetics of THC in humans. This presumed
prolonged exposure of THC due to its pharmacokinetics, as well as other potentially
neuroprotective cannabinoids, such as CBD (Perez et al, 2013), may be responsible for
the survival effects found in cannabis-exposed TBI patients. A finding of increased
clinical relevance, is that post-conditioning (when the mildly noxious stimulus is applied
after the insult) with low dose THC also produced cognitive sparing effects in mice
(Assaf et al, 2011). These findings, however, remain controversial, and are yet to be
replicated in animal models of TBI.
The phytocannabinoid CBD, currently being investigated in clinical trials for its
seizure reduction potential in Tuberous Sclerosis Complex (GW Research Ltd, n.d.),
has known anti-inflammatory properties. Although CBD does not bind CB1 and CB2
receptors, it activates the G-protein coupled receptor GPR55 (Ryberg et al, 2007),
inhibits nucleoside transporter 1 (Carrier et al, 2006), inhibits sodium channels (Hill et al,
2014), and produces increased extracellular adenosine concentrations that
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consequently downregulate inflammatory cells through the adenosine A 2A receptor
(Hasko and Pacher, 2008; Ohta and Sitkovsky, 2001). While there are no studies at
present which have investigated the anti-inflammatory effects of cannabidiol following
TBI, cannabidiol has reduced FosB expression following cryogenic spinal cord injury
(Kwiatkoski et al, 2012), and lowered iNos expression in a mouse model of tauopathy
(Casarejos et al, 2013). As such cannabidiol may be a promising future avenue of
investigation in the study of neuroinflammation in response to brain injury.

Concluding Remarks and Future Directions
The eCB system, through release of its endogenous ligands or by changes in
cannabinoid receptor constitutive activity, possesses promise in the treatment of diverse
TBI pathology. An important step forward in understanding the role that the eCB system
plays in TBI pathology includes not only the full characterization of ligands targeting
cannabinoid receptors and eCB regulating enzymes, but also changes in cannabinoid
receptors, eCB levels, and eCB regulating enzymes as a consequence of TBI. Another
future area of therapeutic interest is non-CB1/CB2 receptor targets, such as TRPV1
receptors, and their potential contribution to the protective effects following TBI.
Furthermore, alternative activation of CB1/CB2 receptors, such as potential entourage
effects from other fatty acid derivatives, antagonism, or allosteric modulation, might
impact functional selectivity and thus TBI-related outcomes also warrants further
investigation. So too do the plant-derived phytocannabinoids represent an understudied
yet promising group of compounds given the neuroprotective results obtained from
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other types of CNS injury. In particular, CBD as well as other phytocannabinoids which
do not bind cannabinoid receptors, represent promising molecules to treat TBI.
To date, the only reported cannabinoid to be specifically evaluated for the
treatment of TBI in patient populations is Dexanabinol, also known as HU211. While
HU211 showed promise in animal models of TBI (Shohami et al, 1995), it failed to
produce long term patient outcomes in one clinical trial despite some acute benefits
(Knoller et al., 2002), and in a second study showed no short or long term benefits
(Maas et al, 2006). Although HU211 has been described as a cannabinoid by virtue that
it is an enantiomer of the potent synthetic cannabinoid agonist HU210, it does not bind
or activate cannabinoid receptors. Instead, HU211acts as a non-competitive NMDA
receptor antagonist (Feigenbaum et al, 1989). This therefore brings to light an important
consideration of the classification of cannabinoids.
One consistently overlooked area across the study of TBI is the evaluation of the
central penetration of systemically administered drugs. Pharmacological treatments will
need to be assessed for their ability to cross the BBB. Also, it should be noted that TBI
rapidly disrupts the BBB and lasts for three days post-injury (Başkaya et al, 1997).
Furthermore, given the often biphasic nature of cannabinoid drugs, it is critical to move
away from single dose pharmacology to full dose-response assessments, which may
yield an increased understanding of the mechanism and potential of cannabinoids to
treat TBI. Overall, the abundant and growing pre-clinical research suggests that the
eCB system possesses many promising targets for new and existing drugs that may
ameliorate diverse TBI pathology.
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Table 1-1. Effect of cannabinoids on TBI-induced cellular and molecular
pathophysiology. Drug targets; CB2 receptor agonist (O-1966), FAAH inhibitor
(PF3845), MAGL inhibitors (JZL184 & URB597), ABHD6 inhibitor (WWL70), and CB 1
receptor antagonist (Rimonabant). TBI Models; CCI (controlled cortical impact), CHI
(closed head injury), and FPI (fluid percussion injury).

Compound
/ mutant

Dose

Species

TBI
Model/
Severity

Effect

Receptor
Mediated

References

↓ Neurodegeneration

CB2

Amenta et al., 2012

↓ Lesion volume
↓ Neurodegeneration
↑ Bcl-2, Hsp70 & 72
↓ Neurodegeneration

Not
evaluated

Tchantchou et al., 2014

Not
evaluated
CB1
CB1 & CB2

Zhang et al., 2014

CNS Cell Death
O-1966
PF3845

JZL184
WWL70

5 mg/kg,
i.p.
5 mg/kg,
i.p.

mouse
C57BL/6
mouse
C57BL/6

CCI,
moderate
CCI,
severe

10 mg/kg,
i.p.
10 mg/kg,
i.p.

mouse
C57BL/6
mouse
C57BL/6

CHI, mild
repetitive
CCI,
severe

Lateral
FPI,
severe
CHI,
severe
CHI, mild
repetitive

mGluR5 receptor
recovery at 6 wks (no
impact on mGluR1)
↑ levels of weak
antioxidants
Glutamate receptor
recovery
Injury-induced ↓ in LTP
protection

CB1

Wang et al., 2016

Not
evaluated
Not
evaluated

Panikashvili et al., 2006

↓ Lesion volume
↓ Neurodegeneration

Tchantchou & Zhang,
2013

Excitotoxicity
Rimonabant

2 mg/kg,
i.p.

2-AG

5 mg/kg,
i.p.
10 mg/kg,
i.p.

rat
SpragueDawley
mouse
Sabra
mouse
C57BL/6

16 mg/kg,
i.p.

rat
Wistar

Lateral
FPI, mild

GluA1 expression
protection
Injury-induced ↑ in
EPSC protection

Not
evaluated

Mayeux et al., 2016

mouse
C57BL/6
mouse
C57BL/6
mouse
C57BL/6
mouse
C57BL/6
rat
SpragueDawley
mouse
Sabra

CHI,
severe
CHI,
severe
CCI,
moderate
CCI,
severe
Lateral
FPI, mild

No effect on NF-κB
transactivation
No effect on NF-κB
transactivation
Microglial activation
protection
↓ COX-2 Expression
↓ iNos expression
Microglial activation
protection

N/A

Panikashvili et al., 2005

N/A

Panikashvili et al., 2005

CB2

Amenta et al., 2012

Not
evaluated
Not
evaluated

Tchantchou et al., 2014

CHI,
severe

↓ TNFα mRNA
↓ IL-1β mRNA
↓ IL-6 mRNA

Not
evaluated

Panikashvili et al., 2006

JZL184

Zhang et al., 2014

Neuroinflammation
CB1 -/-

N/A

CB1 -/- +
2-AG
O-1966

N/A

PF3845
URB597

2-AG

5 mg/kg,
i.p.
5 mg/kg,
i.p.
0.3 mg/kg,
i.p.
5 mg/kg,
i.p.
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Katz et al., 2015

Table 1-1. Continued
TBI
Model/
Severity

Compound
/ mutant

Dose

Species

2-AG

5 mg/kg,
i.p.

mouse
C57BL/6

CHI,
severe

↓ NF-κB translocation &
transactivation

JZL184

10 mg/kg,
i.p.

mouse
C57BL/6

CHI, mild
repetitive

↓ TNFα mRNA
Microglial activation
protection

Not
evaluated

Zhang et al., 2014

16 mg/kg,
i.p.

rat
SpragueDawley
mouse
C57BL/6

Lateral
FPI, mild

Microglial activation
protection

Not
evaluated

Katz et al., 2015

CCI,
severe

↓ COX-2 Expression
↓ iNos expression
M1 to M2 phenotype

Not
evaluated

Tchantchou & Zhang,
2013

Lateral
FPI, mild

BBB integrity protection

Not
evaluated

Katz et al., 2015

CHI,
severe
Lateral
FPI, mild

BBB integrity protection

Not
evaluated
Not
evaluated

Panikashvili et al., 2006

CCI,
severe

BBB integrity protection

Not
evaluated

Tchantchou & Zhang,
2013

Diurnal CB1 expression
abolished
↑ contralateral CB1 &
CB2 Expression
No effect on oedema

N/A

Panikashvili et al., 2005

No effect on oedema

N/A

Panikashvili et al., 2005

↓ CB1 Expression at 6
weeks post-TBI

CB1

Wang et al., 2016

↓ APP
↑ Synaptophysin
↓ CA3 neuron loss
Oedema protection

Not
evaluated

Tchantchou et al., 2014

WWL70

10 mg/kg,
i.p.

Effect

Receptor
Mediated

References
Panikashvili et al., 2005

CB1

Cerebrovascular Breakdown
URB597

0.3 mg/kg,
i.p.

2-AG

5 mg/kg,
i.p.
16 mg/kg,
i.p.

JZL184

WWL70

10 mg/kg,
i.p.

rat
SpragueDawley
mouse
Sabra
rat
SpragueDawley
mouse
C57BL/6

BBB integrity protection

Katz et al., 2015

CNS Cellular Structure/Remodeling
Vehicle
(saline-5%
ETOH)

4 µL

rat
Wistar

CHI,
moderate

CB1 -/-

N/A

CB1 -/- +
2-AG
Rimonobant

N/A

PF3845

5 mg/kg,
i.p.
5 mg/kg,
i.v.

mouse
C57BL/6
mouse
C57BL/6
rat
SpragueDawley
mouse
C57BL/6
mouse
Sabra

CHI,
severe
CHI,
severe
Lateral
FPI,
severe
CCI,
severe
CHI,
severe

5 mg/kg,
i.p.
10 mg/kg,
i.p.

mouse
C57BL/6
mouse
C57BL/6

CHI,
severe
CHI, mild
repetitive

Oedema protection

CB1

Panikashvili et al., 2005

↓ APP
↓ Amyloid-β peptide
↓ TDP-43 & p-tau

Not
evaluated

Zhang et al., 2014

16 mg/kg,
i.p.

rat
SpragueDawley
mouse
C57BL/6

Lateral
FPI, mild

↓ astrocyte activation

Not
evaluated

Mayeux et al., 2016

CCI,
severe

↑ CB1 & CB2
Expression

Not
evaluated

Tchantchou & Zhang,
2013

2-AG

JZL184

WWL70

2 mg/kg,
i.p.

10 mg/kg,
i.p.

32

Martinez-Vargas et al.,
2013

Panikashvili et al., 2001
CB1

Table 1-2. Effect of cannabinoids on TBI-induced behavioral impairments. Drug
targets; CB2 receptor agonist (O-1966), FAAH inhibitor (PF3845), MAGL inhibitors
(JZL184 & URB597), ABHD6 inhibitor (WWL70), and CB1 receptor antagonist
(Rimonabant). TBI Model definitions; CCI (controlled cortical impact), CHI (closed head
injury), and FPI (fluid percussion injury).
Compound/
mutant

Dose

Species

TBI
Model/
Severity

Effect

Receptor
Mediated

References

mouse
C57BL/6
mouse
C57BL/6
mouse
C57BL/6

CCI,
severe
CHI, mild
repetitive
CCI,
severe

Y-maze deficit
protection
MWM deficit reduction

CB1
Partial CB2
Not
evaluated
Not
evaluated

Tchantchou et al., 2014

mouse
C57BL/6
mouse
C57BL/6
mouse
C57BL/6
rat
Wistar
mouse
C57BL/6
rat
SpragueDawley
mouse
Sabra
mouse
Sabra
mouse
C57BL/6

CHI,
severe
CHI,
severe
CCI,
moderate
CHI,
moderate
CCI,
severe
Lateral
FPI, mild

Impaired NSS score

CB1

Panikashvili et al., 2005

Impaired NSS score

CB1

Panikashvili et al., 2005

Rotarod deficit
protection
Improved NSS score

Not
evaluated
Not
evaluated
Partial CB1
CB2
Not
evaluated

Amenta et al., 2012

CHI,
severe
CHI,
severe
CHI, mild
repetitive

Improved NSS score

Not
evaluated
Not
evaluated
Not
evaluated

Panikashvili et al., 2001

16 mg/kg,
i.p.

rat
SpragueDawley

Lateral
FPI, mild

Improved NSS & NBS
score, out to 1 d

Not
evaluated

Katz et al., 2015

16 mg/kg,
i.p.

rat
SpragueDawley
mouse
C57BL/6

Lateral
FPI, mild

Improved NSS & NBS
score, out to 14 d

Not
evaluated

Mayeux et al., 2016

CCI,
severe

Improved NSS score
Rotarod deficit
protection

Not
evaluated

Tchantchou & Zhang,
2013

Learning and Memory
PF3845
JZL184
WWL70

5 mg/kg,
i.p.
10 mg/kg,
i.p.
10 mg/kg,
i.p.

Y-maze deficit
protection
No impact on MWM
deficit

Zhang et al., 2014
Tchantchou & Zhang,
2013

Neurological Motor Deficits
CB1 -/-

N/A

CB1 -/- +
2-AG
O-1966

N/A

Anandamide
PF3845
URB597

2-AG
2-AG + 2-PG
+ 2-LG
JZL184

WWL70

5 mg/kg,
i.p.
1.25 µg/4
µL, ICV
5 & 10
mg/kg, i.p.
0.3 mg/kg,
i.p.
5 mg/kg,
i.v.
1 mg/kg,
i.v.
10 mg/kg,
i.p.

10 mg/kg,
i.p.

Beam-walk deficit
protection
No impact on NSS or
NBS

Improved NSS score
Improved NSS score
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Martinez-Vargas et al.,
2013
Tchantchou et al., 2014
Katz et al., 2015

Panikashvili et al., 2001
Zhang et al., 2014

Table 1-2. Continued
Compound/
mutant

Dose

Species

TBI
Model/
Severity

Effect

Receptor
Mediated

References

mouse
C57BL/6

CCI,
severe

Zero-maze anxiety-like
profile protection

No CB1,
CB2
reversal

Tchantchou et al., 2014

rat
SpragueDawley

Lateral
FPI,
severe

Protective against
seizure threshold
deficits
Lowered seizure
mortality

CB1

Wang et al., 2016

Anxiety-Like Behavior
PF3845

5 & 10
mg/kg, i.p.

Post-Traumatic Seizures
Rimonabant

2 mg/kg,
i.p.
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Figure 1-1. Endocannabinoid System Cell Localization by CNS Cell Type.
Endocannabinoid functional specialization among CNS cell types is determined by the
cellular compartmentalization of biosynthetic and catabolic enzymes (biosynthesis by
NAPE and DAGL-α, -β, catabolism by FAAH and MAGL). Cellular level changes in eCB
biosynthetic and catabolic enzymes as a result of brain injury have yet to be
investigated, though morphological and molecular reactivity by cell type is well
documented.
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Figure 1-2. Enzymatic regulation of anandamide and 2-AG in normal brain, and
following traumatic brain injury. 2-AG levels are approximately 1,000 fold higher than
anandamide levels in brain. MAGL plays a rate-limited role in the production of AA in
brain, lung, and liver (Nomura et al, 2008). Arrows represent known TBI-induced
changes in eCBs, catabolic and downstream enzymes, and their metabolic products
(arrow size has no relation to magnitude of change).
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Dissertation Goals
In light of the evidence that endocannabinoids both regulate processes of learning and
memory and are produced in response to pathogenic events, it is likely their important
contributions to memory function extend to conditions of memory pathology. As such,
the present dissertation project had three goals. The first goal being to establish a
preclinical mouse model of TBI-induced cognitive deficit, second to target diacylglycerol
lipase-β (DAGL-β) as a novel target for the reduction of TBI-induced cognitive
impairment, and the third and final goal was to understand the role of diacylglycerol
lipase-α (DAGL-α) in spatial learning and memory regulation under physiological
conditions.
The initial method development investigated functional deficits following TBI in
mice using the fluid percussion injury model, as measured by spatial memory tasks of
the Morris water maze and tasks of neurological motor impairment, as well as cellular
changes evaluated in both histological outcomes and morphological changes to resident
immune cells of the CNS. The development of this procedure and evaluation of these
outcome measure differences following a left or a right unilateral insult, are described
and discussed in Chapter 2.
Manipulations of endocannabinoid biosynthetic pathways may further reveal their
role in compensatory repair pathways. The selective expression of diacylglycerol lipaseβ (DAGL-β) on resident immune cells of the CNS (microglia) and the role of 2-AG as a
precursor for the production of pro-inflammatory eicosanoids, drove the consideration of
this 2-AG biosynthetic production enzyme contribution to neuroinflammatory responses
to TBI. Therefore a second goal of this dissertation was to focus on DAGL-β as a novel
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target for the reduction of mouse TBI-induced cognitive impairment. Our working
hypothesis was that disrupting DAGL-β activity would provide cognitive protection
following brain injury by reducing pools of 2-AG metabolites (AA and pro-inflammatory
eicosanoids) in microglia, and was funded by an F31 grant (1F31NS095628-01A1).
These studies were conducted using the in vivo measures described in Chapter 2. An
unexpected finding that DAGL-β disruption produced a survival phenotype following
TBI, led us to continue the evaluation of this mortality protective effect. All of which is
described in Chapter 3.
The neuronal expression of diacylglycerol lipase-α (DAGL-α), the second of two
2-AG biosynthetic enzymes, drove the consideration of this enzyme contribution to the
normal regulation of learning and memory processes. Therefore the third and final goal
of this dissertation was to understand the in vivo role of DAGL-α in spatial learning and
memory regulation in mice. This set of studies used complementary genetic and
pharmacological approaches to investigate the role of DAGL-α in various hippocampaldependent memory processes. The dissertation concludes with a discussion of the
overall implications of the entirety of these studies, as well as future directions.
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Chapter II
Chapter Introduction

The first goal of this dissertation was to establish a preclinical mouse model of TBIinduced cognitive dysfunction using the fluid percussion injury model, and learning and
memory evaluation by the Morris water maze.
Memory dysfunction following TBI. TBI frequently results in a heterogeneous
range of persistent comorbidities, with symptoms ranging from psychological (e.g.
personality changes, anxiety, irritability, depression), to physiological (e.g. epilepsy,
sleep disturbance, headache), motor (e.g. balance disorders), and cognitive deficits
(e.g. impaired learning and memory). Learning and memory specifically is one of the
most commonly experienced, and quality of life impacting impairments, following brain
injury. Both retrograde amnesia (loss of event memory prior to TBI onset) and deficits in
prospective memory (remembering to perform previously planned actions) are
commonly reported following brain injury (Carlesimo et al, 1997; Groot et al, 2002).
While very few experience global amnesia (total disruption of short term memory and
impaired access to long term memory) after a TBI, the most commonly reported
vulnerable memory processes include difficulties applying effortful strategies in learning
and retrieval (Vakil, 2005) reminiscent of deficits associated with frontal lobe damage
(della Rocchetta, 1986). Explicit memory (conscious recollection) is widely affected by
TBI, with deficits seen in working memory tasks (Christodoulou et al, 2001; Stablum et
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al, 1994) (during which neural activity becomes more bilateral and dispersed
(Christodoulou et al, 2001), verbal and visual memory deficits (Zec et al, 2001),
impaired learning rate (Zec et al, 2001), and accelerated forgetting rate (Haut et al,
1990). Implicit memory (unconscious and procedural memory) is less consistently
impacted, with well-practiced skills acquired prior to TBI being resistant to injury
induced-impairments (Schmitter-Edgecombe and Nissley, 2000), whereas performance
acquiring new skills post-TBI can be task and injury severity dependent (Vakil, 2005).
Other cognitive domains which in turn affect learning and memory such as attention
(Oddy et al, 1985) and processing speed (Ferraro, 1996) are also frequently negatively
impacted by TBI.
While patients suffering from TBI are not an ideal group to study brain regionbehavior relationships (given the widespread diffuse pathophysiology of TBI), there is a
great need to further understand the selective memory processes affected, as well as
identify novel treatments.
Spatial memory evaluation in mice. To evaluate our primary functional
endpoint, TBI-induced learning and memory deficits, we chose to use spatial memory
tasks of the Morris water maze (MWM). The MWM was first described over 30 years
ago (Morris, 1981) as a model to investigate spatial learning and memory in rats. It has
since been used extensively in behavioral neuroscience, but has also become a well
characterized tool in the study of memory impairments following TBI. Mice have been
repeatedly and successfully used in the MWM, an important adaptation from its original
design using rats, given the utility of transgenic mouse models. However, MWM
performance is affected by mice strain differences. Injured C57BL/6 mice have been
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found to demonstrate deficits in learning compared to their sham controls, whereas
sham controls for 129/SvEMS and FVB/N strains could not acquire the task (Fox et al,
1999). Thus C57BL/6 mice are a useful strain for the study of TBI-induced MWM
impairments.
The MWM is considered a test of spatial memory given it is hippocampaldependent, particularly sensitive to the effects of hippocampal lesions (Morris, 1984).
While alternative hippocampal-dependent learning and memory tasks have been
characterized (e.g. the object in place paradigm; Mitchnick et al, 2016), a unique utility
of the MWM is the number of task variations that can be used to study distinct memory
processes. The fixed platform task is used to assess the acquisition of memory, the
reversal task evaluates cognitive flexibility (a form of fluid intelligence whereby inhibitory
responses are required to explore alternative solution paths, increasing cognitive
demands), and the cued task is used to control for sensory-motor and motivational
confounds (Vorhees and Williams, 2006); are but some examples of such task
variations. As such the MWM is a useful and adaptable tool to study the various types of
memory impairments that brain injury can produce.
Neurological-motor evaluation in mice. Measures of neurological impairment
can also be useful when administered following brain injury as a correlate of injury
severity (Tsenter et al, 2008). We chose to utilize both the Neurological Severity Score
(NSS) assessment and the Rotarod assay to corroborate injury severity between and
within cohorts, but also as control measures to assess motor impairments during
learning and memory assay conditions. The NSS is a neurological motor impairment
assessment battery specifically for mice (Beni-Adani et al, 2001), widely used in pre-
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clinical studies of TBI. The Rotarod is a measure of motor coordination with specific
sensitivity to murine models of TBI (Hamm et al, 1994). While the Rotarod assay itself
requires motor learning processes, the presently used accelerating schedule is
designed to evaluate motor performance while minimizing motor skill learning (Jones
and Roberts, 1968).
Traumatic brain injury induction. The fluid percussion injury (FPI) model of
traumatic brain injury has been extensively used in murine pre-clinical models, where by
an injury is induced by striking a fluid-filled column secured to the exposed dura of the
animal. A FPI creates a mixed focal and diffuse axonal injury (Dixon et al, 1987), which
replicates key features of clinical head injury, and produces motor and memory deficits
commonly seen in clinical cases of TBI (Hamm, 2001).
A unique utility of the FPI is its adaptability in terms of scalable injury severity as
well as injury location. The severity of a FPI can be manipulated by raising or lowering
the height from which the mallet (which strikes the fluid-filled column) is released. Injury
severity is measured by pressure transduction via an oscilloscope, as well as assessed
using standardized outcome measures relating to the status of the animal, such as
righting time, and the previously mentioned neurological motor assessments. The unit of
pressure used to evaluate the injury magnitude (atmospheres (atm), with 1 atm = 14.70
pounds per square inch) is relatable to a category of injury severity (mild, moderate,
severe), though no current standardization exists in the literature. For the purpose of the
present work in mice, a mild FPI is considered <1.5 atm (Spain et al, 2010), a moderate
FPI is considered 1.5 to 2.0 atm (Mukherjee et al, 2013), and a severe FPI is
considered > 2.0 atm (Bolkvadze and Pitkanen, 2012). Further ways to adapt the FPI
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include changing the position of the craniectomy, commonly positioned for either a
central injury (directly
over the sagittal suture
and in between bregma
and lambda) or as
either a right or a left
lateral injury
(craniectomy positioned
approximately 1 mm to
the left or right of the
sagittal suture, between
bregma and lambda).
The lateral FPI is
commonly used (Van
and Lyeth, 2016) and

Figure 2-A: Example of a mouse left-lateral craniectomy
position. Pictured is a DAGL-β transgenic mouse (mixed
background), in a stereotaxic surgical frame under gaseous
isoflurane anesthesia (2.7%, 250 mL/min). Ophthalmic
ointment is applied to the eye area, and iodine and ethanol
sterilized soft tissue prior to the surgical incision.

produces degenerative
cascades in selectively vulnerable brain regions, including the ipsilateral hippocampus
(Hicks et al, 1996). An initial central mild (1.4 atm) FPI produced no change in our
mouse learning and memory assessment behaviors (data not included). This finding
prompted an increase in injury severity, and due to concerns over survivability of a
central moderate FPI, a change to a lateral injury. Both left and right lateral injuries were
then evaluated at a moderate (1.92 atm) injury severity following which modest but
distinct differences in learning and memory assessment performance was noted.

43

Lateralization of brain function. The medial longitudinal fissure separates the
human brain into two distinct cerebral hemispheres with subcortical structures
frequently occurring in duplicate “mirrored” in the left and right hemispheres.
Accordingly, neural functions and cognitive processes (e.g. language; Gazzaniga and
Sperry, 1967) are frequently more dominant in one hemisphere than the other; referred
to as lateralization of brain function. It has long been posited that such functional
lateralization is beneficial, and more recently greater functional lateralization has been
associated with improved cognitive ability (Gotts et al, 2013). Indeed, lateralization of
higher order brain functions has been well described in humans, with the left
hemisphere being dominant for language processing and the right for visuospatial
attention (Hutsler and Galuske, 2003). The hippocampus also demonstrates
lateralization with increased left hippocampal activity occurring in response to task
relevant semantic information, whereas increased right hippocampal activity occurs
from spatial information (Motley and Kirwan, 2012). Left-right hippocampal structures
also support complementary functions in human episodic memory (Iglói et al, 2010).
These unilateral specializations have been speculated to increase efficiency in available
circuitry (Shipton et al, 2014), though the mechanisms by which bilateral neural
structures support differences in cognitive function across hemispheres remains
unknown. Evidence continues to mount in favor of lateralization of function not being a
uniquely human characteristic, with left-right differences in neural processing also being
widespread among vertebrates (Halpern et al, 2005).
Summary. The following work evaluates differences in functional outcome
following a left or a right unilateral insult in mice, specifically; spatial memory tasks of
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the MWM and tasks of neurological motor impairment, as well as cellular changes
evaluated in both histological outcomes and morphological changes to resident immune
cells of the CNS. This initial method development of mouse spatial learning and
memory deficits following TBI thus also investigates functional lateralization and
considers its relevance to pre-clinical models of injury-induced cognition dysfunction.
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Investigation of Left and Right Lateral Fluid Percussion Injury in C57BL6/J Mice:
In Vivo Functional Consequences
(Neurosci Lett 653: 31-38, 2017)
Disclosure: all glial reactivity immunohistochemistry experiments were conducted in the
laboratory of Dr. Linda Phillips, primarily by Dr. Linda Phillips and Nancy Lee.

Introduction
The fluid percussion injury model of traumatic brain injury (TBI) in laboratory animals
elicits functional and pathophysiological hallmarks of human TBI, including cognitive
dysfunction, intracranial haemorrhage, oedema, and progressive grey matter damage
(Graham et al, 2000). Originally developed as a midline injury in cats (Hayes et al,
1987) and rabbits (Hartl et al, 1997), a lateral fluid percussion injury was used in rats
(McIntosh et al, 1989), and further adapted for mice (Carbonell et al, 1998), now widely
used given the utility of transgenic lines. Lateral fluid percussion injury produces a
combined focal cortical contusion and diffuse subcortical neuronal injury in rats (Hicks et
al, 1996), the extent and location of which is subject to small changes in craniotomy
position (Vink et al, 2001). It is noteworthy that small alterations in craniotomy position
in rats lead to differences in cognitive performance (Floyd et al, 2002). In mice, left
(Tchantchou and Zhang, 2013; Fox et al, 1999) and right (Carbonell et al, 1998; Spain
et al, 2010) craniotomy placement generally differs across research groups; however,
there are no systematic studies investigating craniotomy position on measures of
learning and memory or motor effects in mice.
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Several lines of evidence suggest existence of left-right hemisphere molecular
(Kawakami et al, 2003; Shinohara and Hirase, 2009), morphological (Kawakami et al,
2003; Shinohara et al, 2008), and functional differences (Kohl et al, 2011; Shipton et al,
2014) at hippocampal synapses in mice. Left-right morphological differences exist in the
mouse hippocampus where left originating CA3 inputs innervate small spines, whereas
inputs originating from the right CA3 innervate larger, mushroom-shaped spines
(Kawakami et al, 2003; Shinohara et al, 2008). The molecular composition of these
smaller spines also differ, exhibiting a higher density of GluN2B subunits in postsynaptic
spines receiving left CA3 input (Kawakami et al, 2003; Wu et al, 2005). Morphological
differences; size of left infrapyramidal mossy fiber projections, also positively correlate
with precision in swimming navigation (Bernasconi-Guastalla et al, 1994). Furthermore,
long-term potentiation (LTP) reveals hemispheric specialization in which LTP induction
of CA3 synaptic inputs to CA1 when input originates from the left, but not the right CA3,
using spike timing-dependent LTP (Kohl et al, 2011), or conventional high-frequency
stimulation-induced LTP (Shipton et al, 2014). Similarly, in behaving mice silencing of
left, but not right, CA3 pyramidal neurons resulted in Y-maze task deficits (Shipton et al,
2014), and inversus viscerum mice (bred to express only a right phenotype at CA3-CA1
synapses) exhibited dry maze task deficits (Goto et al, 2010).This evidence of structural
and behavioral hemispheric differences raises the question of whether left versus right
hemisphere TBI will reveal differing patterns of cognitive deficits.
The Morris water maze (MWM) is frequently used to assess TBI-induced spatial
learning and memory impairments. Although hippocampal lesions (Gerlai et al, 2002) or
TBI (Fox et al, 1999) severely impairs MWM performance, mice with bilateral
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hippocampal lesions are still able to improve their performance (Gerlai et al, 2002).
Accordingly, MWM performance may employ brain areas in addition to the
hippocampus, such as the striatum (Whishaw et al, 1987), basal forebrain (Waite et al,
1994), insular cortex (Gutiérrez et al, 1999), etc. making this task a useful model to
study the functional consequences of a lateralized brain injury in mice. MWM task
variations are also used to infer the underlying processes affecting performance. Here,
the Fixed Platform task assesses reference memory acquisition, and the reversal task;
cognitive flexibility. Moreover, the Cued task, where the location of the hidden platform
is made visible, infers sensorimotor and motivational influences. Based on the
established left-right molecular and morphological asymmetry in the mouse
hippocampus, we examine whether unilateral TBI of the left and right hemisphere will
elicit differential patterns of spatial memory and motor deficits in mice.

Materials and Methods
Mice. All experiments used adult male C57BL/6J mice (Jackson Laboratories,
Bar Harbor, Maine), left injury (n=10), left sham (n=10), right injury (n=8), right sham
(n=7), (further described in the supplement), and complied with EC Directive
86/609/EEC, conducted in accordance with the National Institute of Health (NIH) Guide
for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978),
and were approved by the Virginia Commonwealth University Institutional Animal Care
and Use Committee.
Craniotomy and Induction of Lateral Fluid Percussion Injury (FPI). Under
isoflurane anesthesia (2.5%, 250 mL/min) a sagittal scalp incision was made and a 2.7
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mm trephine craniectomy performed over the left or right parietotemporal cortex, further
description of which is included in the supplement. After a 2 h recovery period, mice
were anesthetized with isoflurane (4%, 400 mL/min) and immediately subjected to a
moderate lateral fluid percussion injury (1.94±0.1 atm left lateral, 1.92±0.1 atm right
lateral injury), described in the supplement.
Neurological Motor Impairment Evaluation. Mice were evaluated in Rotarod
and Neurological Severity Score, 2 days prior to injury, and 1, 2, 3, 7, 14 and 21 days
post-injury (see Figure 2-1). Single Rotarod (IITC Life Science Rota-Rod, Woodland
Hills, CA, with 3 cm diameter rotating drums) trials per day used an accelerating
protocol, a description of which appears in supplementary information. A 10-point
Neurological Severity Score (NSS) assessed the functional neurological status of mice
based on the presence of reflexes and the ability to perform motor and behavioral tasks
(see Supplementary Table 2-1). Further description appears in supplementary
information.
Learning and Memory Assessment. The MWM consisted of a circular,
galvanized steel tank (1.8 m in diameter, 0.6 m height) filled with opaque water
(maintained at 20ºC±2ºC) with a submerged platform (10 cm diameter) and distal and
proximal visual cues, further described in the supplement. A description of the Fixed
Platform, Reversal, and Cued Tasks also appears in supplementary information, (see
Figure 2-1).
Histology and Lesion Volume Quantification. Animals were anesthetized,
transcardially perfused with paraformaldehyde and brains extracted. Brains were
sectioned (50μm thickness) on a Leica VT1000S vibratome, Nissl stained using cresyl
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violet acetate, and digitally imaged. Microscopy was performed at the VCU Department
of Anatomy and Neurobiology Microscope Facility. Further detail and the lesion volume
quantification description appears in supplementary information.
Qualitative Assessment of Glial Cell Response to Injury.
Immunohistochemistry (IHC) was performed in left and right injured and sham animals
(n=3/group) surviving for 3 days post-injury. Mice were perfused as described for
histology and 40 µm coronal brain sections cut by vibratome were processed for IHC
(Reeves et al, 2016) using antibodies for IBA1 (Wako, Abcam; 1:300), and GFAP
(Dako, Encor Biotechnology; 1:20,000). Images were collected on a Zeiss 700 confocal
microscope for qualitative assessment of each protein.
Statistical Analysis. Differences were considered significant when P < 0.05, and
analyses were conducted using IBM SPSS Statistics 22 (IBM Software, New York, NY).
To assess TBI-induced changes to MWM performance, mean latency-to-goal (seconds)
in left and right injury was compared to left or right sham, respectively. To directly
compare the effects of right vs. left injury, mixed-factor ANOVA analyses were also
conducted on MWM latencies normalized as percent-of-sham-control (using the
corresponding hemisphere right and left sham group: injured animal score / mean sham
score * 100%). This normalization approach increases sensitivity to detect the effects of
TBI and reduces the influence of minor sham control differences (Townend, 2013).
Normalized data were also analyzed using a one sample t-test to compare left or right to
sham performance (value of 100). Motor differences and MWM acquisition were
analyzed using a mixed factor ANOVA, probe trial measures by independent group ttest, and righting times and lesion volume by 2-way ANOVA. Post hoc tests for MWM
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acquisition (Fixed Platform and Reversal tasks) were conducted using a Bonferroni
adjustment, and for NSS and Rotarod used a Tukey HSD adjustment.

Results
Left and right hemisphere injury produced neurological motor deficits.
NSS Measure. NSS scores increased for left and right lateral injury on post-injury day
one. A significant interaction for both left (Figure 2-2A), F(6, 108) = 11.93, P < 0.001;
and right lateral (Figure 2-2C) NSS, F(6, 78) = 2.39, P < 0.05, revealed an increased
NSS in both left and right lateral injured animals on post-injury day 1 (P < 0.01)
compared to day -1, not present in both left and right lateral sham animals.
Rotarod measure. Both left and right lateral Injury produced impaired rotarod
performance, with no left-right performance differences. A significant interaction for both
left lateral (Figure 2-2B), F(7, 126) = 2.47, P < 0.05; and right lateral (Figure 2-2D)
latency to fall, F(7, 91) = 2.54, P < 0.05, revealed a significant decrease in latency to fall
compared to sham in left lateral injury on post-injury day 1 (P < 0.01), and in right lateral
injured animals on post-injury days 1 (P < 0.01), 2 (P < 0.05), 3 (P < 0.05), day 7 (P <
0.05), and 14 (P < 0.05). Direct comparison of left and right cohorts on percent of sham
control revealed no significant interaction (Figure 2-2E) P = 0.10, with no main effect of
hemisphere P = 0.47 in latency to fall.
Both left and right lateral injury produced MWM task deficits, with modest
left-right hemisphere differences. Fixed Platform Task. The right lateral injury group
showed a small but significant delay in the acquisition of reference memory compared
to sham; and poorer performance compared to left injured animals. Both left and right
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lateral injured mice demonstrated reference memory expression impairments. The
acquisition of reference memory showed no significant interaction for left lateral (Figure
2-3A) P = 0.75; or right lateral (Figure 2-3B) P = 0.88 injuries. A significant main effect
of injury was found for the right lateral cohort, F(1, 13) = 10.05, P < 0.01, but not left (P
= 0.15), where the right lateral injured animals demonstrated longer latencies to the
platform than sham animals. A comparison of normalized left-right acquisition
performance revealed a significant main effect of hemisphere, F(1, 16) = 7.87, P< 0.05,
indicating greater acquisition deficits in the right lateral cohort compared to the left
(Figure 2-3C), while the Injury X Day interaction was not significant (P=0.07). The fixed
platform probe trial revealed significantly longer latencies to the platform location in
injured mice compared to sham animals for both left (Figure 2-3D), t(18) = 2.41, P <
0.05, and right lateral injuries (Figure 2-3E), t(13) = 3.17, P < 0.01. Analyses of
normalized probe trial measurements confirmed injury-induced increases in mean
latency for both left, t(9) = 3.16, P< 0.05, and right, t(7) = 3.74, P< 0.01, cohorts relative
to sham levels (one sample t-test), although normalized latencies did not differ between
hemispheres (P=0.16, independent samples t-test).
Reversal Task. No left vs. right performance differences were found in reversal
task learning, however left lateral injury demonstrated modest impairments relative to
sham in reversal acquisition and expression. Reversal acquisition learning revealed no
significant interaction for either left lateral (Figure 2-4A), P = 0.92; or right lateral (Figure
2-4B), P = 0.39; injury. However, a main effect of injury was found for the left lateral
injury cohort, F(1, 18) = 7.93, P < 0.05, but not right, F(1, 13) = 1.89, P = 0.19, where
left injured animals demonstrated longer latencies to the platform than sham animals.
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Direct comparison of left and right injury revealed no significant interaction (Figure 2-4C)
P = 0.39, and no significant main effect of hemisphere P < 0.28 on percent of sham
control. The reversal probe trial revealed significantly longer latencies to the new
platform location in left lateral injured mice compared to sham animals (Figure 2-4D),
t(18) = 2.75, P < 0.05, and but not right (Figure 2-4E), P = 0.37. Direct comparison of
left vs. right injury normalized reversal probe trial latencies, showed performance did not
differ between these injury groups (P=0.17, independent samples t-test), although the
left, t(9) = 2.90, P< 0.05, but not right (P=0.22), injury group differed from sham levels
(one sample t-test) (Figure 2-4F).
Cued Task and Swim Speed. The injury-induced MWM performance impairments
were likely not due to sensory-motor or motivational impairments measured by the Cued
Task (Supplementary Figure 2-1), or swim speed (Supplementary Figures 2-2 and 2-3).
Injury severity and histological outcome in left and right hemisphere injury
groups. The injury procedure produced a mortality rate of 20.8% for the left lateral
cohort, and 22.7% for the right lateral cohort (dead mice were excluded from all
subsequent measures).
Righting Time. Neither the interaction between hemisphere and injury (Figure 25A, 2-5D), P = 0.84, nor the main effect of hemisphere, P = 0.79, achieved significance;
however, a main effect of injury, F(1, 31) = 44.58, P < 0.001, showed longer righting
times in injured animals than shams.
Lesion Volume Percentage. Neither the injury by hemisphere interaction (Figure
2-5B, 2-5E), P = 0.53, nor main effect of hemisphere, P = 0.86, achieved significance;
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however, there was a main effect of injury, F(1, 12) = 23.08, P < 0.001, in which lesion
volumes were significantly larger in injured animals than in shams.
Hippocampal glial cell response to left and right hemisphere injury.
Hippocampal IHC of microglial (IBA1) and astrocytes (GFAP) showed robust glial
response to TBI. IBA1 imaging in the dentate gyrus revealed prominent shift from
ramified microglial phenotype in sham brains (Figure 2-6A), to a reactive state with
larger cell bodies and multiple lobular processes, a phenotype seen ipsilateral to both
left and right hemisphere injury. Similarly, GFAP imaging revealed a reactive astrocyte
response ipsilateral to both left and right hemisphere injury compared to sham (Figure
2-6B), with extensive hypertrophy of cellular processes. Contralateral left and right
injured hippocampus also showed both microglial (Figure 2-6A) and astrocyte (Figure 26B) reactivity, but at a much reduced level.

Discussion
The present study revealed that both left and right hemisphere TBI produce cognitive
deficits. During the Fixed Platform task probe trial, the expression of reference memory
was impaired by both left and right lateral injury, though acquisition was delayed only in
the right lateral injury. In contrast, cognitive flexibility deficits measured by reversal
acquisition and the reversal probe trial did not differ between left and right hemisphere,
yet modest left hemisphere impairments were seen relative to sham.
The left and right lateral injury deficits seen in the Fixed Platform probe trial are
consistent with existing left (Chen et al, 1998) and right (Shinohara et al, 2012) lateral
injury reference memory expression deficits. These results support findings that both
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hippocampal hemispheres contribute to spatial learning (Shinohara et al, 2012). MWM
Fixed Platform acquisition deficits (Carbonell et al, 1998; Spain et al, 2010) have been
shown in right hemisphere injury, though contrary to the present findings, others have
noted acquisition deficits also from left lateral injuries (Tchantchou and Zhang, 2013;
Fox et al, 1999). Comparison of left-right hemisphere injury across studies is difficult
due to methodological differences, such as post-injury training timing, injury magnitude
and model, and varying numbers of training days or trials per day. Accordingly, one
unique contribution of the present work was the identical experimental conditions under
which left and right hemisphere injury was studied.
The reversal task finding where left lateral injury produced modest MWM
performance impairments only relative to sham controls would be intriguing to further
investigate at increased injury magnitudes to determine if unilateral injury would reveal a
differential vulnerability to cognitive flexibility disruption. Although few rodent TBI studies
have employed the MWM reversal task, a left lateral controlled cortical impact injury
study reported deficits in a similar task in mice (Zhao et al, 2012). Furthermore, superior
MWM reversal task accuracy was reported to correlate with larger left mossy fiber
projections (Schöpke et al, 1991), also true in Collins High-lateralized mice known to
exhibit larger left mossy fiber projections (Bernasconi-Guastalla et al, 1994). As such,
the MWM reversal tasks ability to assess changes in cognitive flexibility may yet prove
useful in the study of TBI.
Although the present study did not address mechanisms underlying left and right
hemisphere TBI behavioral deficits, the observations reported are consistent with the ElGaby et al. (2014) theoretical model which accounts for differential use of distinct left-
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right hippocampal synapse populations during learning and memory in mice (El-Gaby et
al, 2014). Specifically, pre-configured CA3-CA1 synapses attributed to stable cell
assemblies of the right hippocampus function to facilitate rapid incorporation of spatial
information (Nakashiba et al, 2008). Left hippocampal CA3-CA1 synapses, however,
recruit new place cells to instruct the formation of de novo cell assemblies (Hollup et al,
2001) facilitating representation of salient new locations (Leutgeb et al, 2007).
Consequently, the fixed platform acquisition impairments of right injured mice may
reflect a heavier reliance on plastic but slower left CA3-CA1 hippocampal synapses.
Whereas left lateral injury reversal task impairments could be explained by heavier
reliance on right CA3-CA1 hippocampal assemblies still pre-assigned to the previous
Fixed Platform location. An adaptive advantage of such anatomical dissociation could
be an efficient division of labor between left and right hemisphere hippocampi.
Neurological motor behavior was also impaired by both left and right lateral
injury, though neither the NSS nor Rotarod performance revealed differential left-right
hemisphere motor vulnerability to TBI. Despite acute post-injury motor impairments,
assessments of sensorimotor and motivational performance in the MWM cued task and
MWM swim speeds revealed no impairment for either left or right lateral injuries. This
suggests that left-right hemisphere injuries which produced cognitive impairments did
not impact MWM sensorimotor performance or impair learning of MWM procedural
components.
Left and right hemisphere injury elicited equivalent injury severity as measured
by post-injury righting time. Also, neurodegeneration in response to injury measured by
cortical lesion volume was not found to differ between left and right hemisphere injury.
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Qualitative assessment of the glial response to left and right hemisphere injury
demonstrated robust activation of hippocampal microglia and astrocytes ipsilateral to
left and right hemisphere injury, reflecting a significant level of traumatic insult.
Contralateral hippocampal structures in both left and right injured mice also evidenced
modest glial reactivity, consistent with previous reports (Shitaka et al, 2012). These data
indicate that left and right hemisphere injury generate a similar cellular response to
trauma pathology, and suggest that variance in left-right behavioral outcome is not
correlated with overt differences in glial reactivity.
Conclusions. Left and right lateral TBI both produced MWM performance deficits
in mice, with modest left-right differences. The investigation of left versus right lateral
injuries contributes to the understanding of the mouse TBI model. Consequently,
laterality in mouse MWM learning and memory impairments may be worthy of
consideration for future study design and interpretation in the investigation of TBIinduced cognitive consequences.
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Figure 2-1. Experimental timeline. Experimental timeline (relative to injury) of
neurological motor battery (indicated by down arrows) and spatial learning and memory
tasks of the MWM, for left lateral and right lateral fluid percussion injuries.
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Figure 2-2. Left and right hemisphere injury produced neurological motor deficits.
NSS scores increased for left (Panel A) and right (Panel C) lateral injury on post-injury
day one. Injury also produced impaired rotarod performance in both left (Panel B) and
right (Panel D) lateral hemispheres, with no significant difference in performance
between hemispheres (Panel E, represents main effect of injury marginal means).
Values represent means ±SEM; Panels A and C **P<0.01 vs. injury day -1. Panels B
and D *P<0.05, **P<0.01 vs. sham.
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Figure 2-3. Both left and right lateral injury produced MWM Fixed Platform task
deficits.
During Fixed Platform acquisition (Panels A, B, C) only the right lateral injury (Panel B)
showed a small but significant delay in the acquisition of reference memory compared
to sham; and compared to left injured animals (Panel C, represents main effect of injury
marginal means). During the Fixed Platform Probe trial (Panels D, E, F), both left and
right lateral injured mice demonstrated latency impairments relative to sham (Panels D,
E, F), but with no left-right differences (Panel F). Values represent mean ±SEM;
*P<0.05, **P<0.01 vs. sham; #P<0.05, ##P<0.01 vs. 100 (sham performance).
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Figure 2-4. The MWM Reversal Task did not reveal any left-right differential
vulnerability to cognitive flexibility.
Both reversal task acquisition (Panels A, B, C) and reversal probe trial (Panels D, E, F)
produced no left-right performance differences in reversal task learning (Panels C [main
effect of injury marginal means] and F). However left lateral injury demonstrated modest
latency impairments relative to sham in both reversal acquisition (Panel A), and reversal
probe trial (Panel D, F). Values represent mean ±SEM; *P<0.05 vs. sham; #P<0.05 vs.
100 (sham performance).
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Figure 2-5. Left and right hemisphere injury produced impaired righting time and
histological outcome.
Both left and right lateral injury produced significantly greater righting times (Panels A,
D) and lesion volume %’s (Panels B, E) compared to sham animals. No left-right
differences were found in righting time or lesion volume %. Representative coronal
sections of left (Panel C) and right (Panel F) lateral injury-induced lesion are shown.
Values represent mean ±SEM; *P<0.05, **P<0.01, ***P<0.001 vs. sham.
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Figure 2-6. Hippocampal glial cell response to left and right hemisphere injury.
Microglial (IBA1 +; green) morphology (Panel A) showed non-reactive, ramified state
within the dentate gyrus of sham controls (see insets for cell detail). A robust reactive
phenotype was observed in the dentate gyrus ipsilateral to both left and right
hemisphere injury, where microglia exhibited enlarged, rounded cell bodies and lobular
processes (arrows; inset). Astrocyte (GFAP +; red) morphology (Panel B) showed thin
process bearing stellate cells within the dentate gyrus of sham controls (see insets for
cell details). Reactive hypertrophic phenotype, with enlarged cell bodies and increased,
thick cell processes (arrows; inset) was seen in the dentate gyrus ipsilateral to both left
and right hemisphere injury. Cell nuclei co-stained with DAPI. IPSI= ipsilateral to injury;
CON= contralateral to injury; H= hilus; GCL= granule cell layer; ML= molecular layer;
Bar = 30 µm large images, 20 µm insets.
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Table 2-I. Neurological Severity Score (NSS) for mice
Task

Description

Exit Circle
Mono-/Hemiparesis
Straight Walk
Startle Reflex
Seeking Behavior
Beam Balancing
Round Stick Balancing
Beam Walk: 3cm
Beam Walk: 2cm
Beam Walk: 1cm

Ability & initiative to exit a circle of 30 cm diameter (2 min)
Paresis of upper &/or lower limb of the contralateral side
Alertness, initiative, & motor ability to walk straight
Innate reflex: mouse will bounce or wince to a loud hand clap
Physiological behavior as exploration of the environment
Balance on a 7 mm width beam, 25 cm high (10 s)
Balance on a 5 mm diameter round stick, 25 cm high (10 s)
Cross a 30 cm long beam of 3 cm width, 25 cm high
Cross a 30 cm long beam of 2 cm width, 25 cm high
Cross a 30 cm long beam of 1 cm width, 25 cm high
Maximal Score

Points
Success/Failure
0
0
0
0
0
0
0
0
0
0

Table 2-I. Neurological Severity Score test battery items.
The modified neurological severity score (NSS) battery of motor, sensory, reflex, and
balance tests to assess neurological damage following closed head trauma in mice.
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1
1
1
1
1
1
1
1
1
1
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Appendix 2. Supplementary Material (cont’d)
Materials and Methods
Mice. Adult male C57BL/6J mice weighed 24-29 g and age 10-11 weeks at the time of
injury. Mice were pair-housed under a 12 h light/12 h dark cycle (0600 to 1800 h), at a
constant temperature (22ºC) and humidity (50-60%), with food and water available ad
libitum.
Craniotomy and Induction of Lateral Fluid Percussion Injury (FPI). The left
or right parietotemporal craniectomy was performed between lambda and bregma,
approximately 1 mm from the sagittal suture. A 3.5 mm (inside diameter) Leur-Loc
syringe hub (modified from a 20G needle) was secured over the craniotomy and
surrounded with dental acrylic. After a 2 h recovery period, mice were anesthetized with
isoflurane (4%, 400 mL/min). The injury cap was attached to a Leur-Loc fitting and filled
with 0.9% NaCl. Mice were then connected to transducer housing of the fluid percussion
injury device (AmScien Instruments, Richmond, VA), and immediately subjected to a
moderate lateral fluid percussion injury (1.94±0.1 atm left lateral, 1.92±0.1 atm right
lateral injury).
The injury was produced by a metal pendulum that struck the piston, transiently
injecting a small volume of saline into the cranial cavity and briefly deforming the brain
tissue (20-millisecond pulse duration). Immediately following the delivery of the injury,
mice were placed on their backs to assess the righting reflex, which was scored as the
duration of time to right itself, and was used as an index of traumatic unconsciousness
and a correlate of injury severity. In succession, mice were again anesthetized with
isoflurane (4%, 400 mL/min), the hub removed, the injury site checked for intactness of
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the dura, and the skin sutured. Mice were placed in a recovery cage atop a heating pad
for 1 h, then returned to their home cage. Sham-injured controls underwent identical
anesthetic and surgical procedures, as well as connection to the injury device, except
that the intracranial pressure pulse was not applied.
Rotarod Assay. Each mouse was placed on the device facing the experimenter
(forward direction), rotating the drum in the opposite direction. The mice were given one
habituation trial to adapt to the testing equipment using a fixed speed of 4 rpm for 60 s.
All subsequent single trials per day used an accelerating protocol, starting at 4 rpm and
ending at 40 rpm ramping over 60 s, with a 120 s test period. Each trial ended prior to
the 120 s cut-off if the mouse fell off the rod, or gripped the device and spun around one
full revolution without attempting to walk on the drum.
Neurological Severity Score. In the 10-point Neurological Severity Score
(NSS), one point is awarded for failing to perform a particular task, and no points for
succeeding. The points of each of the 10 individual tasks are summed to achieve the
NSS, in which a score of zero represents a naïve uninjured mouse, whereas a maximal
score of 10 indicates severe neurological dysfunction. The NSS (Albert-WeiBenberger
et al, 2012) has been shown to correlate with severity of brain damage as determined
by in vivo magnetic resonance studies in mice (Tsenter et al, 2008).
Learning and Memory Assessment. The Morris water maze consisted of a
circular, galvanized steel tank (1.8 m in diameter, 0.6 m height). The tank was filled with
water (maintained at 20ºC±2ºC) with a white platform (10 cm diameter) submerged 1
cm below the water’s surface. A sufficient volume of white paint (Valspar 4000 latex
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paint, Lowe’s Companies Inc., Mooresville, NC) was added to render the water opaque
and the platform invisible. In addition to distal visual cues on the walls of the laboratory
(shapes), five sheets of laminated paper with distinct black-and-white geometric designs
were attached to the sides of the tank serving as proximal cues. Dependant measures
were collected using an automated tracking system (ANY-maze, San Diego
Instruments, Inc., San Diego, CA).
Fixed Platform Task. The Fixed Platform task was used to assess acquisition of
reference memory to a spatial location in the water maze. On post-injury day 6, mice
were given a pre-training acclimation session (habituation) during which they were
allowed to swim in the pool for 4 min without the platform present. Beginning on postinjury day 7, mice were given eight daily acquisition sessions consisting of four-120 s
duration trials per day with an inter-trial interval of 10±2 min. Throughout the course of
this acquisition period the hidden platform remained in a fixed position for all mice. Mice
were released facing the tank wall from four starting points along the perimeter of the
maze arbitrarily designed as N, S, E, W, the order of which was counterbalanced across
trials. Once a mouse located the hidden platform, it was allowed to remain there for 15 s
before being removed from the tank. If a mouse failed to locate the platform within 120
s, it was manually guided to it and removed 15s later. On post-injury day 15 (i.e., one
day following the eighth acquisition day), the platform was removed from the tank, and
the mice were subjected to a 60 s probe trial to measure spatial bias for the previous
platform location. The percentage of time spent in the target quadrant (where the
platform used to be) and control quadrant (the quadrant directly opposite the target
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quadrant) was measured, as well as latency to the prior platform location and the
number of times the mouse traversed the prior platform location. Given that the Fixed
Platform probe trial acts as an extinction trial for prior learning, on post-injury day 16
mice were given a further day of Fixed Platform training in which the hidden platform
was returned to the same fixed position as during the acquisition procedure.
Reversal Task. The Reversal task assesses cognitive flexibility, in which the
initiation of inhibitory responses is required to explore alternative solution paths.
Beginning on post-injury day 18, mice were subjected to a reversal procedure in which
the submerged platform was moved to the opposite side of the tank (now within the
control quadrant of the Fixed Platform task). Mice were given four daily reversal
sessions, with all other task parameters identical to the acquisition procedure. On postinjury day 22, the mice were subjected to another 60 s probe trial, with task parameters
identical to the acquisition probe.
Sensorimotor-Motivational Procedure (Cued Task). The Cued task assesses
the sensorimotor and motivational capacity of the mice to find the submerged platform
irrespective of cognitive ability. Beginning on post-injury day 24, the location of the
submerged platform was made known to the mice by the placement of a black cylinder
(12 cm height; 4 cm diameter) which extended approximately 11 cm out of the water.
Mice were given three cued sessions, during which the location of the submerged
platform was changed daily. The first two daily cued sessions consisted of four-120 s
length trials each, with an inter-trial interval of 10±2 min, and release was
counterbalanced across the four possible start positions (N, S, E, W). The third cued
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session consisted of two-120 s length trials, with start positions counterbalanced across
the two start positions furthest from the cued platform location.
An automated tracking system (ANY-maze, San Diego Instruments, Inc., San
Diego, CA) analyzed the swim path of each subject and calculated escape latencies
(the time between being placed in the water and finding the hidden platform), average
swim speed, number of platform crossings, and percentage of time spent in each
quadrant.
Histology and Lesion Volume Quantification. Animals were anesthetized with
sodium pentobarbital, 360 mg/kg, i.p. (administered at 6 ml/kg [60 mg/ml]), and then
transcardially perfused with 0.9% saline followed by 4% paraformaldehyde in 0.1 M
NaHPO4, pH=7.4. Immediately following, brains were extracted and placed in 4%
paraformaldehyde for 24 h before transfer to storage in 0.03% NaN3 (Sigma Chemical
Co., St. Louis, MO, USA) in 1.0 M phosphate-buffered saline (PBS).
Brains were sectioned (50μm thickness) in PBS on a Leica VT1000S vibratome
in the coronal plane throughout the rostro-caudal extent of the lesion, extending from
approximately -0.5 to -3.5 relative to bregma, and mounted on bovine gelatin and
chromium potassium sulfate-treated Superfrost slides (ThermoFisher Scientific,
Waltham, MA). Every fifth section was processed with a Nissl stain using cresyl violet
acetate and digitally imaged with a Zeiss Discovery V20 StereoZoom microscope using
AxioVision.
The area of normal staining (lacking necrosis, cavitation, or hemorrhage), was
measured in each section using NIH ImageJ software and a Wacom Intuos4 Digitizing
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Tablet. The lesion area was calculated as the area of normal staining on the
contralateral side minus that of the ipsilateral side, and then used to calculate the full
lesion volume as previously described (Dash et al, 2010) using; (A1+A2)*0.5 + (A2
+A3)*0.5 + … + (A6 +A7)*0.5; in which A is the lesion area (mm2) for each slice and 0.5
(mm) is the distance between two sequential slices. Lesion volume was then expressed
as a percentage of remaining normal staining (contralateral + ipsilateral) within whole
brain using; [(C-I) / (C+I)] * 100%.

Results
Neurological Motor Deficits: Rotarod main effect of day. The non-significant Mixedfactor ANOVA (2x8) investigating percent of sham control in latency to fall between left
and right cohorts also revealed a significant main effect of day F(7, 112) = 9.82, P <
0.001, with a Bonferroni adjustment revealing significant differences from day -1 to day
1 (P < 0.01), day 2, 3, and 7 (P < 0.05), and significant differences from day -2 to day 1
(P < 0.001), day 2 and 3 (P < 0.01), and day 7 (P < 0.05).
Fixed Platform Task: main effect of day. In the non-significant Mixed-factor
ANOVA (2x8) investigating the acquisition of reference memory, main effects of day
were found for left lateral, F(7, 126) = 13.90, P < 0.001, and right lateral injury, F(7, 91)
= 16.07, P < 0.001. Left and right cohorts demonstrated significantly faster latencies to
the platform on days 4-8 than on day 1 (P values < 0.01). The non-significant Mixedfactor ANOVA (2x8) investigating percent of sham control in latencies to the platform
between left and right cohorts also did reveal a significant main effect of day F(7, 112) =
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2.31, P < 0.05, despite a Bonferroni adjustment revealing no significant differences
between days.
Reversal Task: main effect of day. In the non-significant Mixed-factor ANOVA
(2x4) investigating the acquisition of reversal learning, Left lateral, F(3, 54) = 5.24, P <
0.01, and right lateral, F(3, 39) = 12.27, P < 0.001, injury cohorts showed a significant
main effect of day, with the left cohort demonstrating significantly shorter latencies to
the platform on days 3 and 4 compared to day 1 (P < 0.05), and the right cohort
demonstrating significantly shorter latencies to the platform on day 4 compared to day 1
(P < 0.001).
Search strategy. Also, a visual inspection of swim paths suggests that injured
animals utilized a looping rather than spatial swim strategy (Zhao et al, 2012), though
they did not appear to differ between unilateral injury cohorts (left; Supplemental Figure
4G and 5G, right; Supplemental Figure 4H and 5H).
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Supplementary Figure 2-1. MWM Cued task.
Left and right hemisphere injury produced no difference in sensorimotor and/or
motivational performance in the Cued Task of the MWM, as measured by latency to a
cued platform location. An independent groups t-test demonstrated no significant
difference in latency between either left lateral (Panel 3A; P = 0.10), or right lateral injury
(Panel 3B; P = 0.06), and their respective sham controls. Also, when analyzed using a 2
x 2 ANOVA no significant interaction, P = 0.40, and no main effects of lateralization, P =
0.22, and injury, P = 0.80 were found. Values represent mean ±SEM.
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Supplementary Figure 2-2. Swim speed during the Fixed Platform task.
Left and right hemisphere injury produced no difference in swimming ability in the Fixed
Platform Task of the MWM, as measured by swim speed. Both left lateral injury (Panel
4A) and right lateral injury (Panel 4B) produced no significant difference in swim speed
between injured and sham animals across any of the Fixed Platform acquisition days or
probe trial. Specifically, in a 2 x 8 mixed factor ANOVA left lateral injury (Panel 4A) had
no effect on swim speed during Fixed Platform acquisition, as the interaction between
day and injury, F(7, 126) = 1.39, P = 0.21, main effect of day, F(7, 126) = 2.02, P = 0.06,
and main effect of injury, F(1, 18) = 0.08, P = 0.78, failed to achieve significance,
revealing no difference in swim speed between left lateral injury and sham groups. An
independent groups t-test was used to analyze the Fixed Platform probe trial where no
difference was found in swim speed between a left lateral injury and sham controls,
t(18) = 0.24, P = 0.81. The right lateral cohort (Panel 4B) also showed no swim speed
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differences during Fixed Platform acquisition. In a 2 x 8 mixed factor ANOVA the
interaction, F(7, 91) = 0.41, P = 0.89, main effect of day, F(7, 91) = 0.83, P = 0.56, and
main effect of injury, F(1, 13) = 2.44, P = 0.14, failed to achieve significance. An
independent groups t-test found no difference in swim speed between a right lateral
injury and sham controls during the Fixed Platform probe trial, t(13) = 0.68, P = 0.51.
Values represent mean ±SEM.
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Supplementary Figure 2-3. Swim speed during the Reversal task.
Left and right hemisphere injury produced no difference in swimming ability in the
Reversal Task of the MWM, as measured by swim speed. Both left lateral injury (Panel
5A) and right lateral injury (Panel 5B) produced no significant difference in swim speed
between injured and sham animals during the Reversal acquisition days or probe trial.
Specifically, A left lateral injury (Panel 5A) had no effect on swim speed during Reversal
acquisition, as the interaction between day and injury, F(3, 54) = 0.56, P = 0.65, main
effect of day, F(3, 54) = 0.46, P = 0.71, and main effect of injury, F(1, 18) = 0.03, P =
0.86, failed to achieve significance, revealing no difference in swim speed between left
lateral injury and sham groups. An independent groups t-test also found no difference in
swim speed between a left lateral injury and sham controls during the Reversal probe
trial, t(18) = 0.11, P = 0.91. In contrast, the right lateral injury group (Panel B)
demonstrated a significant main effect of day, F(3, 39) = 7.68, P < .001, but the
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interaction, F(3, 39) = 1.02, P = 0.39, and main effect of injury, F(1, 13) = 0.12, P = 0.73,
failed to achieve significance. Post-hoc tests did not detect significant differences
across Reversal acquisition days (day 1, P = 0.96; day 2, P = 0.95; day 3, P = 0.61; day
4, P = 0.43). An independent groups t-test also found no difference in swim speed
between a right lateral injury and sham control groups during the Reversal probe trial,
t(13) = 0.06, P = 0.95. Values represent mean ±SEM.
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Supplementary Figure 2-4. Fixed Platform Probe task additional measures.
Independent samples t-tests showed significantly fewer platform crossings in injured
animals than sham animals for both left lateral (Panel 1A), t(18) = 2.75, P < 0.05, and
right lateral injuries (Panel 1B), t(13) = 3.54, P < 0.01. When directly comparing left and
right cohorts (Figure 1C), an independent samples t-test revealed no significant percent
of sham control difference for platform crossings between left and right hemisphere
injury (P = 0.80), and a one sample t-test confirmed that both left, t(9) = 6.04, P < 0.001,
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and right, t(7) = 6.58, P < 0.001, lateral injuries showed significantly poorer performance
to their sham controls.
Independent sample t-tests revealed a spatial preference for the target quadrant
by sham animals through an increase in percent time spent in the target quadrant in the
right (Panel 1E) lateral injury cohort, t(13) = 2.63, P < 0.05, but not the left lateral (Panel
1D; P = 0.70). When directly comparing left and right cohorts (Figure 1F), an
independent samples t-test revealed no significant percent of sham control difference in
preference for the target quadrant between left and right hemisphere injury (P = 0.36),
though a one sample t-test found that right, t(7) = 4.17, P < 0.01, but not left, (P = 0.12),
lateral injuries showed significantly less of a target quadrant preference to their sham
controls. Values represent mean ±SEM; *P<0.05, **P<0.01 vs. respective control;
##P<0.01, ###P<0.001 vs. 100 (sham performance).
A visual inspection of swim paths suggests that injured animals (left; Figure 1G, right;
Figure 1H) utilized a looping rather than spatial swim strategy, though they did not
appear to differ between unilateral injury cohorts.
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Supplementary Figure 2-5. Reversal Probe task additional measures.
Independent samples t-tests showed significantly fewer platform crossings in left injured
animals than sham animals (Panel 2A), t(18) = 2.75, P < 0.05, but not right (Panel 2B),
(P = 0.54). When directly comparing left and right cohorts (Figure 2C), an independent
samples t-test revealed no significant percent of sham control difference for platform
crossings between left and right hemisphere injury (P = 0.13), yet a one sample t-test
showed that left, t(9) = 3.90, P < 0.01, but not right, (P = 0.41), lateral injuries showed
significantly poorer performance to their sham controls.
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Independent sample t-tests revealed no spatial preference for the target quadrant
by sham animals over right (Panel 2E) lateral injury cohort, (P = 0.39), or left (Panel 2D;
P = 0.22). When directly comparing left and right cohorts (Figure 2F), an independent
samples t-test revealed no significant percent of sham control difference in preference
for the target quadrant between left and right hemisphere injury (P = 0.89), also, a one
sample t-test found that neither right, (P = 0.25), nor left, (P = 0.17), lateral injuries were
significantly different in target quadrant preference to their sham controls. Values
represent mean ±SEM; *P<0.05 vs. respective control; ##P<0.01 vs. 100 (sham
performance).
A visual inspection of swim paths suggests that injured animals (left; Figure
2G, right; Figure 2H) utilized a looping rather than spatial swim strategy, though again
they did not appear to differ between unilateral injury cohorts.
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Chapter III
Chapter Introduction

The second goal of this dissertation was to investigate the 2-AG biosynthetic production
enzyme, DAGL-β, as a novel target for the reduction of TBI-induced cognitive
impairment, using DAGL-β-/- mice.
Endogenous cannabinoids and inflammatory signaling. The biological
processes that drive inflammation act as a protective mechanism in response to
pathology (through debris clearing etc), yet they can also lead to tissue damage and
neurodegeneration if chronic and self-perpetuating. The eCB system plays important
dual roles in inflammation; indirectly through the production of precursors for soluble
immunoactive molecules, as well as directly through synaptic cannabinoid receptor
signaling. It is possible that the eCB system may possess biphasic roles; resolution of
inflammation through cannabinoid receptors, yet perpetuate chronic states of
inflammation (often still present years following a TBI) through pro-inflammatory
downstream eCB metabolites. While the biological role played by the eCB system has
frequently been described as pro-homeostatic, the full implications of the interaction
between inflammatory mechanisms and the eCB system are thus still unfolding.
One of the main mediators of the eCB-eicosanoid signaling pathway is the
endogenous cannabinoid ligand 2-arachidonoylglycerol (2-AG), which serves as a major
precursor for the formation of free arachidonic acid (AA) in brain. 2-AG is formed from
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diacylglycerol lipase (DAGL) (Nomura et
al, 2011) and hydrolyzed to AA
predominantly by monoacylglycerol
lipase (MAGL) (Nomura et al, 2011) but
also to a lesser extent by serine
hydrolase α-β-hydrolase domain 6/12
(ABHD6/12) (Blankman et al, 2007). In
turn, AA is a major substrate for the
biosynthetic enyzmes of proinflammatory prostanoids (e.g.
prostaglandins), which play a role in
cytokine release (Nomura et al, 2011).
Figure 3A: 2-AG-Eicosanoid Signaling
Pathway

Cytokines further regulate inflammation,

influence microglial activation sates, induce the activation of neurotoxic astrocytes, as
well as contribute to neurodegeneration following TBI, one such example being that IL1β release stimulates glutamate-mediated synaptic transmission (Viviani et al, 2003)
and limits GABA-mediated inhibitory transmission (Rossi et al, 2012), resulting in
hyperexcitation and potential excitotoxic neurodegeneration. Although the second main
endogenous cannabinoid ligand anandamide (AEA) is also metabolized to AA, it does
not account for appreciable free AA in brain, likely due to its being 1000 times less
abundant than 2-AG (Blankman and Cravatt, 2013; Sugiura et al, 1995).
The prostanoids produced by eCB catalysis exist under physiological conditions
in almost trivial amounts, their biological importance being marginal (Ricciotti and
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FitzGerald, 2011). However, in response to acute inflammation as occurs immediately
following neurotrauma, prostanoid levels rapidly increase prior to the infiltration of
immune cells – perhaps a consequence of 2-AG’s dynamic production capacity, e.g.
increases being found two minutes following an inflammatory challenge (Liu et al,
2003). Therefore, this eCB-eicosanoid signaling pathway can also be understood as a
primed homeostatic rapid-response system.
DAGL-β: 2-AG biosynthesis and localization. Compelling evidence suggesting
that the eCB system plays a distinct immunomodulatory role outside of receptor
signaling, is the expression of DAGL in species that do not express cannabinoid
receptors (e.g. Drosophila) (Elphick and Egertova, 2005). The DAGL enzyme is a multidomain serine hydrolase, the family of which consists of approximately 200 enzymes.
Two DAGL isoforms exist, both of which produce 2-AG, DAGL-α and DAGL-β, and are
found in a wide range of species including rodents and man (Bisogno et al, 2003a).
Both DAGL-α and DAGL-β have 4-transmembrane domains and are expressed at the
plasma membrane in ordered
microdomains. A great deal of
structural conservation exists
between these isoforms, with the
main difference being the
substantial carboxy-terminal tail
of DAGL-α.
Figure 3B: The exon structure and schematics of DAGL-α
and DAGL-β. The transmembrane domain is in blue, the
catalytic domain in red (with a cysteine rich area in
yellow), the regulatory loop in green, and the C-terminal
tail in grey. (Adapted from Reisenberg et al, 2012).
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The relative contribution of
each isoform to 2-AG production

is determined by their respective cellular location. DAGL-α is found predominantly on
neurons (with a major role in synaptic plasticity (Gao et al, 2010) and DAGL-β is most
highly expressed on CNS microglia and peritoneal macrophages (playing an important
role in inflammatory responses (Hsu et al, 2012). While DAGL-α is expressed on
neurons and especially in areas important for learning and memory (hippocampus,
striatum, and prefrontal cortex (Katona et al, 2006; Lafourcade et al, 2007), the
expression pattern of DAGL-β is less well understood (Oudin et al, 2011), though
DAGL-β mRNA has been found to be high in hippocampus (Gao et al, 2010) and the
cerebellar granular layer (Yoshida et al, 2006).
Microglia: function, and the endocannabinoid system. The term “microglia”
was first coined by Pio del Río-Hortega early in the 20th century (Del Río-Hortega,
1932). Unlike other CNS resident cells such as neurons and astrocytes (which are
derived from CNS resident progenitor cells), microglia arise from hematopoietic stem
cells in blood islands of the yolk sac during early embryogenesis, and then migrate
through the embryo vascular system to the brain (Naito et al, 1990). As such, microglia
share a common myeloid progenitor cell lineage with monocytes/macrophages and
have common properties, such as expression of similar markers (e.g. CD11b) (Perry et
al, 1985). Classified as mononuclear phagocytes, microglia act under the protection of
the BBB in response to neuroinflammation, moderating CNS damage and favoring
tissue repair, as well as participating in the resolution of inflammation. In the healthy
CNS, microglia also control neuronal proliferation and differentiation, as well as the
formation of new synapses (Graeber, 2010; Hughes, 2012).
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To perform their assorted functions, microglia adopt various phenotypic activation
states characterized by changes in morphology, cytokine secretion, and marker
expression, largely depending on local environmental cues (Martinez and Gordon,
2014). The M0 phenotype is that of the surveillant microglia, ramified in morphology and
present under homeostatic conditions. In CNS pathology, microglia become activated to
an M1 pro-inflammatory/phagocytic phenotype in which the cell acquires an ameboid
morphology with diminished number and length of processes and enlarged soma
(Stence et al, 2001). M2a and M2b phenotypes are used to describe alternatively
activated microglia, associated with tissue remodeling and immunoregulation

Figure 3C: Microglial phenotypes, markers, and actions (Adapted from Mecha et al, 2016)
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(Ponomarev et al, 2007). The acquired deactivated phenotype of M2c is induced by
immunosuppressive cytokines and further contributes to inflammation resolution (Mecha
et al, 2016).
Microglia express functional components of the eCB system: cannabinoid
receptors (CB1 and CB2) and machinery for the biosynthesis and degradation of 2-AG
and AEA (Mecha et al, 2016), suggesting novel functions of eCBs in autocrine and/or
paracrine control of neuroinflammation. Specifically, microglial 2-AG increases 2- to 3fold in response to calcium ionophore exposure, and increases microglial proliferation
via the CB2 receptor (Carrier et al, 2004). Other components of the eCB system also
change with microglial activation states. CB2 receptors, which in healthy brain tissue are
present only in trace amounts (Maresz et al, 2005), show increased expression during
M2 polarization with IL-4 (Mecha et al, 2015). Also, some evidence suggests that
DAGL-β may be a dynamically regulated enzyme. Mecha et al, 2015 found that DAGL-β
expression showed non-significant decreases during M1 phenotypes, and elevations
during M2c (acquired deactivated) phenotypes in primary cell culture. However, the
contributions eCB microglial expression have on processes of neuroinflammation
remains to be determined. This avenue of inquiry is of particular interest following TBI
given the potential for increased intracellular pools of 2-AG to act as substrate for
microglial eicosanoid production.
Microglia and neurotrauma. A rapid and controlled activation of the immune
system following TBI is necessary to minimize injury and repair damage. The
phenotypes and subsequent functional profiles of microglia change in response to
signals detected in the brain parenchyma. Release of adenosine triphosphate (ATP)
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(Davalos et al, 2005) and extracellular calcium wave propagation (Sieger et al, 2012)
following injury promote polarization from surveillant (M0) to pro-inflammatory (M1)
microglia, as well as proliferation and migration to the site of injury. At the lesion site,
microglia fuse to form a barrier between healthy and damaged cells (microgliosis),
perform cell debris removal (phagocytosis), and release various effector substances
including nitric oxide, proteases, and cytokines. Microglia play a central role in
secondary injury processes when a shift to the anti-inflammatory M2 phenotype (of
angiogenesis, extracellular matrix reconstruction etc) is not prompted, perpetuating proinflammatory responses associated with further CNS damage, compromised BBB,
enhanced peripheral macrophage infiltration, and chronic release of further cytokines,
cytotoxic superoxide, nitric oxide, and proteases. Increased microglia activation can be
present for decades following a TBI (Donat et al, 2017; Ramlackhansingh et al, 2011),
and has been associated with increased risk of neurodegenerative disease such as
Alzheimer’s Disease (Plassman et al, 2000).
Targeting DAGL-β to treat TBI. Studies of enzyme inhibition downstream of 2AG production have thus far produced mixed results in attenuating TBI functional
deficits. Inhibition of 2-AG degradative enzymes has shown both improvement and a
lack of improvement in neurological motor (Katz et al, 2015; Zhang et al, 2014) and
learning and memory assessments (Tchantchou and Zhang, 2013; Zhang et al, 2014).
This contradictory evidence is perhaps attributable to the direct oxidation of 2-AG by
COX-2 (Straiker et al, 2011), which produces prostaglandin glycerol esters (Hu et al,
2008; Sang et al, 2007). COX inhibition has also shown both improvement and a lack of
improvement in neurological motor assessments (Cernak et al, 2002; Girgis et al, 2013)
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and learning and memory assessments (Cernak et al, 2002; Dash et al, 2000), perhaps
a consequence of the availability of alternative AA metabolism pathways such as the
lipoxygenases (Maccarrone et al, 2000) and cytochrome P450 enzymes (Chen et al,
2008). Given the complex degradation pathways of 2-AG, we propose that targets
upstream of production, specifically the biosynthetic enzymes of 2-AG synthesis,
warrant further investigation as to their injury-protective potential when disrupted.
The spatial specificity of 2-AG production provided by the distinct cellular
expression of DAGL-α and -β might be particularly useful following traumatic brain
injury. We anticipated that disruption of DAGL-β would not significantly impede neuronal
2-AG production. Indeed, DAGL-α deletion leads to profound adverse phenotypic
consequences such as memory impairment and changes in neuronal excitability in mice
(Sugaya et al, 2013), as well as impairing AA signaling and function, such as membrane
fluidity and regulation of ion channels (Piomelli, 1996). However, deactivating 2-AG
production specifically in microglial cells through DAGL-β could reduce the capacity for
pro-inflammatory signaling by 2-AG in its role as metabolic intermediate thus affording
cognitive deficit protection following TBI. As such, DAGL-β inactivation could reduce
inflammatory processes in microglial cells, without disrupting other adaptive functions of
2-AG and its downstream pathways.
Summary. The following work evaluates DAGL-β as a novel target for the
reduction of TBI-induced cognitive deficit, using the working hypothesis that disrupting
DAGL-β activity will provide cognitive protection from brain injury by reducing pools of 2AG pro-inflammatory metabolites, specifically in microglia. An unexpected finding that
DAGL-β deletion produced a survival protective phenotype prompted further
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investigation into the extent of this mortality protective effect. This investigation of the
neuroprotective effects of DAGL-β following TBI thus considers the unexpected and
provocative possibility that DAGL-β contributes to acute brain injury pathology.
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Targeting diacylglycerol lipase-β to treat traumatic brain injury

Introduction
A rapid and controlled immune response to traumatic brain injury (TBI) is necessary to
minimize further injury and initiate repair processes. The increase of brain endogenous
cannabinoid (eCB) levels following TBI (Panikashvili et al, 2001) suggests the eCB
system may play a role in such essential repair mechanisms. Shortly following an initial
injury, acute neuroinflammatory processes are triggered as part of a cascade of
secondary injury mechanisms. The acute neuroinflammatory response includes
activation of resident central nervous system (CNS) immune cells, microglia, to an M1
profile and the release of proinflammatory mediators (as well as proliferation and
migration to the injury site (microgliosis), and cell debris removal (phagocytosis).
TBI can be thought of not only in terms of an acute event, but fundamentally as a
chronic disease. Adaptive inflammatory immune responses to TBI can be perpetuated
over time by high levels of pro-inflammatory eicosanoids (prostaglandins and cytokines)
in damaged tissue, prompting a continued state of chronic inflammation. An
unsuccessful resolution of inflammation is frequently seen following TBI in which
persistent and dysfunctional inflammation promotes a failure to shift microglia from a
pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype (which would
prevent angiogenesis, and promote extracellular matrix integrity resolution and tissue
repair, Sica and Mantovani, 2012; Mantovani et al., 2013). An increase in
neuroinflammation accompanied by activated microglial phenotypes has been observed
in humans for years after injury (Johnson et al, 2013), as well as chronically in murine
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TBI models (Holmin and Mathiesen, 1999). The prolonged nature of chronic
neuroinflammation is then linked to further neurodegeneration through synaptic
alterations (Centonze et al, 2009) as well as a compromised blood brain barrier
(enhancing CNS infiltration of peripheral macrophages further promoting inflammation).
Neuroinflammation is widely linked to learning and memory deficits, producing changes
in expression and composition of AMPA receptors (Stellwagen et al, 2005), promoting
neuronal hyperexcitability (Rossi et al, 2012), and impairing long-term potentiation
induction and maintenance (Murray and Lynch, 1998). The learning and memory
deficits commonly seen in clinical TBI cases can persist for decades after injury,
consistent with such neuroinflammatory temporal profiles.
Understanding of the eCB system has recently evolved to include important
contributions toward inflammatory eicosanoid production. The most abundant eCB in
brain, 2-arachidonyl glycerol (2-AG), serves not only as a signaling molecule during
neurotransmission (Hillard, 2000a), but also as an intermediate during lipid metabolism
(Nomura et al, 2011). The hydrolysis of 2-AG by its predominant catabolic enzyme
monoacylglycerol lipase (MAGL) provides the major pool of arachidonic acid (AA) for
the generation of inflammatory eicosanoids in brain (Nomura et al, 2011). 2-AG
production is regulated by two distinct enzymes in a cell specific manner. Diacylglycerol
lipase-α (DAGL-α) is responsible for 2-AG biosynthesis in neurons and astrocytes
whereas diacylglycerol lipase-β (DAGL-β) regulates 2-AG predominantly on immune
cells (microglia in brain and peritoneal macrophages in the periphery) (Bisogno et al,
2003a). DAGL-β regulates pro-inflammatory responses in mammalian macrophages,
with DAGL-β disruption attenuating pro-inflammatory responses in peripheral tissues
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(Hsu et al, 2012; Wilkerson et al, 2016). Given DAGL-β is readily expressed in brain
(Gao et al, 2010; Yoshida et al, 2006), and its disruption perturbs microglia eCBeicosanoid crosstalk (Viader et al, 2015a), this enzyme is also likely to play a role in
CNS neuroinflammation. Bulk levels of brain 2-AG are controlled predominantly via
DAGL-α, as DAGL-α-/- mice show a 90% reduction of brain 2-AG (Gao et al, 2010;
Tanimura et al, 2010), whereas DAGL-β-/- mice show either a 50% reduction (Gao et al,
2010) or no change (Hsu et al, 2012; Tanimura et al, 2012; Viader et al, 2015a). DAGLβ likely plays a smaller role in establishing bulk 2-AG levels than DAGL-α as microglia
compose only 5-12% of CNS cells (Lawson et al, 1990). As such, DAGL-β could
represent a target to attenuate neuroinflammation given its unique expression profile on
microglia in brain without producing global CNS alterations of 2-AG tone.
We hypothesize that DAGL-β participates in TBI-induced neuroinflammation
contributing towards subsequent learning and memory deficits. We therefore
investigated DAGL-β as a novel target for the reduction of TBI-induced spatial learning
and memory impairments in mice, predicting that disruption of DAGL-β activity would
provide cognitive protection from TBI by reducing pools of microglial 2-AG proinflammatory metabolites. Given that selectivity and brain permeability of subtype
selective DAGL inhibitors are yet to be optimized (Janssen and van der Stelt, 2016), we
utilized DAGL-β-/- and -β+/+mice in the present studies. We also investigated if blocking
2-AG production on other cell types would offer protection from TBI functional deficits.
DAGL-α is primarily expressed on neurons (and also astrocytes) (Katona et al, 2006),
therefore we conducted an experiment to assess if DAGL-α-/- mice would be protected
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against TBI-induced spatial memory deficit, however high mortality rates precluded
systematic investigation.

Materials and Methods
Animals. Subjects consisted of adult male DAGL-β-/-, and -β+/+ mice (females were
included in the mortality experiment only) and male DAGL-α-/-, and -α+/+ mice, on a
mixed 99% C57BL/6 (50% J [Jackson Laboratories, Bar Harbor, Maine], 50% N
[Charles River, Wilmington, Massachusetts]) and 1% 129/SvEv background, as
previously described (Hsu et al, 2012). DAGL-β+/- and -α+/- mouse breeding pairs were
originally generated in the Cravatt laboratory and transferred to Virginia Commonwealth
University. All mice (age 8-10 weeks) were pair-housed under a 12 h light/12 h dark
cycle (0600 to 1800 h), at a constant temperature (22ºC) and humidity (50-60%), with
food and water available ad libitum. All experiments were conducted in accordance with
the National Institute of Health (NIH) Guide for the Care and Use of Laboratory Animals
(NIH Publications No. 8023, revised 1978), and were approved by the Virginia
Commonwealth University Institutional Animal Care and Use Committees.
Craniectomy and induction of lateral fluid percussion injury (FPI). Mice were
anesthetized with isoflurane (2.7%, 250 mL/min) and inserted into a stereotaxic frame.
A sagittal incision was made in the scalp and a 2.7 mm craniotomy was performed with
a trephine over the left parietotemporal cortex between lambda and bregma and
approximately 1 mm from the sagittal suture, keeping the dura intact. A 3.5 mm (inside
diameter) luer-Lok syringe hub (modified from a 20G needle) was secured over the
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craniotomy and surrounded with dental acrylic. Mice were then placed in a recovery
cage atop a heating pad.
After a 2 h recovery period, mice were anesthetized with isoflurane (4%, 400
mL/min). An injury cap was attached to the Leur-Lock fitting and filled with 0.9% NaCl.
Mice were then connected to transducer housing of the FPI device (AmScien
Instruments, Richmond, VA), and immediately subjected to lateral FPI (behavioral
assessment experiment; 1.94±0.1 atm, mortality experiments; 2.0±0.1 atm and 2.17±0.1
atm). The injury was produced by a metal pendulum that struck the piston, transiently
injecting a small volume of saline into the cranial cavity and briefly deforming the brain
tissue (20-millisecond pulse duration). The pressure pulse force was measured
extracranially with a transducer, recorded on a storage oscilloscope, (expressed in
atmospheres of pressure). In succession, mice were again anesthetized with isoflurane
(4%, 400 mL/min), the hub removed, the injury site checked for intactness of the dura,
and the skin sutured. Mice were placed in a recovery cage atop a heating pad for 1 h,
after which they were returned to their home cage. Sham-injured controls underwent
identical anesthetic and surgical procedures, as well as connection to the injury device,
except that the intracranial pressure pulse was not applied.
Physiological Measures. Immediately following the delivery of the injury, mice
were placed on their backs to assess the righting reflex, which was scored as the
duration of time to right itself, and was used as an index of traumatic unconsciousness.
When mortality occurred it did so within 2 min following the initial injury, otherwise mice
survived until the end of the 34 day experiment. Therefore, during the separate mortality
experiments at increased injury severity, mortality was considered acute mortality and a
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2 min post-injury cut off was applied. Body weight was taken prior to craniectomy
surgery (day 0) and considered baseline, and then recorded daily for the duration of the
MWM assessments (until day 30 post-TBI). On day 34 post-TBI, rectal temperature was
taken to evaluate body temperature by inserting a thermocouple probe (2 cm) into the
rectum. A baseline rectal temperature was recorded, then further assessments were
made at 1, 3, 10, and 30 min post-2 min MWM swim.
Morris water maze assessments. The MWM consisted of a circular, galvanized
steel tank (1.8 m in diameter, 0.6 m height). The tank was filled with water (maintained
at 20º C ± 2º C) with a white platform (10 cm diameter) submerged 1 cm below the
water’s surface. A sufficient volume of white paint (Valspar 4000 latex paint, Lowe’s
Companies Inc., Mooresville, NC) was added to render the water opaque and the
platform invisible. In addition to distal visual cues (shapes) on curtains surrounding the
tank (30 cm from the tank wall), five sheets of laminated paper with distinct black-andwhite geometric designs were attached to the sides of the tank serving as proximal
cues. An automated tracking system (ANY-maze, San Diego Instruments, Inc., San
Diego, CA) analyzed the swim path of each subject and calculated distance (path length
between being placed in the water and finding the hidden platform), average swim
speed, number of platform crossings, and percentage of time spent in each quadrant as
well as in the outer ring.
After induction of the FPI, mice were given a five day post-injury recovery period
prior to commencing learning and memory assessment (see Fig. 1A). On post-injury
day 6, mice were given a pre-training acclimation session (habituation) during which
they were allowed to swim in the pool for 4 min without the platform present. To assess
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reference memory DAGL-β-/- and -β+/+ mice received 8 MWM Fixed Platform acquisition
training days (i.e. a submerged platform remained in the same location across days)
each day consisting of four-120 s duration trials separated by 10±2 min inter-trial
intervals. Four points along the perimeter of the maze arbitrarily designed as N, S, E, W,
served as starting points from where the mice were released, facing the tank wall. The
order of release location was counterbalanced across trials with each point used only
once per acquisition day. Once a mouse located the hidden platform, it was allowed to
remain there for 15 s before being removed from the tank. If a mouse failed to locate the
platform within 120 s, it was manually guided to it.
Assessment for the expression of spatial memory occurred the next day (postinjury day 17) in a single MWM Fixed Platform Probe Trial (to measure spatial bias for
the previous platform location where the submerged platform was removed from the
tank). Given that the Fixed Platform probe trial acts as an extinction trial for prior
learning, on post-injury day 18 mice were given a further day of Fixed Platform training
in which the hidden platform was returned to the same fixed position as during the
acquisition procedure.
Reversal learning and cognitive flexibility were assessed using a Reversal task in
which the submerged platform was moved to a new location. Thus, mice first must
inhibit responses swimming to the original platform location before exploring alternative
solution paths. In the Reversal training task, mice were given four daily reversal
sessions, with all other task parameters identical to the acquisition procedure, followed
again by a 2 min probe trial on day 25 post-injury.
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A cued task assessed mice for potential sensori-motor/motivational deficits. The
platform location was made visible by placing a 10 cm high, 4 cm diameter black
cylinder on the submerged platform (assessing the capacity of the mice to find the
submerged platform irrespective of reliance on spatial cues). Mice were given three
cued sessions, during which the location of the submerged platform was changed daily.
On two Cued training days mice were given four-120 s trials separated by 10±2 min
inter-trial intervals (release counterbalanced across the four possible start positions N,
S, E, and W). On the third cued session, mice were given two-120 s trials separated by
10±2 min inter-trial intervals (released from the farthest two release points).
Neurological motor assessments. Mice were trained in assays of neurological
motor impairment, Rotarod and Neurological Severity Score (NSS), 2 days prior to
injury, and 1, 2, 3, 7, 14 and 21 days post-injury (see Fig. 1A).
The Rotarod assay used an IITC Life Science Rota-Rod (Woodland Hills, CA)
with 3 cm diameter rotating drums. Each mouse was placed on the device facing the
experimenter (forward direction), rotating the drum in the opposite direction. The mice
were allowed to remain stationary for 10 s at 0 rpm prior to the start of the test. Mice
were given one habituation trial to adapt to the testing equipment using a fixed speed of
4 rpm for 60 s. All subsequent trials used an accelerating protocol, starting at 4 rpm and
ending at 40 rpm ramping over 60 s, with a 2 min test period. Each trial ended prior to
the 2 min cut off if the mouse fell off the rod, or gripped the device and spun around two
full revolutions without attempting to walk on the drum. Mice were given one test per
day.
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The NSS is a 10-point task battery assessment to evaluate the functional
neurological status of mice based on the presence of reflexes and the ability to perform
motor and behavioral tasks (see Schurman et al., 2017 for NSS task battery
description). One point is awarded for failing to perform a particular task, and no points
for succeeding. The points of each of the 10 individual tasks are summed to achieve the
NSS, in which a score of zero represents a naïve uninjured mouse, whereas a maximal
score of 10 indicates severe neurological dysfunction.
Tests of Affective Behavior. Mice were assessed for affective behavior using
the light-dark box and the elevated plus maze on day 32 and 33 post-injury respectively
(see Fig. 1A).
The light-dark box consisted of a small enclosed dark box (36 x 10 x 34 cm) with
an opening (6 x 6 cm) to a larger brightly lit area (36 x 21 x 34 cm). Mice spent 1 h
acclimatization to the testing room, then were placed in the light side of the apparatus to
explore freely for 5 min. An automated tracking system (ANY-maze, San Diego
Instruments, Inc., San Diego, CA) recorded time spent in the light area for each subject,
number of entries into the light side, and the total distance travelled.
The elevated plus maze (Hamilton-Kinder, Poway, CA) consisted of a plusshaped platform elevated 60 cm above the floor, with a central platform (5 x 5 cm)
allowing access to each of the four arms. Two opposing arms (35 x 5 cm) were
enclosed by 15 cm high walls, the further two arms had no walls. Mice were
acclimatized to the testing room for 1 h, then placed on the central platform facing an
open arm and allowed to explore the apparatus for 5 min. An array of photocells
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connected to a MotorMonitor® system (Hamilton-Kinder, Poway, CA) recorded time in
the open arms, number of open arm entries, and the total distance travelled.
Experimental design and statistical analysis. Behavioral data are presented
as mean + SEM, The criterion for significance in all experiments was set at p < 0.05,
and all analyses were conducted using IBM SPSS Statistics 22 for Windows (IBM
Software, New York, NY).
All changes in body temperature, % baseline weight, MWM Fixed Platform and
Reversal acquisition, MWM swim speed, Rotarod, and NSS data were analyzed using a
mixed factor ANOVA (°C, grams, distance, cm/s, and latency measures). All probe trial
and cued task analyses, righting time, baseline temperature, light-dark box, and
elevated plus maze data were analyzed using a two-way ANOVA (% time in quadrant,
% time in outer ring, cm/s, temperature, time, entries, and distance measures). Baseline
weight was analyzed by an independent groups t-test. All survival analyses were
conducted using a Chi Square analyses by each injury severity.

Results
Figure 1: DAGL-β deletion increased FPI survival and injury-induced
righting times, with no impact on body temperature or TBI-induced weight loss.
Per the experimental timeline (Figure 1A), DAGL-β-/- mice were significantly spared from
FPI-induced mortality (day 0) compared to DAGL-β+/+ mice, (X2(1, N=28) = 4.53, p = 0.033,
Chi Square, Figure1B). However, a significant righting time interaction (F(1,51) = 4.63, p =
0.036, ANOVA, Figure 1C) revealed that TBI-DAGL-β-/- mice took longer to recover from
post-traumatic unconsciousness than TBI-DAGL-β+/+ mice (p = 0.003). DAGL-α-/- mice,
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approximately 30-60 min post-surgery, exhibited tonic-clonic seizure-like movements
followed by spontaneous death. Of eight mice tested (DAGL-α+/+ n=1, DAGL-α-/- n=7),
only three lived to receive a TBI (one DAGL-α+/+ and two DAGL-α-/- mouse, all of which
survived) (data not graphed).
No differences in body temperature were seen between DAGL-β+/+ and DAGL-β-/mice at baseline (non-significant 3-way interaction; F(1,51) = 0.004, p = 0.953, ANOVA,
Figure 1D), and no main effect of injury (F(1,51) = 0.532, p = 0.469, ANOVA). However, a
significant main effect of time (F(3,153) = 795, p = 0.000, ANOVA, Figure 1E) revealed
that body temperature recovery (following a 2-min MWM swim) changed over time, with
greater ∆ body temperature at 1 min (p = 0.000), 3 min (p = 0.000), and 10 min (p =
0.000) post-swim compared to 30 min. Although a significant 2-way ∆ body temperature
time by injury status interaction occurred (F(3,153) = 2.95, p = 0.035, ANOVA), sidak posthoc testing revealed no significant difference between sham and injured mice at any
time point (1 min; p = 0.957, 3 min; p = 0.364, 10 min; p = 0.088, 30 min; p = 0.527),
suggesting no relevant effect of injury on body temperature recovery.
Post-injury weight evaluation revealed a main effect of injury (F(1,51) = 16.4, p =
0.000, ANOVA, Figure 1F) in that TBI lowered percent baseline weight, though a main
effect of day showed that all mice increased their percent baseline weight by day 13
through day 30 (consecutively; p = 0.009, p = 0.000, p = 0.001, p = 0.000, p = 0.001, p
= 0.002, p = 0.000, p = 0.000, p = 0.000, p = 0.038, p = 0.002) compared to day 1 postinjury. No pre-existing phenotypic weight differences were seen between DAGL-β+/+ and
DAGL-β-/-mice at baseline (t (53) = 1.14, p = 0.2605, T-test, Figure 1G).
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Figure 2: DAGL-β deletion did not protect against TBI-induced reference
memory deficits or altered search strategy. In MWM Fixed Platform acquisition, a
main effect of injury showed that TBI mice had longer swim distances to the platform
than sham mice (F(1,51) = 0.237, p = 0.000, ANOVA, Figure 2A). This TBI-induced deficit
also occurred in DAGL-β-/- mice (non-significant 3-way interaction; F(7,357) = 0.613, p =
0.745, ANOVA) with no main effect of genotype (F(1,51) = 0.730, p = 0.397, ANOVA),
demonstrating that TBI produced reference memory deficits are irrespective of DAGL-β
deletion. A significant main effect of day (F(7,357) = 32.2, p = 0.000, ANOVA) showed that
all mice had significantly reduced swim distances on Fixed Platform days 2 through 8
(all p = 0.000) compared to day 1. In the evaluation of swim speed, a significant main
effect of injury (F(1,51) = 8.69, p = 0.005, ANOVA, Figure 2B) showed that TBI mice
swam slower than sham mice during Fixed Platform acquisition trials.
The probe trial (Figure 2C, 2D, 2E) test also revealed significant performance
deficits in TBI mice. Specifically, these mice spent a reduced percentage of time in the
target quadrant (main effect of injury; F(1,51) = 8.33, p = 0.006, ANOVA, Figure 2C), a
concomitantly increased percentage of time in the control quadrant (main effect of
injury; F(1,51) = 12.2, p = 0.001, ANOVA, Figure 2C), and had reduced platform location
entries (main effect of injury; F(1,51) = 6.25, p = 0.016, ANOVA, Figure 2E) compared to
sham mice. DAGL-β deletion did not affect any of these indices. No impact of TBI was
evident in probe trial distance to the prior platform location (non-significant main effect;
F(1,51) = 2.42, p = 0.126, ANOVA, Figure 2D). TBI mice also demonstrated altered probe
trial search strategy in which they spent significantly more time in the MWM outer ring
than sham mice (F(1,51) = 5.87, p = 0.019, ANOVA, Figure 2F).
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The absence of significant differences in cued task performance (F(1,51) = 0.323,
p = 0.572, ANOVA; Figure 4H) or cued task swim speed (F(1,51) = 0.159, p = 0.692,
ANOVA; Figure 4I) suggests that TBI mice did not produce overt sensorimotor or
motivational alterations.
Figure 3: DAGL-β deletion did not protect against TBI-induced reversal task
memory deficits or altered reversal search strategy. During MWM Reversal
acquisition, TBI mice had longer swim distances to find the Reversal platform than
sham mice (main effect of injury; F(1,51) = 4.64, p = 0.036, ANOVA, Figure 3A). This
deficit in reversal acquisition was not spared in DAGL-β-/- mice (non-significant 3-way
interaction; F(3,153) = 0.075, p = 0.973, ANOVA: non-significant main effect of genotype;
F(1,51) = 3.64, p = 0.062, ANOVA), demonstrating that while TBI produces deficits in
cognitive flexibility, DAGL-β deletion affords no such protection. A significant main effect
of day (F(3,153) = 14.9, p = 0.000, ANOVA) showed that all mice had significantly reduced
distances to the platform on Reversal days 2 (p = 0.003), 3 (p = 0.004), and 4 (p =
0.000) compared to day 1. In the evaluation of swim speed, a significant main effect of
injury (F(1,51) = 5.72, p = 0.020, ANOVA, Figure 3B) showed that TBI mice swam slower
than sham mice during Reversal acquisition trials. Although a significant 2-way Reversal
swim speed day by genotype interaction occurred (F(3,153) = 4.20, p = 0.007, ANOVA),
sidak post-hoc testing revealed no significant difference between DAGL-β+/+ and DAGLβ-/- mice at any time point (day 1; p = 0.329, day 2; p = 0.708, day 3; p = 0.901, day 4; p
= 0.691), suggesting that genotype did not relevantly affect Reversal swim speed.
The Reversal probe test (Figure 3C, 3D, 3E) also revealed that TBI elicited a
significant performance deficit. Specifically, injury resulted in an increased distance to
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the prior Reversal platform location (main effect of injury; F(1,51) = 6.13, p = 0.017,
ANOVA, Figure 3D), and a reduction in the number of Reversal platform location entries
(main effect of injury; F(1,51) = 11.1, p = 0.002, ANOVA, Figure 3E) compared to sham
mice. Again, DAGL-β-/- mice did not differ from DAGL-β+/+ mice. However, none of the
factors affected the percentage of time spent in the target or control quadrants in the
Reversal probe trial test (non-significant main effect of injury Target quadrant; F(1,51) =
0.782, p = 0.381, non-significant main effect of injury Control quadrant; F(1,51) = 3.07, p =
0.086, ANOVA, Figure 3C). TBI mice also demonstrated an increased duration of time
spent in the MWM outer ring during the probe trial compared with the sham mice (F(1,51)
= 4.61, p = 0.037, ANOVA, Figure 3F).
Figure 4: DAGL-β deletion did not protect against TBI-induced neurological
motor impairments. During Rotarod testing, a significant 2-way interaction of day by
injury (F(7,357) = 6.20, p = 0.000, ANOVA, Figure 4A), irrespective of genotype, revealed
that TBI mice had reduced latencies to fall on post-injury days 1 (p = 0.000), 2 (p =
0.000), and 3 (p = 0.000) compared to sham mice, suggesting that TBI produced
neurological motor Rotarod deficits, which resolved by day 7 post-injury. Similarly,
DAGL-β-/- mice undergoing TBI mice showed Rotarod performance deficits (nonsignificant 3-way interaction; F(7,357) = 0.916, p = 0.494, ANOVA: non-significant main
effect of genotype; F(1,51) = 0.449, p = 0.506, ANOVA), suggesting that DAGL-β deletion
did not protect against neurological motor impairments as measured by the Rotarod.
A significant 2-way interaction of day by injury (F(6,306) = 8.04, p = 0.000, ANOVA,
Figure 4B) revealed increased NSS scores in TBI mice on post-injury days 1 (p =
0.002), 2 (p = 0.028), and 7 (p = 0.010) compared to sham mice, irrespective of
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genotype. These findings suggest that TBI produced neurological motor NSS deficits
resolved by day 14 post-injury. The finding that genotype did not affect NSS scores
(non-significant 3-way interaction; F(6,306) = 0.243, p = 0.962, ANOVA: non-significant
main effect of genotype; F(1,51) = 1.20, p = 0.279, ANOVA) suggests that DAGL-β
deletion did not protect against neurological motor impairments as measured by the
NSS.
Figure 5: Anxiety-like behavior was unaffected by DAGL-β deletion or TBI.
In the light-dark box assay, neither TBI nor DAGL-β deletion produced any change in
time spent in the light area (non-significant main effect of injury; F(1,51) = 0.002, p =
0.964, ANOVA: non-significant main effect of genotype; F(1,51) = 2.69, p = 0.107,
ANOVA, Figure 5A), or entries into the light area (non-significant main effect of injury;
F(1,51) = 0.137, p = 0.713, ANOVA: non-significant main effect of genotype; F(1,51) =
0.005, p = 0.943, ANOVA), suggesting that when evaluated at post-injury day 32 neither
TBI nor DAGL-β deletion affected behavior in this assay. No changes in Light-Dark box
activity were seen between groups as measured by total distance traveled (nonsignificant 2-way interaction; F(1,51) = 0.571, p = 0.453, ANOVA).
Likewise, the elevated plus maze test failed to reveal effects of either TBI or
DAGL-β deletion in time spent in the open arms (non-significant main effect of injury;
F(1,51) = 2.90, p = 0.095, ANOVA: non-significant main effect of genotype; F(1,51) = 0.046,
p = 0.832, ANOVA, Figure 5B), or entries into the light area (non-significant main effect
of injury; F(1,51) = 0.422, p = 0.519, ANOVA: non-significant main effect of genotype;
F(1,51) = 0.355, p = 0.554, ANOVA). These findings suggest that when evaluated at postinjury day 33 neither TBI nor DAGL-β deletion impacted performance in the elevated
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plus maze, a common test used to infer anxiety-related behavior. No changes in
elevated plus maze activity were seen between groups as measured by total distance
traveled (non-significant 2-way interaction; F(1,51) = 1.63, p = 0.207, ANOVA).
Figure 6: The survival protective phenotype of mouse DAGL-β deletion
persisted at increased injury severity. Male DAGL-β-/- mice were significantly spared
from FPI-induced mortality compared to male DAGL-β+/+ mice when injury magnitude
was increased to 2.0 atm, (X2(1, N=31) = 4.31, p = 0.038, Chi Square, Figure1A), as well
as at 2.17 atm, (X2(1, N=28) = 4.09, p = 0.043, Chi Square), suggesting that the survival
protective phenotype of DAGL-β-/- mice persists with increased injury severity. In
contrast, female DAGL-β-/- and -β+/+ mice showed high survival rates at either 2.0 atm
(X2(1, N=30) = 1.03, p = 0.309, Chi Square) or 2.17 atm (X2(1, N=28) = 2.15, p = 0.142, Chi
Square). The high survival rates of females (2.0 atm; DAGL-β+/+ 93%, DAGL-β-/- 100%,
2.17 atm; DAGL-β+/+ 86%, DAGL-β-/- 100%) suggest that being female was generally
protective.

Discussion
TBI disrupted Fixed Platform and Reversal task performance accompanied by nonspatial search strategies, irrespective of genetic deletion of DAGL-β. Thus, contrary to
our hypothesis, deletion of this enzyme did not provide protection from TBI-induced
spatial learning and memory impairments. Injury also produced changes in neurological
motor function and body weight, but without impacting temperature regulation or
performance in common assays used to infer anxiety. In addition, no phenotypic
differences from DAGL-β disruption were evident in these measures. Unexpectedly,
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DAGL-β deletion produced a survival protective phenotype, which persisted at
increased injury severities in male mice. However, female mice did not display injuryrelated mortality, regardless of genotype.
While the disease state following a TBI is composed of heterogeneous
secondary injury mechanisms, chronic neuroinflammation has been a popular
neuroprotective target, perhaps given the neuroinflammatory temporal profile providing
intervention opportunities following the primary insult. Yet, thus far, all late phase clinical
trials have failed to yield an effective anti-inflammatory neuroprotective treatment
(Chakraborty et al, 2016; Narayan et al, 2002). The modulation of neuroinflammation in
murine models of TBI have seen mixed success. While high dose anti-inflammatories
(NSAIDs and glucocorticosteroids) can exacerbate learning and memory deficits (Brown
et al, 2006; Chen et al, 2009, 2010b), isolated stand-alone drugs targeting
neuroinflammation (antibiotics, COX-1 inhibitors, a plant-based alkaloid, and an
apolipoprotein mimetic peptide) attenuate memory impairment (Ferguson et al, 2017;
Laskowitz et al, 2007; Shang et al, 2014; Siopi et al, 2012). The mixed results of antiinflammatory drug targets in preclinical research and the failed translation to clinical
learning and memory protection is perhaps a consequence of the necessity to promote
the beneficial effects of acute neuroinflammation, while minimizing detrimental chronic
effects. The temporal profile of microglia activation phenotypes may also be of
relevance. Specifically, increased 2-AG production during M2a (alternatively activated)
and M2c (acquired deactivated) microglial phenotypes occurs in concert with increased
CB2 receptor expression, driving the acquisition of further M2 phenotypes and
promoting inflammation resolution (Mecha et al, 2015). Furthermore, DAGL-β
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expression is upregulated during an M2c phenotype (Mecha et al, 2015), suggesting
that DAGL-β may play a temporal dependent role with regards to inflammation
pathology. The current constitutive genetic deletion of DAGL-β may therefore mask time
dependent protective effects of DAGL-β disruption. Future experiments using
pharmacological tools would be valuable to manipulate the timing of DAGL-β disruption,
but are currently challenging given the lack of availability of selective and brain
penetrant DAGL-β inhibitors. Furthermore, 2-AG is a potent CB2 receptor agonist
(Hillard, 2000a), consequently DAGL-β gene deletion may also result in decreased
activation of microglial CB2 receptors. Such reduced CB2 receptor signaling could offset
any presumed beneficial effects of reduced AA metabolites.
The high mortality rates of DAGL-α-/- mice following the craniectomy surgery
precluded systematic investigation of neuronal DAGL disruption. DAGL-α-/- mice are
vulnerable to increased mortality in general (Powell et al, 2015) as well as being more
susceptible to seizures (Sugaya et al, 2016) than DAGL-α+/+ mice. This pre-existing
phenotype may be a consequence of alterations across ontogeny (e.g. decreased
neurogenesis and altered inflammatory responses (Gao et al, 2010; Shonesy et al,
2014; Tanimura et al, 2010) and may lead to increased vulnerability to survival
surgeries that compromise the integrity of the CNS.
The unexpected finding that DAGL-β disruption produced a survival protective
phenotype, although not a frequently explored outcome measure in preclinical studies of
TBI, might point to a surprising and novel understanding of DAGL-β as contributing
towards acute TBI pathology. Despite otherwise susceptible DAGL-β-/- mice surviving
the acute injury period (perhaps represented by the increased righting times of DAGL-β-
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/-

mice compared to -β+/+ mice), no potentiated learning and memory deficits in the

DAGL-β-/- mice suggest these mice were not prone to increased functional impairment.
Interestingly, a clinical study exploring the relationship of cannabinoids to TBI mortality
used urine toxicology screen results and showed decreased mortality in individuals with
a positive THC screen (Nguyen et al, 2014b), the primary psychoactive constituent of
the Cannabis sativa plant. The authors hypothesized that chronic low-dose THC was
mildly pro-inflammatory, producing a pre-conditioning effect where a mildly noxious
stimulus proves to be protective against a more severe subsequent insult. Yet this logic
seems contrary to DAGL-β disruption, found to be anti-inflammatory in vitro (Hsu et al,
2012). The observed mortality in the present study occurred within a 2-min post-injury
window. Therefore, consideration of the processes responsible in terms of secondary
injury mechanisms should also be relevant to such a time scale. Both reactive oxygen
species (ROS) production (e.g. peroxynitrite, hydroxyl radical, etc.) and glutamate
excitotoxicity occur within minutes following injury (Nilsson et al, 1990; Singh et al,
2006). Though few studies have examined injury-induced ROS production at time points
earlier than 30 minutes, evidence suggests that TBI-induced ROS elevation magnitude
is subject to injury force manipulations (Marklund et al, 2001), leaving the investigation
of DAGL-β disruption on injury-induced ROS elevations at 2 min post-TBI as an
interesting future experimental direction. Furthermore, a future avenue of investigation
could include in vivo microdialysis measurement of extra-cellular glutamate at 2-min
post injury.
Another mechanism of consideration, which may contribute towards the survival
protective phenotype of DAGL-β-/- mice, includes ceramides, belonging to the family of
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spingolipids. Spingolipids are essential constituents of all eukaryotic cell membranes, of
which ceramide is composed of sphingosine and a fatty acid and its generation occurs
within minutes through the hydrolysis of sphingomyelin by sphingomyelinases
(Kolesnick and Kronke, 1998). Increases in ceramides have been linked to glutamate
toxicity, mitochondrial dysfunction, and extrinsic apoptotic pathways (Novgorodov et al,
2018). In cancer, the reduction of ceramide accumulation is frequently observed (Morad
and Cabot, 2013) and many chemotherapeutic drugs elevate ceramide (Radin, 2004) to
promote cell death. While there is no reported link between DAGL-β activity and
ceramide production, 2 to 3-fold increases in ceramide levels occur following TBI in rats
(Barbacci et al, 2017; Roux et al, 2016). Of future interest would be to measure
ceramide levels in TBI-DAGL-β-/- mice, which if contributing to the survival phenotype of
these animals we would predict lower accumulation of ceramide in brain compared to
TBI-DAGL-β+/+ mice, providing a neurochemical lipid correlate of TBI survival and
mortality.
A growing body of work implicates the importance of sex differences in response
to TBI. While TBI frequently occurs in young males (Langlois et al, 2006) resulting from
automotive accidents, war, etc., the elderly are also a highly vulnerable population
(Thompson et al, 2006) due mostly as a result of falls, in which men and women are
impacted equally. The present observation that female DAGL-β-/- and -β+/+ mice showed
survival phenotypes after injury is consistent with female mice and rats being generally
protected from TBI-induced mortality compared to male mice/rats (Neese et al, 2010;
Umeano et al, 2017). The high rates of survival in both genotypes of females is likely
occurring through alternative mechanisms than DAGL-β gene deletion. The
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mechanisms behind female protection from TBI mortality as of yet, remain unclear; here
we consider several possibilities. Pre-clinical studies show female mice have differing
inflammatory profiles than male mice following TBI. Female mice demonstrate a
biphasic pro-inflammatory response, whereas male mice show a prolonged single
phase increase in inflammatory mediators (Villapol et al, 2017). Inflammation resolution
profiles also differ, with female mice showing a delayed peak of anti-inflammatory
mediators, whereas male mice again show a single phase (Villapol et al, 2017). Preclinical studies also show a potential hormonal role driving sex differences in TBI
mortality profiles. Umeano et al., 2017 using ovariectomized female mice showed
similar mortality rates to males and concluded that female gonadal hormones may
influence murine TBI mortality outcomes. While both estrogen and progesterone are
neuroprotective when administered to male mice in functional and molecular endpoints
(Lopez-Rodriguez et al, 2015; Meltser et al, 2008; Pascual et al, 2013; Schaible et al,
2014), no known work to date has shown a link to mortality protection by these
hormones in murine studies. Future experiments to evaluate if survival phenotypes in
DAGL-β+/+ male mice could be rescued by estrogen/progesterone pre-treatment might
prove a useful addition to our understanding of sex driven differences in mouse TBI
mortality outcomes. However, female mortality in clinical populations differs to male only
when cohorts are evaluated by age, with pubescent (Ley et al, 2013) and postmenopausal women (Berry et al, 2009; Davis et al, 2006) showing mortality protection,
both being life cycle times of estrogen dominance unbalanced by progesterone.
Furthermore, two large randomized clinical trials found no protection of progesterone
(Skolnick et al, 2014; Wright et al, 2014). As such, the mechanisms by which females
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are protected from TBI mortality compared to males strongly suggest the involvement of
estrogen.
Despite the present finding that DAGL-β deletion was not protective against
mouse spatial learning and memory deficits, continued investigation of
neuroinflammation on TBI outcomes is arguably pertinent. The predisposition of TBI
patients to develop other neurological pathologies such as Alzheimer’s disease, thought
to be a product of prolonged neuroinflammation, support the necessity of further
investigation in this area. In sum, while DAGL-β deletion did not protect against TBIinduced learning and memory deficits nor motor deficits, these findings suggest the
provocative possibility that DAGL-β activity contributes towards TBI-induced acute
mortality in males, implicating this enzyme in acute TBI pathology.
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Figure 3-1. Physiology: DAGL-β-/- mice showed increased survival and longer
righting times. A, Experimental timeline, days relative to injury (Sham-DAGL-β+/+ n =
12, Sham-DAGL-β-/- n = 15, TBI-DAGL-β+/+ n = 12, TBI-DAGL-β-/- n = 16). TBI lowered
body weight and increased righting times, with no change in body temperature
regulation. DAGL-β-/- mice showed increased survival and longer righting times with no
change in weight loss. B, DAGL-β-/- mice showed increased survival from TBI compared
to DAGL-β+/+ mice (* p < 0.05, vs. DAGL-α+/+ mice), as well as C, increased righting
times (** p < 0.01, vs. TBI-DAGL-α+/+ mice). No changes between experimental groups
were seen in either D, baseline body temperature or E, body temperature recovery
following a 2-min MWM swim. F, TBI produced lowered % baseline body weights with
no effect of genotype (*** p < 0.001, TBI vs. Sham mice), and G, DAGL-β-/- mice
showed no phenotypic body weight differences to DAGL-β+/+ mice prior to TBI. Values
represent mean + or ± SEM.
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Figure 3-2. DAGL-β-/- mice showed no TBI-induced reference memory deficit
protection. DAGL-β deletion did not protect against TBI-induced MWM Fixed Platform
task impairments or altered search strategy (Sham-DAGL-β+/+ n = 12, Sham-DAGL-β-/n = 15, TBI-DAGL-β+/+ n = 12, TBI-DAGL-β-/- n = 16). A, During MWM Fixed Platform
acquisition TBI mice demonstrated greater distances to find the platform with no
performance difference evident between genotype (*** p < 0.001, TBI vs. Sham mice)
as well as B, slower swim speeds (** p < 0.01, TBI vs. Sham mice). During a MWM
Fixed Platform probe trial C, TBI mice showed less spatial preference for the target
quadrant with no performance difference evident between genotype (** p < 0.01, TBI vs.
Sham mice), while D, no group differences were seen in distance to the prior platform
location, but E, TBI mice showed fewer platform crossings of the prior platform location
(* p < 0.05, TBI vs. Sham mice). During probe trial F, TBI mice also spent more time in
the outer ring of the MWM (* p < 0.05, TBI vs. Sham mice) suggesting that TBI changes
MWM search strategy, illustrated by also by G, representative swim paths of TBI and
Sham, DAGL-β+/+ and DAGL-β-/- mice, where TBI mice show circular search strategies.
During a MWM Cued task H, no differences in distance to a cued platform were evident,
or I, swim speed, suggesting no senori-motor or motivational confounds were present.
Values represent mean + or ± SEM.
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Figure 3-3. DAGL-β-/- mice showed no TBI-induced cognitive flexibility deficit
protection. DAGL-β deletion did not protect against TBI-induced MWM Reversal task
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impairments or altered Reversal search strategy (Sham-DAGL-β+/+ n = 12, ShamDAGL-β-/- n = 15, TBI-DAGL-β+/+ n = 12, TBI-DAGL-β-/- n = 16). A, During MWM
Reversal acquisition TBI mice demonstrated greater distances to find the platform with
no performance difference evident between genotype (** p < 0.01, TBI vs. Sham mice)
as well as B, slower swim speeds (* p < 0.05, TBI vs. Sham mice). During a MWM
Reversal probe trial C, All groups showed no spatial preference for the Reversal target
quadrant, while D, TBI mice showed greater distances to the prior Reversal platform
location (* p < 0.05, TBI vs. Sham mice) E, as well as fewer platform crossings of the
prior Reversal platform location (** p < 0.01, TBI vs. Sham mice). During Reversal probe
trial F, TBI mice also spent more time in the outer ring of the MWM (* p < 0.05, TBI vs.
Sham mice) suggesting that TBI changes MWM Reversal search strategy, illustrated by
also by G, representative swim paths of TBI and Sham, DAGL-β+/+ and DAGL-β-/- mice,
where TBI mice show circular search strategies. Values represent mean + SEM.
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Figure 3-4. DAGL-β-/- mice showed no TBI-induced neurological motor deficit
protection. DAGL-β deletion did not protect against TBI-induced neurological motor
deficits (Sham-DAGL-β+/+ n = 12, Sham-DAGL-β-/- n = 15, TBI-DAGL-β+/+ n = 12, TBIDAGL-β-/- n = 16). A, During the Rotarod assay, TBI mice demonstrated reduced
latencies to fall on post-surgery days 1, 2, and 3, with no performance difference
evident between genotype (*** p < 0.001, TBI vs. Sham mice days 1-3 post-injury). B,
During NSS evaluation, TBI mice demonstrated greater NSS scores on post-injury days
1, 2, and 7 (** p < 0.01, TBI vs. Sham mice on day 1, and * p < 0.05, TBI vs. Sham mice
on days 2 and 7). Values represent mean + SEM.
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Figure 3-5. Neither DAGL-β-/- deletion nor TBI altered performance on tests of
affective behavior. Both light-dark box and elevated plus maze performance was
unaffected by DAGL-β deletion or TBI (Sham-DAGL-β+/+ n = 12, Sham-DAGL-β-/- n =
15, TBI-DAGL-β+/+ n = 12, TBI-DAGL-β-/- n = 16). In the light-dark box no performance
difference was evident as a result of TBI or between genotype for either A, time spent in
the light area, B, entries into the light area, or C, distance travelled. The elevated plus
maze also saw no performance differences as a result of TBI or between genotype for
either D, time spent in the open arms, E, entries into the open arms, or F, distance
travelled. Values represent mean + SEM.
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Figure 3-6. DAGL-β-/- mice exhibit a survival protective phenotype. The survival
protective phenotype of DAGL-β-/- mice persisted at increased injury severity in male
mice (male TBI mice; [2.0 atm]-DAGL-β+/+ n = 16, [2.0 atm]-DAGL-β-/- n = 15, [2.17
atm]-DAGL-β+/+ n = 14, [2.17 atm]-DAGL-β-/- n = 14), whereas being female was
generally protective (female TBI mice; [2.0 atm]-DAGL-β+/+ n = 15, [2.0 atm]-DAGL-β-/- n
= 15, [2.17 atm]-DAGL-β+/+ n = 14, [2.17 atm]-DAGL-β-/- n = 14). In male TBI mice A, at
both 2.0 atm and 2.17 atm DAGL-β-/- mice demonstrated increased survival (* p < 0.05,
DAGL-β-/- vs DAGL-β+/+ mice). Whereas female TBI mice B, showed no significant
difference in survival rates between DAGL-β-/- and DAGL-β+/+ mice.
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Chapter IV
Chapter Introduction

The third and final goal of this dissertation was to understand the in vivo role of
diacylglycerol lipase-α (DAGL-α), the second of the two 2-AG biosynthetic enzymes, in
hippocampal-dependent mouse learning and memory regulation under physiological
conditions.
Hippocampal-dependent learning and memory. The hippocampus and its
connection to other brain regions is fundamental to the memory of our experiences,
their content, and our ability to re-play them. That is, episodic memory. The
hippocampus specifically supports the storage and recollection of temporal-spatial
contextual information. The study of
several patients with selective damage
to the hippocampus has helped provide
insight into the function of this brain
structure in learning and memory. One
such patient, R.B., had complete loss of
neurons from bilateral hippocampal
CA1 region(see Figure 4-A) (where
previously processed information by
other hippocampal regions is sent out

Figure 4-A. Hippocampal regional connectivity:
DG; dentate gyrus, Sub; subiculum, Pre;
presubiculum, Para; parasubiculum, EC;
entorhinal cortex (adapted from publically
available lecture slides by Dr. David S.
Touretzky).
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via the subiculum and entorhinal cortex and projects back to the neocortex, among
other structures) as a result of complications from an artery bypass surgery (ZolaMorgan et al, 1986). R.B. experienced anterograde amnesia, with difficulty acquiring
new information. Specifically R.B. had difficulty remembering word lists and story recall,
and he reported loss of knowledge of events from a previous day such as talking to his
children. A second example, V.C., is a patient who experienced loss of entire rostralcaudal length hippocampal volume as a result of an epileptic seizure (Cipolotti et al,
2001). V.C. also experienced severe anterograde amnesia, profoundly impairing his
ability to acquire new information (story recall, word associations, newly experienced
events and their contexts). While such selective and restricted brain damage to the
hippocampus is rare, these cases support the assertion of Dr. Brenda Milner, who
argued the critical importance of the
hippocampus for episodic memory through
her revolutionary work with H.M. (whose
personal tragedy and removal of his
bilateral temporal lobes led to testable
hypotheses about what regions of the brain
were critical for memory) (Milner, 1970;
Scoville and Milner, 1957).
The ways in which the hippocampus
contributes toward memory storage and
Figure 4-B. Structures adjacent to the Human
Hippocampus (adapted from publically available
lecture slides by Dr. David S. Touretzky).

retrieval has been described by the
indexing theory of memory (Teyler and
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DiScenna, 1986), and since extensively supported by human and murine research
(Teyler and Rudy, 2007). An experience activates patterns of neocortical activity which
project to the hippocampus and responding hippocampal synapses are strengthened by
long-term potentiation mechanisms (see next section). No memory content is stored in
the hippocampus, but it acts as a system to retrieve neocortical stored information
through activation of a hippocampal representation projecting back to the neocortex to
activate patterns representing the entire experience. The neocortex alone is perhaps
not well suited to the acquisition and retrieval of single memory episodes given its low
associative connectivity (which might produce difficulty in distinguishing separate yet
similar experiences) (Rudy, 2014).
Long-term potentiation. The tri-synaptic loop organization of the hippocampus
makes it uniquely suited to the study of neuronal connections, where the stimulation of
fibers known to synapse onto a particular subfield can be measured using a recording
electrode placed near to neurons of that subfield.
The original work by Bliss and Lomo, 1973
stimulated fibers in the perforant path, and then
recorded from dentate gyrus neurons. They
found that a strong stimulus applied after a weak
stimulus produced an enduring increase in the
synaptic response to the same weak stimulus,
which they termed long-term potentiation (see
Figure 4-C). It is now considered that experience
is stored in the brain because it modifies the
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Figure 4-C. Graphical representation
of long-term potentiation. A strong
stimulus (SS) produced an enduring
increase in the synaptic response to
the weak stimulus (WS).

strength of synapses of connecting neurons. As such, Long-term potentiation is the idea
that experience can be stored by altering the strength of neuron to neuron synaptic
connections within networks of neurons, and is currently the best proposed molecular
basis of memory.
DAGL-α and hippocampal-dependent learning and memory. The dominant
production enzyme of 2-AG in brain is DAGL-α (Bisogno et al, 2003a; Jung et al, 2007),
yet the biosynthetic pathways of 2-AG are almost as diverse as its catabolism. Two
further biosynthetic pathways exist (see Figure 4-D), one through LPA phosphatase
(Nakane et al, 2002) and the other through PLA1/lyso-PLC (Higgs and Glomset, 1994).
While the involvement of
these latter and secondary
pathways in the production of
2-AG is yet to be fully
evaluated, they have been
hypothesized as being
responsible for some
endocannabinoid-mediated
Figure 4-D. 2-AG biosynthetic pathways: 2-AG; 2-arachidonyl
glycerol; 2-arachidonoyl-LPA; 2-arachidonoyl-lysophosphatidic
acid, 2-arachidonoyl-LPI; 2-arachidonoyl
lysophosphatidylinositol, 2-LPA phosphatase; 2lysophosphatidic acid phosphatase, DAGL-α/β; diacyglycerol
lipase-α/β; lyso-PLC; lyso-phospholipase C, PIP2;
phosphatidylinositol biphosphate, PIP2 phosphatase;
phosphatidylinositol biphosphate phosphatase, PI;
phosphatidylinositol, PLA1; Phospholipase A1, PLCβ;
phospholipase Cβ.
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synaptic plasticity found to be
insensitive to DAGL inhibitors
(Zhang et al, 2011), and
perhaps are also responsible
for low basal 2-AG levels

measurable in DAGL-α-/- mice.
DAGLs are expressed in bacteria, fungi, plants, and animals. Mammalian DAGLs
are widely expressed in the CNS, and specifically DAGL-α is abundantly expressed in
the hippocampus (Katona et al, 2006; Yoshida et al, 2006). The distinct cellular
expression patterns of DAGLs in part determine their physiological functions. DAGL-α is
expressed on neurons, specifically hippocampal pyramidal cell dendritic spines
(Yoshida et al, 2006), with a growing body of evidence to support its importance for the
modulation of neurotransmission (Gao et al, 2010; Tanimura et al, 2010). While DAGLα-/- mouse models have pointed to the importance of this enzyme in a variety of
physiological/psychological functions; anxiety, seizure activity, and sociability (Shonesy
et al, 2014, 2018; Sugaya et al, 2016), the present work considers the importance of
DAGL-α for hippocampal-dependent spatial memory in the mouse model organism.
Summary. The following work evaluates the hippocampal-dependent learning
and memory contributions of DAGL-α, using pharmacological and genetic manipulations
under the working hypothesis that DAGL-α is necessary for spatial learning and memory
in mice under normal physiological conditions. The present chapter tests this hypothesis
under three levels of investigation; cellular responses to LTP, in vivo spatial learning
and memory deficits, and neurochemical correlates of behavior (eCB lipid levels) in
brain areas important for learning and memory. The unique findings that DAGL-α
disruption impairs acquisition and reversal tasks, but not expression, extinction or
forgetting, implicates DAGL-α as being selectively important for the integration of new
spatial information.
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Diacylglycerol lipase-alpha regulates hippocampal-dependent learning and
memory processes in mice
(Submitted for publication)
Disclosure: all electrophysiology experiments were conducted in the laboratory of Dr.
Qing Song Lui, primarily by Laikang Yu and Xiaojie Liu, and Mass Spectrometry
analysis was conducted by Justin Poklis.

Introduction
A growing body of evidence implicates the importance of 2-arachidonoyl glycerol (2AG), the most highly expressed endogenous cannabinoid in brain, in regulating learning
and memory. Diacylglycerol lipase (DAGL) forms 2-AG through the hydrolysis of
diacylglycerols (Chau and Tai, 1981; Okazaki et al, 1981) and exists as two distinct
biosynthetic enzymes, DAGL-α and DAGL-β (Bisogno et al, 2003a) that are expressed
on distinct cell types, as well as in brain areas important for learning and memory
(Katona et al, 2006; Lafourcade et al, 2007). Within the central nervous system, DAGLβ is highly expressed on microglia, while DAGL-α, expressed on synapse-rich plasma
membranes of dendritic spines (Yoshida et al, 2006), serves as the principal synthetic
enzyme of 2-AG on neurons (Viader et al, 2015a).
DAGL-α modulates neurotransmission through distinct processes of
neurogenesis and endocannabinoid-mediated short-term synaptic plasticity, implicating
it in learning and memory processes. Adult neurogenesis represents a form of cellular
plasticity in the developed brain. Two prominent brain areas showing adult
neurogenesis, the subventricular zone and the hippocampus, that express high levels of
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DAGL-α (Goncalves et al, 2008) undergo marked reductions in the proliferation of
neuronal progenitor cells in DAGL-α-/- mice (Gao et al, 2010). Similarly, the nonselective DAGL inhibitors RHC80267 and tetrahydrolipstatin reduce proliferation of
neuronal progenitor cells in the subventricular zone (Goncalves et al, 2008). DAGL-α
also plays an essential role in endocannabinoid-mediated retrograde synaptic
suppression in which 2-AG synthesized at post-synaptic terminals acts as a retrograde
messenger to activate the pre-synaptic cannabinoid receptor type 1 (CB1), which
inhibits synaptic transmission. Tanimura et al. (2010) reported that deletion of DAGL-α,
but not DAGL-β, annihilated two forms of endocannabinoid-mediated short-term
synaptic plasticity, depolarization-induced suppression of excitation (DSE) and inhibition
(DSI) in hippocampus, striatum, and cerebellum. Similarly, Gao et al. (2010) replicated
these findings in hippocampus, and Yoshino et al. (2011) reported that DAGL-β plays a
necessary role in DSI in prefrontal cortex (PFC). Furthermore, the DAGL inhibitor DO34,
blocked DSE in cerebellar slices and DSI in hippocampal slices in a concentration
dependent manner (Ogasawara et al, 2016).
The cell signaling events that occur after learning are frequently studied in terms
of long-term potentiation (LTP). Carlson et al. (2002) demonstrated that transient
release of endocannabinoids by depolarization facilitated the induction of LTP when
preceded by DSI, suggesting that endocannabinoids may enhance plasticity at Schaffer
collateral-CA1 synapses through a disinhibitory action. However, the role that the major
2-AG biosynthetic enzyme DAGL-α plays in the induction of LTP remains unknown.
Here we hypothesize that this enzyme plays a necessary role in the induction of LTP.
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Accordingly, we predict that pharmacological inhibition or genetic deletion of DAGL-α
will disrupt LTP.
The present study also investigated the in vivo role of DAGL-α in learning and
memory. Specifically, we evaluated whether endocannabinoid-regulated short-term
synaptic plasticity disruption caused by deletion or inhibition of this enzyme translates to
deficits in Morris water maze model (MWM) of learning and memory. Given the
important role of hippocampal neurogenesis in the processing of spatial memory
(Lieberwirth et al, 2016), we investigated the consequences of DAGL-α disruption on
spatial memory processes of acquisition, expression, extinction, forgetting, and reversal
in the MWM. To circumvent known pitfalls related to constitutive genetic deletions, such
as the role of DAGL-α in axonal guidance during development (Williams et al, 2003), we
utilized the DAGL-α/β inhibitor, DO34, and DAGL-α-/- mice. Because DO34 also inhibits
other serine hydrolases (i.e., ABHD2, ABHD6, CES1C, PLA2G7, PAFAH2), we also
evaluated DO53, a structural analog of DO34 that cross-reacts with these off-targets but
does not inhibit DAGL (Ogasawara et al, 2016).
In the present study, we ascertain the consequences of DAGL-α disruption at
three levels of investigation; cellular responses to LTP, in vivo spatial learning and
memory deficits, and alterations of endocannabinoid lipids, their substrates and
metabolites, in hippocampus, prefrontal cortex, striatum, and cerebellum (brain areas
important for learning and memory showing high DAGL-α activity [Baggelaar et al.,
2017]).
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Materials and Methods
Animals. Subjects consisted of adult male C57BL/6J mice (Jackson
Laboratories, Bar Harbor, Maine), and DAGL-α-/-,-α+/-, and -α+/+ mice on a mixed 99%
C57BL/6 (30% J, 70% N) and 1% 129/SvEv background, as previously described (Hsu
et al, 2012). DAGL-α+/- mouse breeding pairs were originally generated in the Cravatt
laboratory and transferred to Virginia Commonwealth University. All mice (age 8-10
weeks) were pair-housed under a 12 h light/12 h dark cycle (0600 to 1800 h), at a
constant temperature (22ºC) and humidity (50-60%), with food and water available ad
libitum. All experiments were conducted in accordance with the National Institute of
Health (NIH) Guide for the Care and Use of Laboratory Animals (NIH Publications No.
8023, revised 1978), and were approved by the Virginia Commonwealth University and
Medical College of Wisconsin Institutional Animal Care and Use Committees.
Electrophysiology. For LTP experiments, DAGL-α+/+, -α+/-, -α-/- and C57BL/6J
mice were anaesthetized under isoflurane inhalation and decapitated. Hippocampi were
dissected (in C57BL/6J mice 2 h post vehicle [VEH], DAGL-α inhibitor DO34 (Cravatt
Laboratory, La Jolla, CA) [30 mg/kg], or its control analog and ABHD6 inhibitor DO53
[30 mg/kg] administration) and were embedded in low-melting-point agarose (3%,
Sigma-Aldrich A0701). Transverse hippocampal slices (400 μm thick) were prepared
using a vibrating slicer (Leica VT1200s) (Pan et al, 2011; Zhang et al, 2015). Slices
were prepared at 4-6°C in a solution containing (in mM): 68 sucrose, 2.5 KCl, 1.25
NaH2PO4, 5 MgSO4, 26 NaHCO3, and 25 glucose. The slices were transferred to and
stored in artificial cerebrospinal fluid containing (in mM): 119 NaCl, 3 KCl, 2 CaCl2, 1
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MgCl2, 1.25 NaH2PO4, 25 NaHCO3, and 10 glucose at room temperature for at least 1
hour before use. All solutions were saturated with 95% O2 and 5% CO2.
Field excitatory postsynaptic potentials (fEPSPs) were recorded with patch clamp
amplifiers (Multiclamp 700B) under infrared-differential interference contrast
microscopy. The recordings were made blind to drug treatment and mouse genotype.
Data acquisition and analysis were performed using digitizers (DigiData 1440A and
DigiData 1550B) and the analysis software pClamp 10 (Molecular Devices). Signals
were filtered at 2 kHz and sampled at 10 kHz. Field recordings were made using glass
pipettes filled with 1 M NaCl (1-2 MΩ) placed in the stratum radiatum of the CA1 region
of the hippocampal slices, and fEPSPs were evoked by stimulating the Schaffer
collateral/commissural pathway at 0.033 Hz with a bipolar tungsten electrode (WPI).
Stable baseline fEPSPs were recorded for at least 20 minutes at an intensity that
induced ~40% of the maximal evoked response. LTP was induced by theta burst
stimulation (TBS), which consisted of a series of 15 bursts, with 4 pulses per burst at
100 Hz with a 200 ms inter-burst interval. TBS is designed to mimic the in vivo firing
patterns of hippocampal neurons during exploratory behavior (Larson et al, 1986). All
recordings were performed at 32 ± 1°C by using an automatic temperature controller.
Morris water maze (MWM) assessments. The MWM consisted of a circular,
galvanized steel tank (1.8 m in diameter, 0.6 m height). The tank was filled with water
(maintained at 20º C ± 2º C) with a white platform (10 cm diameter) submerged 1 cm
below the water’s surface. A sufficient volume of white paint (Valspar 4000 latex paint,
Lowe’s Companies Inc., Mooresville, NC) was added to render the water opaque and
the platform invisible. In addition to distal visual cues (shapes) on curtains surrounding
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the tank (30 cm from the tank wall), five sheets of laminated paper with distinct blackand-white geometric designs were attached to the sides of the tank serving as proximal
cues. An automated tracking system (ANY-maze, San Diego Instruments, Inc., San
Diego, CA) analyzed the swim path of each subject and calculated distance (path length
between being placed in the water and finding the hidden platform), average swim
speed, number of platform crossings, and percentage of time spent in each quadrant.
To assess MWM acquisition DAGL-α+/+, -α+/-, -α-/- mice received 10 Fixed
Platform training days (i.e. a submerged platform remained in the same location across
days), and then were assessed for expression of spatial memory on day 11 in a single
MWM Fixed Platform Probe Trial (i.e. the submerged platform was removed). C57BL6/J
Mice received a 2 h pretreatment of the DAGL-α inhibitor DO34 (0.3, 3, and 30 mg/kg
(Wilkerson et al, 2017), or its inactive analog and ABHD6 inhibitor DO53 (30 mg/kg), or
VEH on each of 10 Fixed Platform training days. A cued task test assessed sensorimotor/motivational confounds by placing a 10cm high black cylinder on the submerged
platform and mice were released from the farthest two release points. In order to assess
whether DO34 affects the expression of spatial memory, separate groups of mice were
given 10 days of drug-free Fixed Platform training. On day 11, each subject was
administered 30 mg/kg DO34 or VEH, and 2 h later underwent a single 2 min MWM
Fixed Platform Probe Trial. The extinction of spatial memory was assessed in drugnaïve acquisition trained mice, which received injections of 30 mg/kg DO34 or VEH (2 h
pretreatment) and tested in 2 min probe trials at 1, 2, 3, 4 and 6 weeks post-acquisition.
To assess forgetting, a group of drug-naïve acquisition trained mice were administered
30 mg/kg DO34 or VEH on day 11 and then returned to their home cage, given DO34 or

131

VEH at 6 weeks post-acquisition and administered a probe trial 2 h later. Reversal
learning was assessed in drug-naïve acquisition trained mice, which received injections
of 30 mg/kg DO34 or VEH (2 h pretreatment) and trained in reversal task trials where
the submerged platform was moved to the opposite side of the tank over 5 days postacquisition, followed by a 2 min drug-free probe trial on day 6 post-acquisition.
Lipid extraction and mass spectrometry. DAGL-α+/+, -α+/-, -α-/- mice, and
C57BL6/J mice receiving a 2 or 24 h pretreatment of DO34 (30 mg/kg) or VEH, were
anaesthetized under isoflurane inhalation and decapitated. Hippocampi, prefrontal
cortex, striatum, and cerebellum were dissected out from brain, flash frozen in liquid
nitrogen, and stored at −80°C until assay. On the day of lipid extraction, as previously
described (Kwilasz et al, 2015), the pre-weighed mouse brains were homogenized with
1.4 ml chloroform:methanol (containing 0.0348 g PMSF/ml). Six point calibration curves
ranged from 0.078 pmol to 10 pmol for AEA, 0.125 nmol to 16 nmol for 2-AG, AA, and
SAG, a negative control and blank control were also prepared. Internal standards
(Cayman Chemicals, Michigan, USA) (50 µl of each of 8 nmol SAG-d8, 1 pmol AEA-d8,
1 nmol 2-AG-d8, 1 nmol AA-d8) were added to each calibrator, control, and sample,
except the blank control. Each calibrator, control, and sample was then mixed with 0.3
ml of 0.73% w/v NaCl, vortexed, and centrifuged (10 min at 4000 × g and 4°C). The
aqueous phase plus debris were collected and extracted again twice with 0.8 ml
chloroform, the organic phases were pooled and organic solvents were evaporated
under nitrogen gas. Dried samples were reconstituted with 0.1 ml chloroform, mixed
with 1 ml cold acetone, and centrifuged (10 min at 4000 × g and 4°C) to precipitate
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proteins. The upper layer of each sample was collected and evaporated to dryness and
reconstituted with 0.1 ml methanol and placed in auto-sample vials for analysis.
An Ultra performance liquid chromatography-tandem mass spectrometer (UPLCMS/MS) was used to identify and quantify the DAGL-α substrate 1-Stearoyl-2Arachidonoyl-sn-Glycerol (SAG, a nuclear diacyglycerol [Deacon et al., 2001]
preferentially used by DAGLs [Balsinde et al., 1991; Allen et al., 1992]), the DAGL-α
metabolites 2-AG and arachidonic acid (AA), and anandamide (AEA, a biosynthetically
distinct endogenous cannabinoid ligand), in brain. Sciex 6500 QTRAP system with an
IonDrive Turbo V source for TurbolonSpray® (Ontario, Canada) attached to a Shimadzu
UPLC system (Kyoto, Japan) controlled by Analyst software (Ontario, Canada).
Chromatographic separation was performed on a Discovery® HS C18 Column 15cm x
2.1mm, 3µm (Supelco: Bellefonte, PA) kept at 25°C with an injection volume of 10 µL.
The mobile phase consisted of A: acetonitrile and B: water with 1 g/L ammonium
acetate and 0.1% formic acid. The following gradient was used: 0.0 to 2.4 minutes at
40% A, 2.5 to 6.0 minutes at 40% A, hold for 2.1 minutes at 40% A, then 8.1 to 9 min
100% A, hold at 100% A for 3.1 min and return to 40% A at 12.1 min with a flow rate
was 1.0 mL/min. The source temperature was set at 600°C and had a curtain gas at a
flow rate of 30 ml/min. The ionspray voltage was 5000 V with ion source gases 1 and 2
flow rates of 60 and 50 ml/min, respectively. The mass spectrometer was run in positive
ionization mode for AEA and 2-AG and in negative ionization mode for AA, and the
acquisition mode used was multiple reaction monitoring. The following transition ions
(m/z) were monitored with their corresponding collection energies (eV) in parentheses:
AEA: 348>62 (13) and 348>91 (60); AEA-d8: 356>63 (13); 2-AG: 379>287 (26) and
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379>296 (28); 2-AG-d8: 384>287 (26); AA: 303>259 (-25) and 303>59 (-60); AA-d8:
311>267 (-25). The total run time for the analytical method was 14 min.
Chromatographic analysis of SAG was performed on a Hypersil Gold® 3 X 50mm, 5 µ
column (Thermo Scientific, Waltham, MA) kept at 25°C with an injection volume of 2
µL. The mobile phase consisted 10:90 mM ammonium formate: methanol mobile with a
flow rate of 0.5 mL/min. The source temperature, curtain gas at a flow rate, ionspray
voltage and source gas flow rates were the same as indicated above. The mass
spectrometer was run in positive ionization mode. The following transition ions (m/z)
were monitored with their corresponding collection energies (eV) in parentheses: SAG:
646>341 (34) and 646>287 (38); SAG-d8: 654>341 (34). The total run time for the
analytical method was 5 min. Calibration curves were analyzed with each analytical
batch for each analyte. A linear regression ratio of the peak area analyte counts with the
corresponding deuterated internal standard versus concentration was used to construct
the calibration curves.
Experimental design and statistical analysis. Electrophysiological data are
presented as mean ± SEM. The magnitude of LTP (%) was calculated as follows: 100 ×
[mean fEPSP slope during the final 10 min of recording/mean baseline fEPSP slope].
Post-tetanic potentiation was calculated as the magnitude of the fEPSP slope relative to
baseline for the first 5 min after TBS. Results were analyzed with one-way ANOVA
followed by Tukey’s post hoc analysis.
Behavioral data are presented as mean + SEM. All MWM acquisition, extinction,
forgetting, reversal, and swim speed data, were analyzed using a mixed factor ANOVA
(distance, percent time in outer ring, and cm/s measures). All probe trial analyses
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focused on the first minute of exploration, with all gene deletion measures analyzed by
one-way ANOVA and Sidak post hoc test, and DO34 measures analyzed by
independent groups t-test. All MWM cued task data were analyzed by one-way ANOVA.
MWM swim path selection metrics were assigned per Wagner et al., 2013 into three
categories; spatial (direct, indirect, and self-orienting), non-spatial (scanning, circling,
and random) and thigmotaxic, and were analyzed for gene deletion using a Chi Square
analysis with pairwise comparisons and Bonferroni corrections (MacDonald and
Gardner, 2000), and for drug-treatments using a Kruskall Wallis analysis. From the
sample sizes, power was calculated using G*power 3 (Faul et al, 2007a) and was
found, with alpha at .05, to range from 0.67 to 0.84 for mixed factor ANOVAs, from 0.45
to 0.99 for one-way ANOVAs, and from 0.34 to 0.51 for independent group t-tests.
Prior to data analysis, brain level data were transformed to pmol/g of brain tissue
for AEA, and nmol/g of brain tissue for SAG, 2-AG and AA, and AEA. Drug and gene
manipulations on brain endocannabinoids were evaluated by one-way ANOVA, for each
lipid in each brain area, followed by a Sidak post hoc test. The criterion for significance
in all experiments was set at p < 0.05, and all analyses were conducted using IBM
SPSS Statistics 22 for Windows (IBM Software, New York, NY).

Results
Experiment 1: Genetic deletion or pharmacological blockade of DAGL-α
attenuates LTP in CA1 region of the hippocampus. In hippocampal slices prepared
from DAGL-α+/+ and DAGL-α+/- mice (n = 9-11), TBS induced robust LTP that remained
stable during the 60 min recording period (Figure 4-1A). The fEPSP slope in
hippocampal slices from DAGL-α-/- mice (n = 8) subjected to the same TBS stimulation
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slowly decayed toward baseline. The magnitude of LTP as measured between 50-60
min after TBS stimulation significantly differed among the three groups (F (2,27) = 5.37, p
= 0.011, ANOVA), and post hoc tests indicated that TBS-induced LTP was significantly
greater in DAGL-α+/+ and DAGL-α+/- mice than in DAGL-α-/- mice (DAGL-α+/+ vs. DAGLα-/-, p = 0.039; DAGL-α+/- vs. DAGL-α-/-, p = 0.013). However, the magnitude of LTP did
not differ between DAGL-α+/+ mice and DAGL-α+/- mice (p = 0.926).
Hippocampal slices from C57BL/6J mice treated with VEH, DO34 (30 mg/kg), or
DO53 (30 mg/kg) showed significant differences in the magnitude of LTP (F(2,23) = 7.90,
p = 0.003, ANOVA; Figure 4-1B). Post hoc tests indicated that TBS induced similar LTP
in hippocampal slices prepared from VEH-treated (n = 9) and DO53-treated mice (n = 8;
p = 0.514 vs. vehicle), but slices prepared from DO34-treated mice displayed a
significantly decreased magnitude of LTP (n = 7; p = 0.002 vs. vehicle; p = 0.031 vs.
DO53). Moreover, the magnitude of post-tetanic potentiation (PTP) during the first 5 min
of LTP induction significantly differed among the three treatment groups (F(2,23) = 7.17, p
= 0.004, ANOVA), in which DO34 administration produced a significant decrease in the
PTP compared with vehicle (p = 0.007) and DO53 (p = 0.011).
Experiment 2.1: DAGL-α-/- mice display profound phenotypic MWM spatial
memory deficits and altered MWM search strategies. Per the experimental timeline
(Figure 4-2A), the first acquisition day of fixed platform training (extended data Figure 42-1A) yielded no significant differences among groups and across trials (F(6,114) = 1.67, p
= 0.135, ANOVA). However, across the ten days of MWM fixed platform acquisition
training (Figure 4-2B), a significant interaction (F(18,342) = 2.48, p = 0.001, ANOVA)
revealed DAGL-α-/- mice (n = 13) had longer distances to the platform than DAGL-α+/+ (n
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= 15) or DAGL-α+/- mice (n = 15) on acquisition days 2 (p = 0.001, p = 0.005), 3 (p =
0.000, p = 0.000), 4 (p = 0.000, p = 0.000), 5 (p = 0.000, p = 0.000), 6 (p = 0.000, p =
0.000), 7 (p = 0.000, p = 0.001), 8 (p = 0.001), 9 (p = 0.000, p = 0.001), and 10 (p =
0.000, p = 0.000) respectively. Also, DAGL-α+/+ mice and DAGL-α+/- mice, respectively,
showed significant reductions in distances to the platform on days 4 (p = 0.005, p =
0.014), 5 (p = 0.000, p = 0.025), 6 (p = 0.001, p = 0.004), 7 (p = 0.000, p = 0.000), 8
(α+/+; p = 0.000), 9 (p = 0.000, p = 0.007), and 10 (p = 0.000, p = 0.001) compared to
day 1. In contrast, DAGL-α-/- mice showed no significant difference in distance
compared to day 1 across subsequent fixed platform acquisition days (2; p = 1.000, 3; p
= 1.000, 4; p = 1.000, 5; p = 1.000, 6; p = 1.000, 7; p = 0.625, 8; p = 0.399, 9; p = 0.373,
and 10; p = 0.0670). Furthermore, during the fixed platform probe trial (Figure 4-2C,D,E)
DAGL-α-/- mice demonstrated significantly longer distances to the platform location
(F(2,38) = 5.81, p = 0.006, ANOVA) than DAGL-α+/+ mice (p = 0.022) and DAGL-α+/- mice
(p = 0.011), significantly fewer platform entries (F(2,38) = 7.40, p = 0.002, ANOVA) than
DAGL-α+/+ mice (p = 0.001), and a lower spatial preference for the target quadrant
(F(2,38) = 7.73, p = 0.002, ANOVA) than DAGL-α+/+ mice (p = 0.002) and DAGL-α+/- mice
(p = 0.016). No significant difference in cued task performance (Figure 4-2F), (F(2,38) =
0.926, p = 0.405, ANOVA), or swim speed (Figure 4-2G), (F(18,342) = 0.648, p = 0.860,
ANOVA), suggest the DAGL-α-/- mice performance deficits were unaffected by
sensorimotor or motivational impairments. Also, no significant differences in body
weight (extended data Figure 4-2-2A,C) at baseline (F(2,38) = 3.08, p = 0.057, ANOVA)
or during fixed platform acquisition (F(2,38) = 2.84, p = 0.071, ANOVA) were evident
among the genotypes.
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On Fixed Platform day 10 (Figure 4-3A), DAGL-α-/- mice used significantly more
non-spatial and thigmotaxic swimming strategies than DAGL-α+/+ or DAGL-α+/- mice,
(X2(4, N=41) = 21.9, p = 0.000, Chi Square). The change in DAGL-α-/- mice strategy
proportion was indicated by pairwise comparisons (p = 0.001). Furthermore, during
Fixed Platform acquisition (Figure 4-3B) a significant main effect of genotype (F(2,38) =
7.29, p = 0.002, ANOVA) indicated that DAGL-α-/- mice spent more time in the MWM
outer ring than DAGL-α+/+ mice (p = 0.002) and DAGL-α+/- mice (p = 0.028). A significant
main effect of day (F(9,342) = 13.9, p = 0.000, ANOVA) also showed that collectively
DAGL-α+/+, -α+/-, and -α-/- mice spent a decreased proportion of their time in the outer
ring on days 4 (p = 0.015), 5 (p = 0.034), 6 (p = 0.001), and 7-10 (p = 0.000) compared
to day 1.
Experiment 2.2: Pharmacological inhibition of DAGL-α produces impaired
MWM spatial acquisition. Per the experimental timeline (Figure 4-4A), fixed platform
day 1 (extended data Figure 4-2-1B), yielded no significant differences among groups
and across trials (F(12,171) = 1.65, p = 0.082, ANOVA). During MWM fixed platform
acquisition (Figure 4-4B) a significant main effect of drug (F(4,57) = 8.77, p = 0.000)
revealed 30 mg/kg DO34-treated mice (n = 12) required longer swim path distances to
the platform than mice in the VEH (n = 15, p = 0.000), 0.3 mg/kg DO34 (n = 12, p =
0.002), and 30 mg/kg DO53 (n = 12, p = 0.000) conditions, However, these mice did not
statistically differ from mice in the 3 mg/kg DO34 group (n = 11, p = 0.103). Also, mice
treated with VEH (F(9,126) = 12.7, p < 0.001, repeated measures ANOVA), 30 mg/kg
DO34 (F(9,99) = 12.3, p = 0.000, repeated measures ANOVA), 3 mg/kg DO34 (F(9,90) =
8.01, p = 0.000, repeated measures ANOVA), 0.3 mg/kg DO34 (F(9,99) = 8.48, p = 0.000,
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repeated measures ANOVA), and 30 mg/kg DO53 (F(9,99) = 15.8, p = 0.000, repeated
measures ANOVA) showed significantly reduced distances to the platform days 3 (VEH
p = 0.022), 4 (VEH p = 0.000), 5 (VEH p = 0.005; 30 mg/kg DO34 p = 0.021; 3 mg/kg
DO34 p = 0.019; 30 mg/kg DO53 p = 0.005), 6 (VEH p = 0.001; 30 mg/kg DO34 p =
0.004; DO53 p = 0.003), 7 (VEH p < 0.001; 30 mg/kg DO34 p = 0.003; 3 mg/kg DO34 p
= 0.008; DO53 p = 0.002), 8 (VEH p = 0.003; 30 mg/kg DO34 p = 0.034; 3 mg/kg DO34
p = 0.038; DO53 p = 0.001), 9 (VEH p = 0.001; 30 mg/kg DO34 p = 0.000; 3 mg/kg
DO34 p = 0.002; DO53 p = 0.000), and 10 (VEH p = 0.000; 30 mg/kg DO34 p = 0.000; 3
mg/kg DO34 p = 0.024; 0.3 mg/kg DO34 p = 0.011; DO53 p = 0.000) compared to day
1.
In order to test whether DO34 affects memory of the platform location (Figure 44C), a probe trial revealed similar distances to the platform location (t(15) = 0.0880, p =
0.931, independent t-test; Figure 4-4D) in DO34-treated and VEH-treated mice, similar
number of platform entries (t(15) = 1.17, p = 0.260, independent t-test; Figure 4-4E), and
similar percentages of time spent in the target quadrant (t(15) = 1.28, p = 0.220,
independent t-test; Figure 4-4F). The absence of significant differences in cued task
performance (F(4,57) = 1.09, p = 0.368, ANOVA; Figure 4-4G), suggests that DO34 does
not elicit sensorimotor or motivational impairments.
During fixed platform acquisition, a significant swim speed interaction (F(36,513) =
1.60, p = 0.016, ANOVA; Figure 4-4H), showed that mice administered 30 mg/kg DO34
swam faster than VEH-treated mice on days 1 (p = 0.019), 2 (p = 0.010), 4 (p = 0.042),
5 (p = 0.009), and 8 (p = 0.003), but 0.3 mg/kg DO34-treated mice swam slower than
VEH-treated mice on days 7 (p = 0.026), 9 (p = 0.044), and 10 (p = 0.022). Also, while
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no significant difference in body weight was evident at baseline (F(4,57) = 2.03, p = 0.103,
ANOVA; extended data Figure 4-2-2B,D), a significant interaction between drug and
day for this measure occurred throughout acquisition training (F(56,798) = 7.06, p = 0.000,
ANOVA). DO34 elicited body weight reductions compared to VEH at 30 mg/kg DO34
(days 2 through 15, p = 0.000), 3 mg/kg DO34 (days 4, p = 0.006; 8, p = 0.032; and 13,
p = 0.015), 0.3 mg/kg DO34 (day 4, p = 0.001), and 30 mg/kg DO53 (days 2, p = 0.000;
3, p = 0.000; days 4, p = 0.041; 5, p = 0.003; 7, p = 0.008; and 13, p = 0.000).
On Fixed Platform day 10, DO34-treated mice showed no significant change in
swim path strategy (X2(3, N=49) = 7.0;97, p = 0.069, chi square; Figure 4-5A). However, a
significant main effect of drug was found for time spent in the outer ring of the MWM
throughout the ten acquisition sessions (F(4,57) = 2.96, p = 0.027, ANOVA; Figure 4-5B).
DO34 (30 mg/kg) produced a modest increase in the time spent in the MWM outer ring
compared with VEH-treated mice (p = 0.035). A significant main effect of day (F(9,513) =
59.4, p = 0.000, ANOVA) also showed that mice spent a smaller proportion of their time
in the outer ring on all subsequent days, 2, 3, 4, 5, 6, 7, 8, 9, and 10 (p < 0.001) than on
day 1.
Experiment 2.3: Pharmacological inhibition of DAGL-α impairs MWM
reversal, but not extinction or forgetting. The next experiments examined the effects
of DO34 (30 mg/kg; n = 8) vs. VEH (n = 9) on extinction (Figure 4-6A), forgetting (Figure
4-6B), and reversal learning (Figure 4-6D, 30 mg/kg; n = 15, VEH; n = 15). As shown in
Figure 6C, subjects displayed evidence of extinction following fixed platform day 10 and
exposure to six sessions (including probe trial) in the MWM without the hidden platform
present via a main effect of day (F(5,75) = 3.08, p = 0.014, ANOVA). Subjects had
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significantly longer distances to the previous platform location on extinction weeks 4 (p
= 0.047), and 6 (p = 0.027) compared to probe trial. The lack of a statistical interaction
between drug and day (F(5,75) = 0.292, p = 0.916, ANOVA) and lack of significant main
effect of drug (F(1,15) = 1.98, p = 0.180, ANOVA) indicate that DO34 did not affect
extinction. In the probe trial assessment of forgetting (Figure 4-6C), the lack of a
statistically significant interaction between drug and day (F(1,10) = 0.638, p = 0.443,
ANOVA) or a main effect of drug (F(1,10) = 2.50, p = 0.145, ANOVA) indicates DO34 did
not impact forgetting performance. In the evaluation of reversal learning (Figure 4-6E),
the statistically significant interaction between drug and day (F(5,140) = 4.43, p = 0.001,
ANOVA) indicates that DO34 delayed reversal, specifically on days 1 (p = 0.007), 2 (p =
0.007), and 5 (p = 0.016). Yet all subjects displayed evidence of reversal learning after
exposure to five reversal sessions (and probe trial) via a main effect of day in VEH
(F(5,70) = 6.05, p = 0.000, repeated measures ANOVA) and DO34 (F(5,70) = 13, p = 0.000,
repeated measures ANOVA) mice. VEH-treated subjects had significantly reduced
distances to the new platform location on reversal days 2 (p = 0.011), 3 (p = 0.0005)
and 5 (p = 0.000) compared to day one. Similarly, DO34-treated subjects showed
reduced distance to the platform on days 2 through probe (2, p = 0.033; 3, p = 0.000; 4,
p = 0.008; 5, p = 0.010; and probe p = 0.001) compared to day one.
Experiment 3.1: Genetic deletion of DAGL-α produces profound alterations
to eCB and related lipid profiles. DAGL-α-/- mice (n = 8) possessed elevated levels of
the DAGL-α substrate, SAG, across all four brain regions; hippocampus, (F(2,21) = 174, p
= 0.000, ANOVA; Figure 4-7A), PFC (F(2,21) = 753, p = 0.000, ANOVA; Figure 4-7B),
striatum (F(2,21) = 52, p = 0.000, ANOVA; Figure 4-7C), and cerebellum (F(2,21) = 32, p =
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0.000, ANOVA; Figure 4-7D), compared to both DAGL-α+/+ (n=8, p = 0.000) and DAGLα+/- mice (n=8, p = 0.000). DAGL-α-/- mice also showed profound reductions of 2-AG and
its metabolite AA, respectively, across each brain region: hippocampus, (F(2,21) = 246, p
= 0.000, ANOVA; Figure 4-7E; F(2,21) = 156, p = 0.000, ANOVA; Figure 4-7M), PFC
(F(2,21) = 29, p = 0.000, ANOVA; Figure 4-7F; F(2,21) = 207, p = 0.000, ANOVA; Figure 47N), striatum (F(2,21) = 48, p = 0.000, ANOVA; Figure 4-7G; F(2,21) = 126, p = 0.000,
ANOVA; Figure 4-7O), and cerebellum (F(2,21) = 70, p = 0.000, ANOVA; Figure 4-7H;
F(2,21) = 155, p = 0.000, ANOVA; Figure 4-7P), compared to both DAGL-α+/+ (p = 0.000)
and DAGL-α+/- mice (p = 0.000). DAGL-α+/- mice showed only modest reductions in
striatal (p = 0.04), hippocampal (p = 0.002), and cerebellar (p < 0.002) 2-AG compared
to DAGL-α+/+ mice. Also, region selective reductions of AEA were found in DAGL-α-/mouse hippocampus (F(2,21) = 51, p = 0.000, ANOVA; Figure 4-7I), and cerebellum
(F(2,21) = 10.2, p = 0.001, ANOVA; Figure 4-7L), but not in PFC (Figure 4-7J) or striatum
(Figure 4-7K) compared to both DAGL-α+/+ and DAGL-α+/- mice.
Experiment 3.2: Pharmacological inhibition of DAGL produces brain region
selective alterations in eCB and related lipid profiles. DO34-treated mice possessed
elevated levels of SAG at 2 h post-injection (n = 5) across all four brain regions;
hippocampus, (F(2,15) = 7.48, p = 0.006, ANOVA; Figure 4-8A), PFC (F(2,15) = 30, p = 0.000,
ANOVA; Figure 4-8B), striatum (F(2,15) = 5.46, p = 0.017, ANOVA; Figure 4-8C), and
cerebellum (F(2,15) = 6.83, p = 0.008, ANOVA; Figure 4-8D) compared to VEH (n = 5, p =
0.005, p = 0.000, p = 0.038, and p = 0.006 respectively), but not at 24 h post-injection (n
= 8) compared to VEH (p = 0.232, p = 0.992, p = 0.999, p = 0.145). PFC and striatal SAG
was also lower at 24 h compared to 2 h (p = 0.000, p = 0.027 respectively). DO34-treated
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mice also showed consistent reductions of 2-AG in hippocampus (F(2,15) = 37, p = 0.000,
ANOVA; Figure 4-8E), PFC (F(2,15) = 11.6, p = 0.001, ANOVA; Figure 4-8F), striatum
(F(2,15) = 4.82, p = 0.024, ANOVA; Figure 4-8G), and cerebellum (F(2,15) = 94, p = 0.000,
ANOVA; Figure 4-8H) at 2 h (p = 0.000, p = 0.001, p = 0.036, p = 0.000 respectively), and
hippocampus and cerebellum at 24 h (p = 0.000, p = 0.000). PFC and cerebellar 2-AG
was also higher at 24 h compared to 2 h (p = 0.008, p = 0.013 respectively).While no
significant change in AEA was found in hippocampus (F(2,15) = 0.92, p = 0.421, ANOVA;
Figure 4-8I), PFC (F(2,15) = 3.04, p = 0.078, ANOVA; Figure 4-8J), striatum (F(2,15) = 2.70,
p = 0.099, ANOVA; Figure 4-8K), or cerebellum (F(2,15) = 2.44, p = 0.121, ANOVA; Figure
4-8L), reductions of AA following DO34-treatment were seen in all brain regions;
hippocampus (F(2,15) = 13.8, p = 0.000, ANOVA; Figure 4-8M) at 2 h (p = 0.005) and 24 h
(p = 0.000), PFC (F(2,15) = 65, p = 0.000, ANOVA; Figure 4-8N) at 2 h (p = 0.000) and 24
h (p = 0.000), striatum (F(2,15) = 145, p = 0.000, ANOVA; Figure 4-8O) at 2 h (p = 0.000)
and 24 h (p = 0.000), and cerebellum (F(2,15) = 59, p = 0.000, ANOVA; Figure 4-8P) at 2
h (p = 0.000) and 24 h (p = 0.000). AA levels were also significantly greater at 24 h than
2 h in PFC (p = 0.000) and striatum (p = 0.000).

Discussion
The present study makes the novel observations that either genetic deletion or
pharmacological inhibition of DAGL-α profoundly disrupts hippocampal LTP
accompanied by varying magnitudes of learning and memory deficits in the mouse
MWM Fixed Platform and Reversal tasks. Specifically, DAGL-α-/- mice display nonspatial search strategies and concomitantly disrupted Fixed Platform acquisition,
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whereas DO34-treated mice show significantly delayed MWM acquisition and reversal
learning but performance is spared in probe trial memory, extinction, and forgetting
tasks. Additionally, these alterations in LTP and in vivo learning and memory paradigms
occur in concert with distinct altered patterns of endocannabinoids and related lipids,
across brain areas integral to learning and memory.
The observation that DAGL-α disruption decreases CA1 LTP is consistent with
non-selective DAGL inhibitors blocking CA1 pairing-induced potentiation in rats (Xu et
al, 2012). The lowered production of 2-AG following DAGL-α disruption implicates 2-AG
as a possible LTP facilitator, corroborated also by 2-AG catabolism inhibition facilitating
CA1 LTP (Silva-Cruz et al, 2017). Given that endogenously produced
endocannabinoids facilitate LTP at CA1 hippocampal synapses through stimulation of
astrocyte-neuron signaling (Gomez-Gonzalo et al, 2015), as well as when preceded by
DSI (Carlson et al, 2002), suggests that endocannabinoids enhance plasticity by
disinhibition. 2-AG is well recognized as an integral retrograde modulator of short-term
CB1 receptor-mediated synaptic plasticity (i.e., DSE/DSI), (Tanimura et al., 2010;
Yoshino et al., 2011). Furthermore CB1 receptor activation correlates with enhanced
CA1 LTP (Chevaleyre and Castillo, 2004). Thus, reducing 2-AG production decreases
CB1 receptor signaling and thereby disrupting LTP. However, CB1 receptor deletion or
antagonism leads to a different pattern of behavioral impairments compared with
analogous DAGL-α disruption in the present study. Specifically, wild type mice
administered the CB1 receptor antagonist Rimonabant or CB1-/- mice acquired MWM
Fixed Platform at a similar rate as control mice, but showed impaired MWM extinction
(Varvel et al, 2005; Varvel and Lichtman, 2002). In the case of DAGL-α, its close spatial
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localization to excitatory CB1 receptor synapses (and adjacent to group I metabotropic
glutamate receptors) and distance from inhibitory synapses (Katona et al, 2006;
Yoshida et al, 2006), may account for the resilience of DAGL-α compromised mice in
the MWM extinction task.
Contrary to the present work, Sugaya et al., 2013 found DAGL-α-/- mice show no
change in CA1 LTP, while facilitating entorhinal cortex-dentate gyrus LTP. The lack of
CA1 LTP change was observed in DAGL-α-/- mice with in-dwelling electrodes in vivo,
where lipid profile disruption interacts with on-going milieu changes in an awake brain,
suggesting the possible involvement of model system differences with the present work.
The impairment by DO34 of post-tetanic potentiation within minutes of TBS suggests
that pharmacological inhibition of DAGL-α reduced Ca2+ buildup in presynaptic axon
terminals (Zucker and Regehr, 2002). Furthermore, off-target effects of DO34 (e.g.
ABDH6) are unlikely to be responsible for the observed decrease in LTP magnitude
given DO53 did not impact SC-CA1 LTP, consistent with its inability to alter
hippocampal DSI (Ogasawara et al, 2016). As DO34 also inhibits DAGL-β, a
contribution of this 2-AG biosynthetic enzyme cannot be ruled out. Yet its low
expression on neurons and high expression on microglia (Hsu et al, 2012) argues
against its involvement in the present study.
The phenotypic MWM deficits displayed by DAGL-α-/- mice and impaired
acquisition and reversal learning performance in DO34-treated mice, represent the first
evidence supporting a role of DAGL-α in a laboratory animal model of spatial learning
and memory, specific to the integration of new information, but not memory retrieval,
extinction, or forgetting. The findings show deletion of DAGL-α profoundly disrupt fixed
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platform MWM learning, compatible with the body of evidence highlighting the necessity
of hippocampal neurogenesis for spatial memory processing (Snyder et al., 2005;
Sahay et al., 2011), to which this enzymes significantly contributes (Gao et al, 2010;
Goncalves et al, 2008). The altered search strategy may reflect a stress-induced shift
from utilizing hippocampal-cognitive to striatal-habit learning (Wirz et al, 2017). The
anxiety-like phenotype of DAGL-α-/- mice (Jenniches et al, 2016; Shonesy et al, 2014)
as well as the stress-inducing component of the MWM may drive a heavier reliance on
non-spatial circular search strategies after DAGL-α disruption.
The difference in behavioral impairment magnitude between DAGL-α-/- and
DO34-treated mice warrants discussion. Previous DSI/DSE disparities between DAGL-α
inhibition and gene deletion have been explained by insufficient inhibitor slice
penetration (Ohno-Shosaku and Kano, 2014), yet DO34 is brain penetrant (Ogasawara
et al, 2016), and both inhibitor and gene deletion led to impaired LTP. The relatively
modest 2-AG lipid profile differences between DO34-treated mice and DAGL-α-/- mice
may contribute, in part, to the profound disruption of spatial learning in DAGL-α-/- mice
compared with the delay-related deficits observed following DO34 treatment. However,
developmental alterations in the brains of the DAGL-α-/- mice across ontogeny may also
be a contributing factor. In the developing brain DAGL-α is expressed at presynaptic
terminals (Bisogno et al, 2003a), participating in the control of axonal growth and
guidance (Brittis et al, 1996; Williams et al, 1994), but is expressed on post-synaptic
neurons in the adult brain. As such, DAGL-α switches roles from growth and guidance
during development, to a modulator of synaptic signaling. The present phenotypic
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learning and memory deficits and altered search strategy in DAGL-α-/- mice, may
therefore be influenced by both roles of this enzyme.
The unique finding that DAGL-α inhibition selectively impairs acquisition and
reversal learning, but not expression, extinction, or forgetting, suggests that DAGL-α is
selectively important for the integration of new spatial information. While DAGL-α
disruption has not previously been evaluated in reversal learning, contrary to the
present findings DAGL-α disruption by DO34 (Cavener et al, 2018) and in DAGL-α-/mice (Cavener et al, 2018; Jenniches et al, 2016) produces extinction, but not
acquisition, deficits in fear memory. While DAGL-α is expressed in areas important
during fear conditioning such as the basolateral amygdala (Yoshida et al, 2011), stress
reduces amygdala-hippocampal connectivity (Wirz et al, 2017). Accordingly, DAGL-α
may yet differentially modulate memory processes based on brain region or neuronal
type.
The spatial memory impairments of DAGL-α-/- mice were accompanied by
profound lipid profile changes, specifically reductions of 2-AG across all four brain
areas. Likewise, other lines of DAGL-α-/- mice show 80% reductions in whole brain 2-AG
(Gao et al., 2010; Tanimura et al., 2010), as well as in PFC, amygdala, striatum
(Shonesy et al, 2014), and hippocampus (Jenniches et al, 2016). Yet the modest DAGLα+/- mice reductions in striatal, hippocampal, and cerebellar 2-AG did not translate to
fixed platform acquisition or probe trial deficits. Previous studies showed that DO34
produces large reductions in whole brain 2-AG (Ogasawara et al, 2016; Wilkerson et al,
2017), consistent with the current finding that DO34 reduced 2-AG in all four brain
regions evaluated. Given the region dependent reductions of AEA in DAGL-α-/- mice,
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DAGL-α substrates and metabolites may also play a more complex role in the
biosynthetic pathway of AEA. Similarly, reduced AEA levels in DAGL-α-/- mice were
seen in forebrain (Shonesy et al, 2014) and hippocampus, but not striatum (Jenniches
et al, 2016). Unexpectedly, DO34 did not significantly reduce AEA levels in any brain
region investigated, despite 50% reductions of AEA in whole brain (Ogasawara et al,
2016; Wilkerson et al, 2017). Reductions of AEA in hippocampi of DAGL-α-/- mice must
be considered, given elevations of AEA impair LTP (Basavarajappa et al, 2014) and
enhance acquisition in aversively motivated spatial memory tasks (Varvel et al, 2007).
As inhibiting the primary hydrolytic AEA enzyme fatty acid amide hydrolase (FAAH)
elevates brain levels of this endocannabinoid and concomitantly accelerates extinction
rates (Varvel et al, 2007), we might expect that region specific reductions of AEA in
DAGL-α-/- mice would manifest with impaired MWM extinction learning phenotype.
However, this outcome is not observed, and furthermore FAAH inhibition failed to
reverse fear extinction deficits in DAGL-α-/- mice (Cavener et al, 2018). To fully exclude
the role of lowered AEA after DAGL-α deletion, future experiments to evaluate the
administration of a FAAH inhibitor to DAGL-α-/- mice prior to MWM assessment and LTP
would be necessary.
Another consideration for the present results is the impact of DAGL-α blockade
on downstream and upstream lipid signaling molecules. The expression of DAGL in
invertebrate species without cannabinoid receptors (e.g. Drosophila; Elphick and
Egertova, 2005) underscores the important role of this enzyme in regulating lipid
signaling molecules independent of substrate production for cannabinoid receptor
activation. As anticipated, both DAGL-α-/- mice and DO34-treated mice showed
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consistent elevations of the DAG substrate for DAGL-α, SAG, across all four brain
areas, previously seen in forebrain of DAGL-α-/- mice (Shonesy et al, 2014) and whole
brain following DO34 (Ogasawara et al, 2016). Diacylglycerols such as SAG are known
protein kinase C (PKC) activators (Hindenes et al, 2000), and while PKC activation
facilitates memory (Bonini et al, 2007) little is known of the effects following sustained
activation through elevated SAG. The dramatically reduced levels of AA across all four
brain regions in DAGL-α-/- mice and after DO34 suggest DAGL-α is an important
intermediate for the maintenance of basal AA levels in brain, previously seen in whole
brain (Gao et al, 2010) and forebrain (Shonesy et al, 2014). DO34-induced reductions of
AA were often still evident at 24 h (consistent with 24 h partial DAGL-α activity recovery
following DO34 (Ogasawara et al, 2016). Given hippocampal neurons also activate PKC
through AA cascades (Hama et al, 2004), the DAGL-α disruption-induced AA reductions
may also contribute to the observed learning and memory deficits.
Collectively this work supports the importance of DAGL-α in modulating
hippocampal learning and memory. Thus, reductions in DAGL-α expression or function
may contribute to cognitive pathologies, consistent with this idea are correlations
between decreased DAGL-α expression and impaired verbal memory (Bioque et al,
2016). Age-related decreases in DAGL-α expression (Piyanova et al, 2015), and
decreased neurogenesis in DAGL-α rich areas (Goncalves et al, 2008; Knoth et al,
2010), suggest DAGL-α dysregulation may be a fruitful area of study, particularly with
respect to age-related cognitive decline (Bilkei-Gorzo et al, 2017). In sum, the present
findings that DAGL-α disruption lead to learning and memory impairments at cellular
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and selective behavioral levels implicate this enzyme as playing a key role in spatial
learning and memory.
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Figure 4-1. DAGL-α-/- mice and C57BL/6 mice treated with the DAGL inhibitor DO34
show disrupted TBS-induced LTP in CA1 of the hippocampus. The magnitude of
LTP was significantly decreased in both A, DAGL-α-/- mice (n = 8) compared to DAGLα+/+ (n = 9) and DAGL-α+/- mice (n = 11), as well as in slices from B, DO34-treated
C57BL/6J mice (n = 7) compared with VEH-treated (n = 9) or DO53-treated mice (n =
8). The magnitude of PTP during the initial induction phase was also significantly
decreased in the DO34 group compared with VEH or DO53. Values represent mean ±
SEM.
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Figure 4-2. DAGL-α -/- mice are profoundly impaired in MWM fixed platform task
performance. A, Fixed platform task experimental timeline (days). B, During MWM
fixed platform acquisition, DAGL-α-/- mice (n = 13) exhibited longer distances to the
platform than both DAGL-α+/+ mice (n = 15) and DAGL-α+/- mice (n = 13), as well as
showed probe trial performance deficits of C, longer distances to the prior platform
position D, fewer platform entries and E, a lower spatial preference for the target
quadrant. No significant difference in F, cued task performance or G, swim speed
suggest the DAGL-α-/- mice performance deficits were unaffected by sensorimotor or
motivational impairments. No significant differences were evident between genotype on
fixed platform training day one across trials (extended data Figure 2-1A), or in body
weight at either baseline or during fixed platform acquisition (extended data Figure 22A,C). Values represent mean +SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. DAGLα+/+ mice, and $ p < 0.05, $$ p < 0.01, $$$ p < 0.001 vs. DAGL-α+/- mice.
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Figure 4-3. DAGL-α -/- mice exhibit altered MWM search strategy. DAGL-α-/- mice (n
= 13) A, used more non-spatial and thigmotaxic swim paths than DAGL-α+/+ mice (n =
15) on fixed platform day 10, as well as B, spent more time in the MWM outer ring than
both DAGL-α+/+ and DAGL-α+/- mice (n = 13) during fixed platform acquisition. C, Fixed
platform day 10 representative swim traces show spatial (direct and self-orienting) swim
paths in DAGL-α+/+ mice, spatial (direct) and non-spatial (circling) swim paths in DAGLα+/- mice, and non-spatial (circling and thigmotaxic) swim paths in DAGL-α-/- mice.
Values represent mean +SEM; ** p < 0.01, *** p < 0.001 vs. DAGL-α+/+ mice, and $ p <
0.05 vs. DAGL-α+/- mice.
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Figure 4-4. DO34 delays MWM fixed platform acquisition, but does not affect
probe trial performance. A, Fixed platform task acquisition experimental timeline
(days). B, During MWM fixed platform acquisition, mice treated with 30 mg/kg DO34 (n
= 12) exhibited longer distances to the platform than VEH (n = 15), 0.3 mg/kg DO34 (n =
12), and 30 mg/kg DO53 (n = 12). C, Fixed platform task probe trial (expression)
experimental timeline (days). Following drug-free MWM fixed platform acquisition
training, no change in performance was seen at probe trial between drug treatments
(VEH n = 9 or 30 mg/kg DO34 n = 8) for any measure; D, distances to the prior platform
position E, platform entries or F, spatial preference for the target quadrant. No
difference in G, cued task performance suggest the high dose DO34 did not affect
sensorimotor or motivational components of MWM performance. H, Mice administered
30 mg/kg DO34 showed increased swim speeds during fixed platform acquisition
compared to VEH-treated mice on days 1, 2, 4, 5, and 8, but 0.3 mg/kg DO34 reduced
swim speeds on days 7, 9, and 10. No significant differences were evident between
groups on fixed platform training day 1 across trials (extended data Figure 2-1A), or in
body weight at baseline, yet a significant interaction between drug and day on body
weight throughout acquisition training showed reductions compared to VEH at 30 mg/kg
DO34 (days 2 through 15), 3 mg/kg DO34 (days 4, 8,13), 0.3 mg/kg DO34 (day 4), and
30 mg/kg DO53 (days 2, 3, 4, 5, 7, 13) (extended data Figure 2-2A,C). Values represent
mean +SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. VEH; $$$ p < 0.001 vs. 0.3 mg/kg
DO34; and ## p < 0.01 vs. 30 mg/kg DO53.
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Figure 4-5. DO34 produces modest and selective changes to MWM search
strategy. DO34-treated mice (0.3 mg/kg; n = 12, 3 mg/kg; n = 11, 30 mg/kg; n = 12) A,
showed no significant change in swim path strategy than VEH-treated mice (n = 15) on
fixed platform day 10 B, but mice administered 30 mg/kg DO34 showed a modest
increase in the time spent in the MWM outer ring during fixed platform acquisition, than
VEH-treated mice. C, Fixed platform day 10 representative swim traces show spatial
(self-orienting and direct) and non-spatial (circling and scanning) swim paths in VEH,
and DO34-treated (0.3, 3, 30 mg/kg) mice. Values represent mean +SEM; * p < 0.05
DO34 (30 mg/kg) vs VEH-treated mice.
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Figure 4-6. DO34 delays reversal learning but does not affect extinction or
forgetting MWM tasks. A, Experimental timeline for the extinction (days/weeks) of
mice trained drug-free in fixed platform task (same cohort as per probe trial [expression]
Figure 4). B, Experimental timeline for additional mice trained drug-free in fixed platform
task prior to a forgetting task (days/weeks). C, No change in either the extinction of the
fixed platform task, or forgetting performance, was seen between VEH (n = 9 and n = 6
respectively) and 30 mg/kg DO34-treated mice (n = 8 and n = 6 respectively), (MWM
fixed platform acquisition day 1 and 10 of VEH and 30 mg/kg DO34 for both extinction
and forgetting tasks included for comparison). D, Experimental timeline for mice trained
in a reversal task (days) following drug-free fixed platform training. E, During MWM
reversal, mice treated with 30 mg/kg DO34 (n = 15) exhibited longer distances to the
platform than VEH (n = 15) on reversal days one, two, and five (MWM fixed platform
acquisition day 1 and 10 of VEH and 30 mg/kg DO34 included for comparison). Values
represent mean +SEM; * p < 0.05, ** p < 0.01.
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Figure 4-7. Lipid profile changes in DAGL-α -/- mice show consistently elevated
SAG, and lowered 2-AG and AA across all four brain regions. A, B, C, D, The
DAGL-α substrate SAG, was elevated in all four brain regions in DAGL-α-/- mice (n = 8)
compared to both DAGL-α+/+ (n = 8) and DAGL-α+/- mice (n = 8). DAGL-α-/- mice
possessed decreased levels of 2-AG and AA, respectively in, E and M, hippocampus, F
and N, PFC, G and O, striatum, and H and P, cerebellum. DAGL-α+/- mice showed
modest 2-AG reductions in striatum, hippocampus, and cerebellum compared to DAGLα+/+ mice. AEA levels of DAGL-α-/- mice were significantly reduced in I, hippocampus,
and L, cerebellum, but not in J, PFC, or K, striatum. Values represent mean +SEM; * p
< 0.05, ** p < 0.01, *** p < 0.001 vs DAGL-α+/+ mice, and $$ p < 0.01, $$$ p < 0.001 vs
DAGL-α+/- mice.
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Figure 4-8. Lipid profile changes in DO34-treated mice show consistently elevated
SAG, and lowered 2-AG and AA across all four brain regions. A, B, C, D, The
DAGL-α substrate SAG, was elevated in all four brain regions at 2 h post-DO34
injection (n = 5) compared to VEH (n = 5), and compared to 24 h (n = 8) in PFC and
striatum. At 2 h post-DO34 injection, 2-AG and AA were reduced respectively in, E and
M, hippocampus, F and N, PFC, G and O, striatum, and H and P, cerebellum, while at
24 h post-DO34 injection, 2-AG was reduced only in E, hippocampus and H,
cerebellum, whereas AA showed reductions across M, N, O, P, all four brain areas. No
changes in, I, J, K, L, AEA were evident compared to VEH. Values represent mean
+SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 vs VEH, and # p < 0.05 vs 24 h.
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Appendix 4. Extended Data

Extended Data Figure 4-2-1 Both genetic deletion and pharmacological inhibition
of DAGL-α produce no change in MWM fixed platform day one performance. A,
During MWM fixed platform day one, no performance difference was seen across the
four acquisition trials between DAGL-α-/- (n = 13), DAGL-α+/- (n = 13), and DAGL-α+/+
mice (n = 15). B, Also during MWM fixed platform day one, no performance difference
was seen across the four acquisition trials between DO34-treated mice (30 mg/kg
DO34, n = 12; 3 mg/kg DO34, n = 11; 0.3 mg/kg DO34, n = 12), DO53 treatment (30
mg/kg, n = 12), and VEH (n = 15). Values represent mean +SEM.
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Appendix 4. Extended Data (cont’d)

Extended Data Figure 4-2-2. High dose DAGL-α inhibition produces body weight
loss, not evident in mice with DAGL-α genetic deletion. On day 0 prior to MWM
habituation, baseline weight for naïve mice did not significantly differ between
experimental groups for both A, DAGL-α genetic deletion, or B, pharmacological
inhibition. During the MWM fixed platform task, C, no change in body weight was
evident in DAGL-α-/- (n = 13) and DAGL-α+/- (n = 13) compared to DAGL-α+/+ mice (n =
15), whereas D, 30 mg/kg DO34 (n = 12) mice exhibited consistently lower body weight
to VEH (n = 15). D, upright arrows indicate days of drug administration, and values
represent mean +SEM or ±SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 vs VEH.
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Chapter V
General Discussion

Summary
The overall objective of this dissertation research was to understand the in vivo roles of
DAGL-α and DAGL-β disruption on mouse learning and memory. The endocannabinoid
(eCB) 2-arachidonyl glycerol (2-AG), produced by these enzymes, is elevated in
response to pathogenic events such as traumatic brain injury (TBI) (Panikashvili et al,
2001). As such, we hypothesized that eCB biosynthetic enzyme contributions to
learning and memory function may extend to conditions of memory pathology. Prior to
evaluating this hypothesis, Chapter II focused on developing a mouse model of learning
and memory impairment resulting from TBI, using spatial memory tasks of the Morris
water maze (MWM). During the development of this mouse model of TBI-induced
spatial memory deficit we found modest but distinct differences following a left vs a right
unilateral insult. While both left and right lateral TBI impaired MWM Fixed Platform task
probe performance, mild Fixed Platform acquisition differences were evident between
left and right injuries despite similar motor deficits, histological damage, and glial
reactivity. This finding suggests that laterality in mouse learning and memory deficits
might be worthy of consideration when investigating TBI-induced functional
consequences.
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The experiments in Chapter III investigated the first of two biosynthetic
production enzymes of 2-AG, diacylglycerol lipase-β (DAGL-β), as a target to protect
against TBI-induced learning and memory deficits. The selective expression of DAGL-β
on
CNS microglia and the role of 2-AG as a precursor for the production of proinflammatory eicosanoids led to the hypothesis that disrupting DAGL-β activity would
provide protection from TBI-induced learning and memory impairments in mice (by
reducing pools of 2-AG pro-inflammatory metabolites). Contrary to our hypothesis,
DAGL-β deletion did not protect against TBI-induced spatial learning and memory
impairments, nor did it protect against other functional assessments after injury such as
neurological motor deficits. Unexpectedly, a survival protective phenotype was
observed in male DAGL-β-/- mice, suggesting that while DAGL-β activity does not
contribute towards injury-induced memory deficit, it may contribute to TBI-induced acute
mortality.
Finally, Chapter IV investigated the role of the second biosynthetic production
enzyme of 2-AG, diacylglycerol lipase-α (DAGL-α) in mouse spatial learning and
memory under physiological conditions. The use of a pharmacological as well as a
genetic approach facilitated the investigation of DAGL-α disruption in various MWM
hippocampal-dependent memory assessments. Here, we show that DAGL-α gene
deletion or inhibition disrupts CA1-hippocampal LTP and eCB lipid levels, but elicits
varying magnitudes of deficits in behavioral learning and memory tasks. Specifically,
DAGL-α-/- mice display profound MWM acquisition deficits, whereas C57BL6/J mice
treated with the DAGL-α inhibitor DO34 show impaired acquisition and reversal
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learning, but no change in expression, extinction, or forgetting. These results suggest
that DAGL-α may play a selective role in the integration of new spatial information in the
normal mouse brain.

Functional lateralization and mouse models of TBI-induced memory deficit.
The investigation of learning and memory deficits in response to left vs right unilateral
TBI, as well as utilization of the MWM reversal task, was an important contribution by
the present work to the TBI preclinical literature. The reversal task models cognitive
flexibility through increased task complexity in that mice suppress former spatial
memory influences (inhibition as a result of non-reinforced trials) in order to explore
alternative platform locations. The use of preclinical behavioral assessments that
capture the variety and complexity of memory impairment seen in clinical populations
could only benefit the translational potential of initial TBI mouse model work. Although
presently, normalization of the reversal task dependent measures did not reveal
significant left-right hemisphere injury differences, the finding that a left lateral injury
produced MWM performance impairments compared to sham controls (not found after a
right lateral injury) raises questions about functional lateralization in response to MWM
task variation worthy of consideration.
The hippocampal molecular, morphological, and cellular signaling differences
that exist between left and right hemispheres may influence MWM performance after
TBI. Figure 5-A summarizes a conceptual model of the previously described left-right
hippocampal molecular and morphological differences and how they may be impacted
after a unilateral TBI. A left lateral TBI may perturb axons and projections ipsilateral to
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the left injury as well as
projections from the left CA3
to the contralateral right CA1,
leaving perhaps a heavier
reliance on right originating
CA3-CA1 projections that are
GLuA1 receptor subunit rich
with mushroom-shaped
spines. Conversely, a right
lateral TBI may perturb axons
and projections ipsilateral to
the right injury as well as
projections from the right CA3
to the contralateral left CA1,
leaving perhaps a heavier
reliance on left originating
CA3-CA1 projections that are
GLuN2B receptor subunit rich
with smaller spines and intact
CA3-CA1 LTP. The cognitive
flexibility required by the
reversal task might be
facilitated by the molecular,
Figure 5-A. A conceptual model of how hippocampal
molecular and morphological differences are impacted by TBI
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and functional asymmetry of the plastic left hippocampus, in which a higher density of
GluN2B subunits exists in postsynaptic spines receiving left CA3 input (Kawakami et al,
2003; Wu et al, 2005), and LTP induction occurs only when the presynaptic input
originates in the left, but not the right, CA3 (Kohl et al, 2011; Shipton et al, 2014). As
such the reversal task deficits seen in left injured mice might be a consequence of
heavier reliance on the stable right hippocampus. Left injured mice also demonstrated a
spatial preference for the control quadrant during the reversal probe trial (data not
shown), which might be interpreted as a deficit in their ability to inhibit the previously
learned fixed platform location as well as an inability to integrate new spatial
information, suggesting injury-induced perseverative behavior in left lateral TBI mice.
While Chapter 2 did not empirically address the molecular mechanisms of left
and right hemisphere TBI MWM deficits, here I expand the discussion of the previously
proposed theoretical model by El-Gaby et al, 2014 to account for the presently observed
functional differences in left-right hemisphere injury. El-Gaby et al, 2014 proposed that
the adult mouse hippocampus may use distinct left-right hippocampal synapse
populations differentially during learning and memory. Specifically, pre-configured CA3CA1 synapses are attributed to the right hippocampus where stable cell assemblies
formed during post-natal development function to facilitate one-trial formation of spatial
representations (Nakashiba et al, 2008). Such right hippocampal pre-configured
synapses can be selected to represent a particular trajectory following a spatial learning
event (Dragoi and Tonegawa, 2012, 2014), thus rapidly incorporating spatial
information. In the left hippocampus, evidence suggests plastic CA3-CA1 synapses
recruit new place cells throughout adulthood to instruct the formation of de novo cell
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assemblies (Hollup et al, 2001) (potentially through LTP (El-Gaby et al, 2014),
facilitating the accurate representative of a particularly salient location (Leutgeb et al,
2005, 2007). Applying this model to the present findings, the fixed platform deficits in
right-injured mice could reflect the inability to rapidly incorporate a spatial location into
pre-configured stable cell assemblies, yet the lack of performance impairments in the
reversal task may reflect the continued functioning of plastic left CA3-CA1 hippocampal
synapses. Whereas the reversal task impairments and perseverative behavior produced
by a left hemisphere injury, may be exacerbated by a reliance on stable right CA3-CA1
hippocampal assemblies, already pre-assigned to a spatial representation and unable to
integrate new salient information by plastic left CA3-CA1 synapses. The adaptive
advantage of such anatomical dissociation between spatial learning processes in mice
would produce efficient division of labor between left and right hemisphere hippocampi,
while still being able to integrate these functions at the level of the CA1 through
convergent left-right CA3 inputs (El-Gaby et al, 2014).
The composition of the hippocampal trisynaptic circuit, in addition to pyramidal
cells in the CA3 and CA1, includes granule cells of the dentate gyrus. In this brain area,
the mammalian hippocampus continues to be modified by additions of adult neurons
(neurogenesis) (Altman and Das, 1965; Gage, 2000). Granule cells of the dentate gyrus
are also distinct in that they are subject to a large degree of GABAergic inhibition (Jung
and McNaughton, 1993), showing low levels of excitability. As such, the dentate gyrus is
a predominantly silent network that incorporates new functional units. The specific
functional role the dentate gyrus plays in hippocampal spatial learning and memory
processes; however, remains unresolved. Recent studies suggest the integration of
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adult-born neurons contribute to spatial learning and memory as pattern integrators,
encoding the degree of similarity of events that occur closely in time (Deng et al,
2010a). Learning and memory tasks utilizing repeated trials such as used in the MWM
produce similar events, which occur closely in time over a number of days, all of which
could be encoded through dentate gyrus newborn neurons. The dentate gyrus has also
been linked to spontaneous exploration of novel environments (Saab et al, 2009). In the
present studies, while both left and right injured mice show altered MWM search
strategies compared to their sham controls, no swim path lateralization differences were
evident. This pattern of findings suggests that injury-induced MWM exploration
differences were not subject to left-right hemisphere injury differences and likely did not
drive the distinct left-right MWM Fixed Platform task behavioral impairments. The
functionality of the dentate gyrus has been further linked to anterograde, not retrograde
memory (Nanry et al, 1989); however, there is no evidence to suggest that there are
left-right morphological, cellular, or functional differences in the hippocampal dentate
gyrus. Therefore, while the dentate gyrus clearly plays important roles in spatial memory
as assessed by MWM tasks, at present there is no evidence connecting any role to the
lateralization of hippocampal function presently observed.
To understand the brain regions responsible for the presently observed functional
asymmetry of the left and right lateral injuries, the structural and molecular asymmetry
of the hippocampus are a logical first consideration given the MWM is a hippocampaldependent learning task (Morris, 1984) particularly sensitive to the effects of
hippocampal lesions (Gerlai et al, 2002). However, the neuronal loss and diffuse axonal
injury from a lateral fluid percussion injury span beyond hippocampal regions. Cortical
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neuron loss contributes greatly to trauma-induced MWM impairments, and others have
found bilateral lesions of both the medial prefrontal cortex (Kosaki and Watanabe, 2012)
and the medial striatum (Furtado and Mazurek, 1996) to result in reversal learning
deficits. Interference with many other brain regions such as the cerebellum (Lalonde,
1994), insular cortex (Gutiérrez et al, 1999), thalamic structures (Mumby et al, 1999),
and fimbria-fornix fibers (Eichenbaum et al, 1990), also impair MWM performance. As
such, damage to any of these regions may also potentially contribute to the presently
observed functional asymmetry.
Overall, the principle of functional asymmetry of learning and memory is invoked
to account for differential MWM performance between mice subjected to left or right
traumatic brain injury. Despite evidence in human research, which points to increased
left hippocampal activity in response to task relevant semantic information, and
increased right hippocampal activity from spatial information (Motley and Kirwan, 2012),
the possible circuit basis and whether it is similar to that of the mouse remains unknown
(El-Gaby et al, 2014). Drawing direct comparisons between mouse models and humans
is inappropriate given the large number of functional differences. One such example
being hippocampal neurogenesis, around which there is an extensive body of mouse
model work in support. Recent evidence proposes that dentate gyrus neurogenesis,
present in children, is extremely rate or complete absent in adult humans (Sorrells et al,
2018). Perhaps the disparity in such findings is a consequence of typical animal model
work being performed on adolescent rodents. Nevertheless, left-right hemispheric
asymmetry of spatial memory task deficits contributes to the understanding of the
mouse model system of traumatic brain injury. Indeed, considerations of laterality in
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MWM learning and memory impairments in mice are important for future study design
and interpretation in the investigation of traumatic brain injury-induced cognitive
consequences, as well as pharmacological and nonpharmacological treatments to
mitigate the deficits.
The studies in this dissertation investigating DAGL-β as a target to protect
against TBI-induced learning and memory deficits utilized a left lateral injury. A left FPI
was chosen given it produced both a fixed platform probe trial performance deficit as
well as reversal task performance deficit, suggesting a diverse model of the learning
and memory impairments experienced in clinical populations after TBI. TBI mice of the
DAGL-β experiments showed fixed platform acquisition deficits as well as probe trial
deficits after a left lateral FPI, perhaps an artifact of an increased injury severity in these
studies (1.96 atm compared to the previous 1.92 atm). This is perhaps then evidence to
consider that changes in injury severity magnitude might reveal differential MWM deficit
across tasks, possibly by left and right hemisphere injury.

Inflammation as a target to treat TBI-induced memory deficit.
The neuroflammatory processes that unfold following a TBI have been a popular target
of interest to address TBI-induced functional deficits in pre-clinical studies. However,
manipulation of TBI-induced neuroinflammation in murine models has seen mixed
success in protecting against functional deficits. Moreover, no late phase clinical trials
have yet yielded an effective anti-inflammatory neuroprotective treatment (Chakraborty
et al, 2016; Narayan et al, 2002). It seems logical therefore to consider whether the
continued exploration of neuroinflammation is a worthwhile avenue of investigation for
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the treatment of learning and memory impairments brought about by TBI. In February
2018, the US Food and Drug Administration (FDA) authorized the first blood test to
predict the presence of intracranial lesions resulting from mild TBI. The test assesses
levels of two biomarkers of TBI, ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial
fibrillary acidic protein (GFAP). While UCH-L1 is involved in altering the function/fate of
neurons and is associated with axonal health and stability (Chen et al, 2010a), GFAP is
a protein important for the structural integrity of astrocytes which participate in
astrogliosis and the formation of glial scars following CNS injury, one function of acute
neuroinflammation. Therefore, the connection of the first FDA approved TBI biomarker
to inflammation suggests this avenue of great interest has perhaps yet to be exhausted.
The current strategy of inhibiting upstream precursors of AA metabolism within
microglial cells through DAGL-β does not account for the nuanced signaling of the
various AA metabolism pathways (see Chapter 3, Figure 3-A, pg 82). In addition to
inflammatory signaling through COX pathways, the cytochrome P450 epoxygenase
enzymes (in liver, kidney, heart etc.) produce pro-inflammatory epoxides;
epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatrienoic acids (DHETs), and
lipoxygenases (expressed in lung and CNS glial cells) produce pro-inflammatory
leukotrienes, lipoxins, and hepoxilins (Brash, 2001). Specifically, epoxide products of
cytochrome P450 epoxygenase play important roles in the regulation of cardiovascular
inflammation (Deng et al, 2010b), pertinent given the frequent peripheral multisystem
failure in heart, lungs, and peripheral vasculature that occurs following TBI.
Furthermore, inhibition of spinal lipoxygenase enzymes have reversed NSAIDunresponsive inflammatory hyperalgesia (Gregus et al, 2018) through toll-like receptor 4
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(TLR4) (Gregus et al, 2018) and transient receptor potential cation channel, subfamily
V, member 1 (TRPV1) (Gregus et al, 2012) signaling in rats. These findings suggest
that inhibition of alternative AA metabolic pathways outside of COX inhibition are worthy
of investigation in the context of functional deficit protection following TBI.
The present results refuting our hypothesis that DAGL-β disruption would protect
against TBI-induced memory deficit in mice, perhaps is a result of the global reduction
of microglial arachidonic acid (AA) metabolites. While AA is the primary precursor for
the production of pro-inflammatory prostaglandins, AA is also the precursor for the
production of prostaglandins whose role contributes to the resolution of inflammation.
Prostaglandins, while ubiquitously produced, are usually dominantly generated by cell
type. Specifically, prostaglandin E2 (PGE2) is produced by microglia and macrophages
(Tilley et al, 2001) and its effects are mediated through microglial EP2 and EP4
receptors (Ricciotti and FitzGerald, 2011). PGE2 is one of the most abundant
prostaglandins, and exhibits dual pro- and anti-inflammatory signaling roles. As a proinflammatory mediator PGE2 contributes to the regulation of cytokine expression (Egan
et al, 2004), whereas in its anti-inflammatory capacity PGE2 blocks ATP-induced
cytokine synthesis (Noda et al, 2007). Therefore, the global reduction of microglial
prostaglandins may prevent some nuanced signaling involving the resolution of
inflammation. Whether our mouse model of DAGL-β deletion reversed levels of PGE2
we did not presently evaluate, however the importance of evaluating changes in
prostaglandin levels following injury is discussed further in the Future Directions section
at the end of this chapter.
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An alternative approach to globally blocking 2-AG derived AA metabolites to
achieve neuroprotection from TBI, would be to selectively block novel products of 2-AG
oxidation (see figure 1-2, pg 36). Cyclooxygenase-2 (COX-2), both produces
oxygenation products of AA (Xie et al, 1991); classic prostaglandins, as well as directly
oxygenates 2-AG to produce prostaglandin glyceryl esters (PG-Gs) (Kozak et al, 2000);
novel prostaglandins. Previously PG-Gs have only been observed in vitro (Kozak et al,
2002), though recently have been quantified in vivo in COX-2 overexpressing mice
(Morgan et al, 2018). COX-2 is a dynamically regulated enzyme where CNS insults
such as TBI lead to COX-2 induction (Lapchak et al, 2001), perhaps then also leading to
increased PG-Gs after injury. COX-2 oxygenation of 2-AG has been implicated in
glutamate-induced excitotoxicity (Sang et al, 2007), therefore the upregulation of COX-2
and production of PG-Gs after TBI may contribute towards TBI-induced neurotoxicity.
The evaluation of COX-2 inhibitors that preferentially block the direct oxygenation of 2AG (Duggan et al, 2011) after TBI might be useful in evaluating the neuroprotective
potential of preventing PG-G production while not impacting the inflammation resolution
capacities of classic prostaglandins such as PGE2.
The idea that DAGL-β may play a temporal dependent role with regards to
inflammation pathology is also worthy of further consideration. The current constitutive
genetic deletion model of DAGL-β disruption may mask any time dependent protective
effects of DAGL-β disruption. As such investigation of detailed intervention timing
regarding DAGL-β disruption would be beneficial in future experiments. In a previous
experiment (data not shown), administration of DAGL-β inhibitor KT109 (30 min, 24 h
post-injury, i.p.) produced no change in TBI-induced MWM deficit. Since this work was
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completed KT109 was found to show poor brain penetrance and low DAGL-β activity
inhibition in brain when administered i.p. (Donvito et al, in compilation). Even though
KT109 administration occurred at a time post-TBI when blood brain barrier integrity is
presumably compromised, the extent to which KT109 penetrated the brain and inhibits
DAGL-β was not quantified. A recurring challenge with currently available DAGL-β
inhibitors is inadequate brain penetrance and only modest selectivity for DAGL-β over α, making pharmacological investigation of DAGL-β inhibition after TBI not currently
viable. The use of a mouse model of inducible DAGL-β genetic deletion may prove a
valuable tool to study time-dependent inhibition of inflammation pathology through
DAGL-β inactivation. However, the temporal resolution of a chemically inducible Cre-lox
recombination system is relatively low, taking days to weeks for gene inactivation to
complete.
The endocannabinoid system contains a rich source of targets to treat TBIinduced neuroinflammation. Therefore, the exploration of manipulating several
endocannabinoid system signaling pathways at once might have advantages over a
focus on a single target. One such example could be the combined activation of
cannabinoid receptors with DAGL-β disruption. Microglial cells have most of the
components of the endocannabinoid system, their receptors, and production and
degradation enzymes, perhaps suggesting they participate in autocrine and paracrine
signaling in response to neuroinflammation. Specifically, cannabinoid receptor 2 (CB 2)
expression increases with the change in microglia activation state (Mecha et al, 2015).
The activation of CB2 receptors elicit a wide range of effects both within microglia (e.g.
cell migration (Walter et al, 2003), induction of an anti-inflammatory M2 phenotype
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(Mecha et al, 2015) as well as on their surroundings (e.g. induction of phagocytosis
(Tolon et al, 2009), diminishing free radicals (Ribeiro et al, 2013) and reducing proinflammatory cytokines (Lu et al, 2015). Indeed after TBI CB2 receptor activation
reduces oedema, enhances cerebral blood flow, increases M2 polarization, and
improves neurological motor deficits (Braun et al, 2018). One consideration for the lack
of protection from TBI-induced MWM performance deficits may in part be due to a
decrease in CB2 receptor signaling because of reduced 2-AG levels in microglia. As
such the administration of a CB2 receptor agonist in a DAGL-β-/- mouse post-injury might
be an interesting avenue to explore the dual effectiveness of CB 2 receptor inflammation
resolution signaling combined with the inhibition of 2-AG into microglial eicosanoid
production pathways on TBI-induced cognitive deficit. In support of this strategy of dual
CB2 receptor activation and reduced eicosanoid signaling, monoacylglycerol lipase
(MAGL) inhibition (which increases 2-AG and lowers AA in a non-cell type specific
manner) shows protection from the molecular and cellular damage inflicted by TBI (see
Chapter I, Table 1-1, pg 31 & 32). However, given TBI-induced functional deficit
protection was mixed following MAGL inhibition (see Chapter I, Table 1-2, pg 33 & 34),
global reduction of AA production across all cell types might have wider reaching
biological implications that in part mitigate the neuroprotective potential of reduced
eicosanoid signaling.

TBI-induced memory deficit protection by cell type.
Despite our original hypothesis, that disrupting DAGL-β activity would provide protection
from TBI-induced learning and memory impairments in mice (by reducing microglial
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pools of 2-AG pro-inflammatory metabolites), complementary genetic and
pharmacological approaches indicated that disrupting DAGL-β is not sufficient to
ameliorate motor or cognitive deficits following TBI. A remaining question is whether
blocking 2-AG production on other cell types would offer protection from TBI-induced
memory deficit. DAGL-α, the other biosynthetic enzyme of 2-AG production, is primarily
neuronal, as well as expressed on astrocytes in the CNS (Gao et al, 2010). As such, we
conducted an experiment to assess if DAGL-α-/- mice would be protected from TBIinduced spatial memory deficit (see Chapter 3). The DAGL-α-/- mice responded poorly
to the craniectomy surgery and approximately 30-60 min post-surgery exhibited tonicclonic seizure-like movements followed by spontaneous death. Of the eight DAGL-α
mice (DAGL-α+/+ n=1, DAGL-α-/- n=7) undergoing surgery, only three survived to receive
a TBI (one DAGL-α+/+ and two DAGL-α-/-, all of which survived). Constitutive DAGL-α-/mice have distinct phenotypes which include decreased survival (Powell et al, 2015)
and seizure-susceptibility (Sugaya et al, 2016), and as such future experiments to
investigate the role of neuronal/astrocyte 2-AG production inhibition following TBI might
be conducted in an inducible mouse model of DAGL-α deletion. Pharmacological
blockade of DAGL-α also has associated challenges. The DAGL-α inhibitor, DO34,
lacks selectivity for this enzyme in that it is equipotent for DAGL-α and DAGL-β
(Ogasawara et al, 2016). However, DO34 could yet prove a useful tool to answer
questions about the role of 2-AG in neurons and astrocytes if administered to a DAGL-β/- mouse

(known to show no TBI memory protection) after TBI. We did however conduct

an additional experiment administering DO34 to C57BL6/J mice daily for 2 days prior to
injury and for 6 days post-injury. We found no significant change in MWM performance
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in the DO34-treated TBI mice compared to the vehicle-treated mice, suggesting that
disrupting DAGL-α (and therefore lowering neuronal and astrocytic 2-AG), is also not
sufficient to ameliorate motor or cognitive deficits following TBI.

TBI Mortality protection by DAGL-β.
The survival protective phenotype observed in mice with a DAGL-β deletion suggests
that DAGL-β activity may contribute to TBI-induced acute mortality. The expression
pattern of DAGL-β in brain is not yet well understood; however, the brain areas
responsible for autonomic function and basic life support such as cardiac, respiration,
and blood pressure control are well understood and are predominantly located in the
brain stem (medulla oblongata, pons) and hypothalamus (arcuate nucleus) (as well as
other aspects of voluntary control occurring in higher motor cortices). Specifically,
murine models of TBI have found respiratory dysfunction to occur within seconds postinjury (Dixon et al, 1987), frequently in proportion to the magnitude of the injury severity
(Atkinson et al, 1998), and result in either transient or irreversible pulmonary oedema,
hypoxemia, endothelial damage, and respiratory failure (Koutsoukou et al, 2016). The
mortality that occurs from fluid percussion injury in mice is frequently attributed to acute
lung failure. In clinical cases of TBI acute lung injury is also reported in as high as 30%
of cases (Nicolls and Laubach, 2014), with a similar resulting pathology to that seen in
mice and rats (Alvarez et al, 2015).
The pathophysiology behind TBI-induced lung injury is not well understood,
though currently three mechanisms have been considered; an increase in intracranial
pressure affecting pulmonary control centers in the brain, a sympathetic surge
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producing increased plasma adrenaline driving capillary bed pressure and endothelial
damage, and/or macrophage activation and migration increasing systemic production of
inflammatory mediators (Koutsoukou et al, 2016). Increased numbers of macrophage in
mouse lung occur post-TBI (Kalsotra et al, 2007) suggesting macrophage migration in
response to injury. DAGL-β is highly expressed on intraperitoneal magcrophages in the
periphery (Hsu et al, 2012), a possible population from which this migration occurs. A
substantial population of lung resident macrophages are also present. This population
of mouse and human lung resident macrophages has been found to express several
components of the endocannabinoid system; CB1 and CB2 receptors, with basal levels
of tonic lung 2-AG and anandamide (Avraham et al, 2008; Nomura et al, 2008; Staiano
et al, 2015). Furthermore, increases in lung 2-AG occur in response to LPS-induced
inflammation in mice (Staiano et al, 2015). Given the basal levels of 2-AG present in
lung it is possible that DAGL-β may be expressed on lung resident macrophages, or
that increased lung 2-AG (in response to an inflammatory challenge) might be in part a
consequence of infiltrating intraperitoneal macrophages. Regardless, it is an interesting
possibility that DAGL-β may play a role in acute lung injury and thus acute mortality
after TBI. An avenue of future interest would be the investigation of whether DAGL-β is
expressed on lung resident macrophages, and if 2-AG levels in lung increase following
TBI in mice. In a model of LPS-induced acute lung injury the MAGL inhibitor JZL184
reduced lung leukocyte migration and cytokine levels (Costola-de-Souza et al, 2013),
perhaps as a result of the prevention of 2-AG oxidation to AA pro-inflammatory
metabolites. As such, evaluating outcome measures such as macrophage migration
and levels of pro-inflammatory mediators after TBI in DAGL-β-/- and -β+/+ mice may
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provide answers as to whether the survival protective effect of DAGL-β deletion occurs
concurrently with reduced inflammation in lung.

DAGL-α regulation of learning and memory: physiology to pathophysiology.
The varying magnitudes of behavioral learning and memory deficit evidenced between
DAGL-α-/- mice (displaying profound MWM acquisition deficits), versus DAGL-α
inhibition (showing modestly impaired acquisition rate) could be a result of various
factors; such as developmental alterations across ontogeny, off target engagement at
high dose DO34, or the relative magnitude of lowered 2-AG and AA. The future use of
inducible DAGL-α-/- mice may prove useful in resolving this disparity. Should the MWM
impairment profile of inducible DAGL-α-/- mice mirror that of DO34-treated mice in
acquisition deficit magnitude, or lack of expression impairment, then conclusions about
DAGL-α also being important for normal neural development and its impact on future
learning and memory could be drawn. Regardless, the impaired acquisition and reversal
learning as a result of DAGL-α inhibition (with no effect on expression, extinction, or
forgetting processes) suggests that DAGL-α may play a selective role in the integration
of new spatial information in the normal mouse brain.
The varying magnitudes of lipid profile alterations between DAGL-α-/- mice and
wild type mice treated with a DAGL-α inhibitor could also be a consequence of
developmental alterations across ontogeny. While 2-AG levels were lowered across all
brain regions in both DAGL-α-/- mice and DO34-treated mice, changes in anandamide
(AEA) levels differed by intervention and brain area. Only DAGL-α-/- mice showed
reductions in AEA, and these changes were regionally dependent. Compensatory
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changes to the production, metabolism, and signaling of AEA in response to the
constitutive deletion of DAGL-α could be partly responsible for the lowered AEA in
DAGL-α-/- mice. While AEA has distinct biosynthetic and catabolic pathways from 2-AG,
the metabolic product of both, AA, is also a substrate for one AEA production pathway
(Izzo and Deutsch, 2011). Therefore, the large reduction of AA in DAGL-α-/- mice (fourfold that of DAGL-α inhibition) may also contribute to lowered AEA. On the other hand,
DAGL-α-/- mice showed significant AEA decreases in hippocampus and cerebellum, but
not in PFC or striatum, despite having profoundly decreased AA levels in all four brain
regions evaluated. Thus, factors beyond AA reductions many also contribute to the
phenotypic AEA decreases, such as brain region selective expression levels of FAAH
(Egertova et al, 2003). As elevated AEA (by FAAH inhibition or deletion) accelerates
MWM extinction rates (Varvel et al, 2007), reducing hippocampal and cerebellum AEA
might therefore be predicted to impair MWM extinction learning; however, this outcome
was not observed. Furthermore, FAAH inhibition does not reverse fear extinction deficits
in DAGL-α-/- mice (Cavener et al, 2018). Therefore, while AEA was lowered in
hippocampus and cerebellum, it was not sufficient to alter extinction vehicle-control level
performance of DAGL-α inhibitor treated mice.
The cerebellum specifically showed modest basal differences in cannabinoid
related lipids as well as across both pharmacological and genetic manipulations. Basal
levels of AA in control mice (DAGL-α+/+ and veh-treated mice) were lower in cerebellum
than the other brain areas tested. Also, elevations of cerebellar SAG in DAGL-α-/- and
DO34-treated mice were modest in comparison to hippocampal, PFC, and striatal
elevations. The understanding of the cerebellar role in spatial memory has progressed
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from simple motor learning to considerations about goal directed navigation specifically
through distinguishing between self- and externally-generated vestibular signals
(Rochefort et al, 2013). Furthermore, destruction of cerebellar Purkinje cells produce
impaired MWM acquisition (Gandhi et al, 2000), and MWM reversal task deficits (Leggio
et al, 1999). The reduction in cerebellar basal AA tone and modest SAG elevations after
DAGL-α disruption might indicate a spatially dependent role for these upstream and
downstream bioactive lipids of DAGL-α in the presently disrupted tasks of MWM spatial
memory.
The finding that DAGL-α is important for the integration of new spatial information
in the healthy mouse brain, may point to DAGL-α dysregulation as a target for disease
states where learning is impaired. Given that DAGL-α expression decreases with age
(Piyanova et al, 2015), one such example of DAGL-α-related pathology could exist in
the form of age-related cognitive decline. Future experiments evaluating if age-related
MWM performance deficits in C57BLB6/J mice correlate with lowered DAGL-α
expression/activity would be of interest. Furthermore, I would predict that mice showing
age-related MWM performance deficits would be more vulnerable to the learning and
memory impairing effects of DAGL-α inhibitors than young C57BL6/J mice. Finally,
investigation into the mechanisms of how DAGL-α is impacting memory would valuable,
specifically in identifying which lipid, upstream or downstream of DAGL-α, is responsible
for the presently observed effects. To evaluate if lowered 2-AG is responsible for the
learning and memory impairing effects of DO34, co-administration of a MAGL inhibitor
could be used to assess if rescue of memory impairing effects is possible through
elevation of 2-AG in the presence of DAGL-α inhibition.
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Future Directions
While the hypothesis that DAGL-β disruption would protect against TBI-induced
cognitive impairments was not supported, the evaluation of perturbations to
neurochemical lipid correlates of DAGL-β deletion, and downstream pro-inflammatory
mediators, to assess their relationship to the survival protective phenotype of DAGL-β-/mice will be important. Changes in whole brain 2-AG levels are however not evident in
DAGL-β-/- mice (Tanimura et al, 2010; and data not shown) perhaps a result of the cell
specific location of DAGL-β on microglia, which make up only 5-12% of total CNS cells
depending on brain area (Lawson et al, 1990). Yet in vitro DAGL-β regulates the levels
of 2-AG, AA, and prostaglandins in primary cultured microglia (Viader et al, 2015b). As
such, development of a procedure to measure ex vivo levels of endocannabinoids and
their related lipids specifically in microglia from adult mouse brain collected following a
TBI would be a valuable addition to the present work. Such a procedure could be
established using cell sorting by magnetic immunoprecipitation. Magnetic cell sorting
uses a magnetic antibody which when incubated with cells from CNS tissue and passed
over a magnetic column, produces isolation of a microglial positive fraction. The use of
a magnetic CD11b+ antibody has previously produced CD11b+ fractions with low
expression of astrocytic, oligodendrocyte, and neuronal mRNA, and enrichment of
microglial protein expression (Holt and Olsen, 2016). As such, I predict that microglial 2AG and AA would be lower in DAGL-β-/- mice compared to DAGL-β+/+ mice. Also I would
predict that TBI might yield increased microglial 2-AG and AA in DAGL-β+/+ mice,
whereas TBI DAGL-β-/- mice might show no change in 2-AG and AA compared to their
sham controls, and also possible protection from increased AA metabolites. However, if
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ex vivo mouse brain tissue is collected at the 2 min acute mortality cut off time,
elevations of AA metabolites (e.g. prostaglandins) may not yet be present. Future
adaptation of this procedure to evaluate endocannabinoid and related lipids in aveolar
macrophage from mouse lung tissue (using a magnetic CD11C antibody) would also be
a useful endeavor. A correlation of blunted lipid level changes in lung resident
macrophages of TBI DAGL-β-/- mice to survival protection might connect this survival
effect to acute lung injury protection following TBI.
The conclusions made about the role of DAGL-α in mouse spatial learning and
memory might be further strengthened through the use of a second hippocampaldependent learning and memory task. Specifically, a single trial spatial learning and
memory task such as the Object Location assay, a hippocampal dependent adaptation
of the Object Recognition task (Assini et al, 2009). The Object Recognition task consists
of 2 identical objects which are explored in sample phase, then during choice phase (3
h later) one object is moved to a new location, the novelty of which being sufficient to
produce increased exploration of the moved object in naïve C57BL6/J mice.
Comparable deficits in two distinct hippocampal learning and memory tasks would add
weight to the present conclusions that DAGL-α is an important mediator in the
regulation of hippocampal learning and memory. Given anandamide (AEA) was also
lowered following DAGL-α deletion, inclusion of a future experiment where a FAAH
inhibitor is administered to DAGL-α-/- mice to evaluate if the return of AEA levels to
baseline would reverse the behavioral impairment would be a useful inquiry to rule out
any effect of AEA.
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The dissertation data presented suggest that DAGL-α, but not DAGL-β, is an
important contributor to the neurobiology of learning and memory, whereas DAGL-β
contributes to TBI-induced acute mortality. Knowledge of the differential contributions of
these enzymes to the normal regulation of memory, and memory following disease
states such as TBI are invaluable as the search for effective treatments for memory
pathology continues.
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